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    Amino acid based poly(ester amide)s are a family of biodegradable polymers 
which have been designed and synthesized for various biomedical applications 
including tissue engineering scaffold, hydrogels, coating for cardiovascular stents, 
nanofibrous membrane and sutures etc. The aim for this study is to investigate the 
potential of poly(ester amide)s materials as nano-carriers for the delivery of multiple 
therapeutics including chemotherapeutics, photosensitizers and proteins, in the 
treatment of cancer. The amino acid based poly(ester amide)s provided the physical 
encapsulation of the payloads, and further impact the interactions and communication 
with cancer cells, comparing to the direct administration of free therapeutics. In 
addition, by adjusting different amino acids on poly(ester amide)s, or froming hybrid 
nanomaterials with other biodegradable polymers, functionalities can be introduced 
into the delivery systems so that “smart” delivery can be achieved. The therapeutic 
potency of poly(ester amide)s based delivery systems, are closely related to a series of 
stimuli, which includes biological cues such as enzymatic degradation, or physical 
cues such as light. The thesis demonstrated the potency of poly(ester amide) nano-
carriers from both in vitro and in vivo characterization, and further validated their 
application potential to be developed as spatio-temporally controllable delivery 
systems.  
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 1 
 
CHAPTER 1 
 
SUMMARY OF POLYMERIC NANOMEDICINE AS TREATMENT OF CANCER 
  
 2 
1.1 Nanomedicine in the treatment of cancer 
    Cancer is a leading cause of death worldwide and rapid growth in 
nanotechnology towards the development of nanomedicine products holds great 
promise to improve therapeutic efficiency against cancer. As suggested in Figure 1.1, 
different nanomedicine products such as drug conjugates, lipid-based nanocarriers, 
polymer-based nanocarriers, inorganic nanoparticles, and viral nanoparticles are used 
in clinical cancer care [1].  
 
Figure 1.1. Schematic illustration of most extensively studied nanotherapeutic 
platforms [1].  
 
    These Nanocarriers can improve the solubility and chemical stability of anti-
cancer drugs; protect anti-cancer compounds from degradation or excretion and 
influence their pharmacokinetic profile; improve the distribution and targeting of anti-
tumor medication; and stimuli-sensitive release of payloads can be achieved in 
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response to a series of biological, chemical or physical triggers [2]. All the advantages 
mentioned here helped to improve the therapeutic efficiency of anticancer medication, 
compared to the direct administration of free drug. Table 1.1 summarized the drug-
conjugates or nanocarrier based anticancer drug delivery systems that have been 
approved by FDA for cancer therapy. To date, the majority of the approval 
nanomedicine are polymer based or lipid based. 
 
Table 1.1.  Approved drug conjugates and nanocarriers for cancer therapy [1]. 
     
    In addition to the approved nanomedicine, a total of 1575 nanomedicine 
formulations had been registered for clinical trials by December 2015 according to the 
registry maintained by clinicaltrials.gov. As many as 1381 of these are in the field of 
cancer therapy [3]. The following of this section summarized the varieties of 
nanomedicine formulations that have been in the process of clinical trial, which 
include polymer-drug conjugates (Table 1.2), polymer-based Nanocarriers (Table 1.3), 
and inorganic Nanocarriers (Table 1.4). In addition to the traditional nanoparticles, 
newly-developed nanomedicines with stimuli-responsiveness, and still in the 
 4 
experimental stages, were also listed in Table 1.5. 
    Thousands of publications suggest that nanomedicine therapeutics are effective in 
cancer treatment. However, only very few nanomedicine formulations have 
successfully entered clinical trials. It is important to address the detailed 
characterization of nano-carriers, as well as the safety issues in developing optimized 
nanomedicine products for clinical use. The quality assessment of nanomedicine is 
important, which involves the characteristics such as structure, composition, size, 
surface properties, porosity, charge, and aggregation behavior that may impact the 
performance of the nanomedicine in vivo. Characterization of stability of the 
nanomedicine in interaction with biological fluids (such as serum), and from the 
storage aspects (shelf-life), are also of great importance. The intracellular fate of the 
nanomedicines, as well as the long-term toxicological studies, are aspects that should 
be addressed to elucidate the safety issues of the nanomedicine. 
 
Table 1.2. Polymer-drug conjugates in clinical trials [1]. 
 5 
 
Abbreviation for Table 1.2:  Poly(N-(2-Hydroxypropyl)methacrylamide) (HPMA); 
Human serum albumin (HSA); Poly(ethylene glycol) (PEG); poly-1-
hydroxymethylethylene hydroxymethylformal (Fleximer). 
 
 
Table 1.3. Polymer-based nanocarriers in clinical trials [4].  
 6 
 
 
Table 1.4. Inorganic nanocarrier under clinical trial [1]. 
 
 
 
Table 1.5. Novel polymeric nanoparticles in experimental stages [5]. 
 7 
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1.2 Endocytosis of nanomedicine 
1.2.1 General endocytosis pathway of polymeric delivery vehicles 
    Small molecules such as ions, amino acids and oligosaccharide can directly enter 
cells through the membrane protein pumps or channels [6], driven by the 
transmembrane concentration gradient of the solute. On the other hand, 
macromolecules and nano-delivery vehicles must be internalized via endocytosis 
which involves the specific interaction with surface receptors on plasma membrane, 
the formation of membrane-bound vesicles and the consumption of ATP [7]. 
    Endocytosis, the common pathway for the internalization of extracellular 
substances, can be divided in two major categories [8]: phagocytosis and pinocytosis. 
Phagocytosis occurs for the engulfment of nutrient, pathogens and cell debris, and is 
achieved by membrane-bound vacuoles known as phagosomes [9]. Phagocytosis is 
central to tissue homeostasis and immunity, and is restricted to some specialized cells 
such as macrophages, monocytes and neutrophils, etc. Pinocytosis is common in all 
cells in which the transportation of cargo is mediated by high-affinity receptors. The 
cargo first binds with the receptors on the surface of cells, which produces a localized 
decrease in the Gibbs free energy, and induces the plasma membrane to wrap around 
the cargo to form a closed-vesicle structure [8]. The vesicle eventually buds off the 
plasma membrane and fuses with endosomes and lysosomes [7]. The pinocytic 
pathway is classified into: macropinocytosis, clathrin-mediated endocytosis, caveolae-
mediated endocytosis and clathrin- and caveolae-independent endocytosis, as 
suggested in Figure 1.2. The particular pathway that should be followed is driven by 
the physical, chemical and biological properties of the cargo molecules, as well as the 
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type of cells. In general, endocytosis plays an important role in the communication 
between cells and extracellular environment, and impact the intracellular fate of 
engulfed biomaterials. 
 
 
Figure 1.2. Schematic illustrations of different endocytosis pathways [10]. 
 
1.2.2 Clathrin-mediated endocytosis 
    In clathrin-mediated endocytosis, a protein named clathrin-1 polymerizes on the 
cytosolic side of the plasma membrane where the cargo is internalized, and form 
clathrin coated vesicles that wrap around the cargo. The assembled vesicle (ca.120 
nm) is pinched off from the plasma membrane by a small GTPase, dynamin [11]. 
Various accessory proteins like amphiphysin, Eps15 and intersectin, have been shown 
to act as scaffolds that connect the endocytic machinery with actin cytoskeleton. Actin 
defines the spatial regulation and movement of the endocytic vesicle towards the 
interior of the cells [12]. Within cells the clathrin coated vesicles migrate and fuse with 
 10 
the early endosomes where they are sorted to late endosomes or lysosomes, to trans-
Golgi network or to the recycling endosomes to be transported back to plasma 
membrane. Clathrin-mediated endocytosis is the most common pathway for the entry 
of nanoparticles. For example, poly(ethylene glycol-co-lactide) (PEG-co-PLA) 
nanoparticles with average diameter of 100 nm by HeLa cervical cancer cells [10], 
cationic chitosan nanoparticles (ca. 360 nm) by human lung carcinoma A549 cells [13], 
mesoporous silica nanoparticles (ca.110 nm) by human mesenchymal stem cells and 
fibroblasts [14], the entrance of above nanoparticles are all dependent on clathrin-
mediated endocytosis. 
 
1.2.3 Caveolae-mediated endocytosis 
    Caveolae are abundant in muscle, endothelial cells, fibroblasts and adipocytes 
and absent in neurons and leukocytes. The definitive characteristic of caveolae is the 
presence of the hairpin-like membrane protein, caveolin. There are three isoforms of 
caveolin in mammalian cells. Caveolin-3 is muscle specific, while caveolin-1 and -2 
are abundant in most non-muscle cells (such as endothelial cells, fibroblasts and 
adipocytes) and absent in neurons and leukocytes [8]. The binding of cargo molecules 
with surface receptors induces the formation of flask-shaped structure (60–80 nm) 
coated with caveolin [15], which is recognized as the hallmark for caveolae-mediated 
endocytosis. Other components of the caveolae endocytic machinery include proteins 
like cavin, which induces membrane curvature, dynamin, which enables vesicle 
scission, as well as vesicle-associated membrane protein (VAMP2) and synaptosome-
associated protein (SNAP), which mediate subsequent vesicle fusion, etc [16]. After 
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budding off the plasma membrane, the caveolae vesicles transport and fuse with 
caveosomes or multivesicular body [15]. Caveolae-mediated endocytosis is involved in 
the internalization of several pathogens including Simian virus 40 and cholera toxin, 
and is reported to bypass the fusion with endolysosomes to prevent degradation of the 
pathogens [17]. In addition, polymeric nanoparticles were also reported to be 
internalized by cells via caveolae pathway. Poly(3-aminopropyl)siolxane nanoparticles  
modified with stearic acid and galactose were shown to selectively target caveolae in 
human aortic endothelial cells [18]. DOXIL®, a PEGylated liposomes loaded with 
doxorubicin, utilize caveolae-mediated endocytosis to enter human ovarian cancer 
cells [19]. 
 
1.2.4 Macropinocytosis 
    Macropinocytosis is initiated by transient activation of receptor tyrosine kinases 
induced by growth factors. The receptor activation mediates a signaling cascade that 
leads to changes in the actin cytoskeleton and triggers formation of membrane ruffles 
[20]. These membrane ruffles protrude to engulf the surrounding fluid and nutrients in 
the extracellular environment. They can simply fuse with the plasma membrane or 
form an intracellular vacuole, termed as a macropinosome [21]. The macropinosomes 
are larger (0.5–10 µm) and distinct from other vesicles formed during pinocytosis. 
Many particles like bacteria, apoptotic bodies, necrotic cells and viruses can induce 
the ruffling behavior independently of the growth factors, and internalize in 
macropinosomes [20]. In macrophages, after pinching off from plasma membrane, 
macropinosomes fuse with lysosomes [22]. In contrast, in human A431 epidermoid 
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carcinoma cells, the macropinosomes travel back to the plasma membrane and release 
the cargos extracellularly [22]. The fate of engulfed cargos by macropinocytosis is 
highly dependent on cell types. Macropinocytosis was reported [23] to contribute to 
cellular entry of plasmid DNA complexed to polyhisidine and polylysine.  
Submicron-sized and greater particles [24], such as PLGA microparticles and 
polystyrene microparticles, are generally known to internalize the cells via 
macropinocytosis. However; most of the literature reported the nanoparticles undergo 
cellular internalization via more than one endocytic pathway. For example, Zhang et 
al. [25] reported nanoparticles from a core of albumin and a lecithin corona, were 
internalized by BT-474 human ductal carcinoma cells through both clathrin-dependent 
pinocytosis and macropinocytosis. The complexity of endocytic transport requires 
multiple quantitative techniques to elucidate the pathways involved.  
 
1.2.5 CD44-mediated endocytosis 
    CD44 is a cell surface glycoprotein that serves as the endocytic receptor for 
hyaluronic acid in keratinocytes, chondrocytes, and breast cancer cells [26]. Hyaluronic 
acid (HA) is a non-sulfated linear glycosaminoglycan composed of multiple copies of 
the disaccharide unit of D-glucuronic acid and N-acetyl-D-glucosamine. In addition to 
being one of the major component of extracellular matrix, HA is known to participate 
in a variety of physiological and pathophysiological processes, including tumor 
metastasis, wound healing and leukocyte extravasation at sides of inflammation, etc. 
[27] Internalization of HA through CD44 mediated endocytosis has been shown to 
require acylation of the CD44 cytoplasmic tail [26]. Palmitoylation of CD44 on two 
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cysteine residues, Cys286 in the transmembrane domain and Cys295 in the 
cytoplasmic domain, was found to be essential for lipid raft association [28], which 
further facilitated the internalization of HA.  
    CD44 is endogenously expressed at low levels on various cell types in normal 
tissues, but it requires activation before it can bind to HA. Importantly, the minimal 
size of HA fragments binding to CD44 are six monosaccharide units(HA6) [27]. 
Activated CD44 is overexpressed in solid tumors, but much less, or not at all on their 
non-tumorigenic counterparts [29]. Targeting HA-CD44 receptor interactions on tumor 
cells may identify promising therapeutic approaches in cancer treatment [29]. HA has 
also been formulated into a series of nano-features for biomedical application [30], such 
as polymeric nanoparticles from HA-modified poly(lactic-co-glycolic acid)(PLGA), 
HA-modified polycaroplactone (PCL) or HA-modified Poly(n-butyl cyanoacrylate) 
(PBCA); liposomes with HA surface coating; polymeric micelles from HA-grafted-
5β-cholanic acid, HA grafted deoxycholic acid (DOCA) and HA grafted 
polyethyleneimine (PEI), HA grafted poly(histidine) (PHis) and d-α-tocopheryl 
polyethylene glycol 2000 succinate (TPGS2k), mulberry-like dual-drug complicated 
nanocarriers (MLDC) from hyaluronic acid nanoparticles, etc. As summarized in 
Table 1.6, HA based biomaterials have been reported as various delivery vehicles [31] 
for the tumor-targeting delivery of chemotherapeutics such as doxorubicin, epirubicin, 
paclitaxel, mitomycin, etc.  
 
Table 1.6.  HA based anti-tumor drug delivery systems [30]. 
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1.2.6 Pathways for endosomal escape  
    The sequestration of engulfed nanoparticles in endolysosomes result in bottleneck 
for the intracellular release of payloads as well as the fulfillment of the biological 
functions of the payloads. Techniques to achieve endosomal escape of internalized 
cargos have major impact on non-viral delivery systems for nucleic acid and proteins. 
The major mechanisms for sequestered cargos to escape endosomes are suggested in 
Figure 1.3. 
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Figure 1.3. Pathways for endosomal escape of sequestered cargos [32]. 
 
  Flip-flop and pore formation. The outer layers of endosomal membranes are 
composed of phospholipids with negative charge, the interaction between cationic 
cargos with the endosomal membrane is thought to induce a ‘‘flip-flop’’ mechanism 
[33], where anionic phospholipids from the cytosolic side will flip to the intraluminal 
side on the endosomal membrane. This charge-neutralized ion pair will result in non-
lamellar phase changes and subsequent membrane destabilization [33]. The cationic 
charge can result from quaternary amine groups, such as cationic lipid 1,2-dioleyl-3-
trimethylammonium-propane (DOTAP), or protonable amine groups from polymers 
such as poly(ethylene imine) (PEI), poly(L-lysine) (PLL) and chitosan. In the case of 
endosomal destabilizing peptide, pore formation is another mechanism [32]. GALA 
 16 
peptide [34], which contains 30 amino acids, with glutamic acid-alanine-leucine-alanine 
repeating units and histidine, undergoes a pH-dependent conformational change to 
give a helical structure at acidic endosomal environment. Li et al. [34] proposed that 
GALA becomes incorporated into the vesicle bilayer and aggregates to form a pore 
with diameter ranges from 5 to 10 Å, which results in the leakage of endosomal 
content.    
  Membrane fusion. This mechanism highlighted the fusion of the membrane of 
cargos with the membrane of endosomes. For example, haemagglutin subunit (HA2) 
of influenza virus, is responsible for facilitating membrane fusion [35]. The C-terminal 
end is embedded in the viral membrane whereas the N-terminal end contains a fusion 
peptide with a sequence of hydrophobic amino acids. Once inside the endosomes, 
HA2 undergoes conformation change in response to the low pH environment and 
exposes the highly conserved hydrophobic region. Subsequently, this triggers the 
fusion of viral membrane with the endosomal membrane, leading to the leakage of 
viral genome to cytosol [35]. 
    Endosome rupture. “proton sponge effect’’, which is based on cationic polymers 
or lipids with excess uncharged protonable amine groups that can buffer endosomal 
acidification by absorbing protons in the endolysosomal compartment [36]. As long as 
ATP is present in the cytosol, ATPases will keep pumping protons against their 
electrochemical gradient across the endolysosomal membrane, with an associated 
influx of counterions to balance the transmembrane voltage difference [32]. The 
osmotic swelling leads to the rupture of endolysosomal membrane, followed by the 
subsequent release of cargos into cytosol.  
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    Table 1.7 summarized the current non-viral delivery vehicles functionalized with 
the above modalities for endosomal escape. The cationic charges, fusogenic functional 
groups have been introduced to cholesterol lipids including DOPE (1,2-dioleoyl-sn- 
glycero-3- phosphoethanolamine), DOTAP (1,2-dioleyl-3-trimethylammonium-
propane) and GAP-DMORIE (N-(3-aminopropyl)-N, N-dimethyl-2,3-bis(cis-9-
tetradecenyloxy)-1-propanaminium bromide); PEG-PEI (polyethylene glycol-
polyehtylenimine), poloxamer or polysaccharide based Nanocarriers. These delivery 
systems for nucleic acid have been in the process of clinical evaluations [37]. In 
addition to the aforementioned mechanisms, endosome rupture can also be achieved 
by photochemical internalization (PCI) technique, which will be discussed in details in 
the following section. 
 
Table 1.7. Non-viral gene delivery vehicles with endosomal escape modalities under 
clinical evaluation [37]. 
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1.3 Photochemical internalization (PCI) and photodynamic therapy (PDT) 
1.3.1 Photosensitizing reaction 
    Photosensitizers are molecules in which photosensitizing reaction occurs when 
activated by light irradiation. The photosensitizer is excited by absorption of photons 
with appropriate wavelength, and reaches the first excited singlet state. The 
deactivation of photosensitizer in singlet state via an intersystem crossing leads to the 
excited triplet state [38]. The lifetime of the triplet state is relatively long so that the 
excited photosensitizer has enough time to encounter other molecules and lead to two 
types of photosensitizing reactions [38], as illustrated in Figure 1.4. Firstly, the triplet 
photosensitizer can react directly with a substrate to form free radicals by transfer of a 
proton or an electron (type-1 reaction) [39]. These radicals can further interact with 
oxygen and form reactive oxygen species (ROS). Secondly, the triplet photosensitizer 
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can also transfer its energy directly to molecular oxygen, to form excited singlet 
oxygen (type-2 reaction) [39]. The production of singlet oxygen or ROS is considered 
to be a key factor to evaluating the efficacy of photosensitizing reactions. 
 
Figure 1.4. Schematic illustration of photosensizting reactions [39]. 
 
1.3.2 Photosensitizers for photodynamic therapy (PDT) 
    Photodynamic therapy (PDT), a photosensitizer-based anti-tumor treatment, 
enables the localized therapeutic effect by the application of light, and provides a 
promising strategy as an alternative and complementary modality for the conventional 
chemotherapy [40]. In PDT, the administration of photosensitizers is followed by the 
application of light irradiation to the tumor site. Upon irradiation, photosensitizers 
generate ROS and singlet oxygen via photon-induced energy transfer, and anti-tumor 
effect is achieved via the direct inhibition of tumor cells, vasculature damage in tumor 
tissues, and enhancement of host immune process in response to PDT. The PDT 
efficacy is attributed to the chemical structures of the photosensitizers. Figure 1.5 
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shows the basic structure of the most commonly studied photosensitizers for PDT: 
porphyrin, chlorin, bacteriochlorin and phthalocyanine. The PDT photosensitizers are 
usually planar and aromatic. The core structure is called “macrocycle” which is 
composed of four pyrroles linked by azone bridges in the case of phthalocyanine or by 
methine bridges for the others [41]. The extensive aromatic structure (i.e. π-
conjugation) enables photosensitizers to absorb light in the visible region of light 
spectrum. The absorption spectra among these compounds are similar with a strong 
peak at around 400 nm called Soret band and other weaker bands between 600 nm and 
800 nm called Q-bands [42]. The extended π-conjugation in these molecules results in 
lower electronic repulsion and therefore lowers the energy of the molecular states 
involved. A lower transition energy (ΔE) results in longer absorption wavelength. As a 
result, the maximum absorption of porphyrin is around 630 nm, shorter than the peak 
absorption of chlorin at 650 nm and phthalocyanine at 670 nm [41]. 
Figure 1.5. Common photosensitizers for photodynamic therapy. 
 
1.3.3 Challenges for PDT photosensitizers  
    A good photosensitizer should absorb photons efficiently, have a high quantum 
yield of triplet formation, and the triplet state should exhibit enough lifetime to react 
with neighboring target molecules such as molecular oxygen [42]. However, 
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aggregation is a common phenomenon for most chlorin and phthalocyanine based 
PDT-photosensitizer. The fluorescence and the singlet oxygen quantum yields of 
aggregated species are lower than those of monomeric form [43]. Aggregation of the 
photosensitizer reduce the probability of the photosensitizer to undergo intersystem 
crossing, and most of the energy in the excited state will be dissipated through non-
radiative decay, producing only heat [44]. Even dimers of some photosensitizers could 
be photochemically inactive [43]. In addition, the formation of large-scale aggregates 
upon systemic injection of hydrophobic photosensitizer may considerably modify their 
pharmacokinetics as compared to monomer forms [45], and hence impact the PDT 
efficacy. Binding of photosensitizers to proteins, other macromolecules or nano-
delivery vehicle, are reported [46] to increase the lifetime of the triplet state, enhance 
the monomerization of aggregated species, and improve the efficacy of PDT. 
 
1.3.4 Nano-delivery vehicles for PDT 
    Due to the minimized toxicity of photosensitizer in the absence of light, which 
reduces the risk of systemic toxicity in normal tissues, PDT provides a promising 
strategy as an alternative and complementary modality in addition to the conventional 
chemotherapy. Several PDT photosensitizers [47] such as Photofrin®, Levulan® and 
Visudyne®, have been clinically approved for the treatment of head and neck cancer, 
skin cancer, etc. However, there’re also several challenges that impact the efficiency 
of PDT via direct administration of photosensitizers [45]. In addition to aggregation, 
most PDT photosensitizers are highly hydrophobic and difficult to be incorporated 
into intravenously deliverable formulations. Due to the lack of tumor selectivity, the 
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direct administration of PDT photosensitizers can lead to the accumulation of 
photosensitizers in easily light-exposed normal tissues like the eyes and skin, which in 
turn result in prolonged phototoxicity and photosensitivity in patients when exposed to 
ambient light. 
    The nano-delivery vehicles can provide an effective approach to resolve the 
challenges associated with intravenous administration and selective delivery of the 
photosensitizers to tumor tissues [48]. Enhanced tumor-specific delivery [36] can be 
achieved by nano-delivery vehicles that keep the photosensitizers in circulation for 
longer periods of time (by preventing renal clearance and non-specific uptake) and 
allow increased uptake within the tumors via extravasation through the tumor-
associated leaky vasculature (the enhanced permeation and retention or EPR effect).  
Various nanoparticles [45] have been reported for the encapsulation and controlled 
release of photosensitizers. Table 1.8 summarized the nano-delivery vehicles for PDT 
photosensitizers that exhibited enhanced PDT efficiency in the inhibition of tumors 
both in vitro and in vivo. 
  
Table 1.8. Studies reported on nanoparticle-based formulation of PDT 
photosensitizers [45]. 
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1.3.5 Photosensitizers for photochemical internalization (PCI) 
    Photochemical internalization (PCI), developed by Berg and colleagues [49], is a 
highly efficient technology which takes advantage of photochemical rupture of 
endocytic vesicles by light-activated photosensitizers and enables the cytosolic release 
of therapeutic agents. Different from PDT, PCI helps to further improve the anti-tumor 
efficacy of other therapeutic agents, instead of the photosensitizers themselves take the 
lead in the inhibition of tumors.   
    It was documented that many photosensitizers enter the cells via pinocytosis 
pathway, and target endolysosomes [50]. However, not all photosensitizers that 
localized in endolysosomes are suitable as PCI-photosensitizers. In the chemical 
structure of photosensitizers, the hydrophobic/hydrophilic balance is modulated by the 
presence of lipophilic and charged side-chains around the macrocycle. The general 
findings have shown that hydrophobic photosensitizers bearing a few negative charges 
can enter the cells via receptor-mediated endocytosis and redistribute between the 
membranes of endolysosomes, while hydrophilic photosensitizers with many positive 
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or negative charges are too polar to be inserted into the endolysosomal membrane [51]. 
PCI-photosensitizers are a class of amphiphilic phthalocyanine, porphine or chlorin 
derivatives, with proper number of polar substitution groups on the macrocycles, that 
exhibit specific affinity with the membrane of endolysosomes. 
   Typical PCI photosensitizers include aluminum phthalocyanine disulfonate 
(AlPcS2a), tetraphenylporphine disulfonate (TPPS2a) and tetraphenylchlorin 
disulfonate (TPCS2a or Amphinex), and their chemical structures are shown in Figure 
1.6.  The two sulfonate groups on the macrocycles render the amphiphilic properties 
of the PCI photosensitizers, and effective endolysosomal rupture upon light irradiation 
were reported [52]. The activation wavelength is 660 to 670 nm for AlPcS2a, and 430 – 
450 nm for both TPPS2a and Amphinex [49]. In this regard, AlPcS2a may be preferable 
to TPPS2a or Amphinex for in vivo utilization, due to the better penetration depth of 
red light in tumor tissues. 
 
Figure 1.6. Chemical structures for typical PCI photosensitizers. 
 
1.3.6 PCI-facilitated delivery of macromolecular therapeutics 
    Membrane impermeable macromolecular therapeutics are internalized by cells 
via endocytosis and are usually sequestered in the endocytic vesicles before being 
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subsequently degraded by the digestive enzymes in lysosomes, hence greatly hinder 
their therapeutic efficacy. Photochemical rupture of endolysosomal membrane enables 
the release of such macromolecular therapeutics into cytosol, to further fulfill their 
biological functions. PCI effect has been demonstrated in >80 different cell lines and 
>10 different xenograft models of various cancers [51], and improve the delivery and 
efficacy of the following macromolecular therapeutics. 
    Gene delivery. PCI has been studied as a tool to facilitate gene delivery both with 
several non-viral and adenoviral vectors, by using reporter genes [53] such as genes 
encoding EGFP (enhanced green fluorescent protein) or p53 tumor suppression gene. 
In an in vivo study by Ndoye et al. [54], mice xenograft with p53-mutated head and 
neck squamous carcinomas was treated by intratumoral injection of the photosensitizer 
AlPcS2a and a plasmid encoding p53 complexed to a glycosylated polyethyleneimine, 
which resulted in dramatic tumor regression in all the transfected animals. Mice 
receiving plasmid DNA alone (without PCI) or receiving PCI treatment but not 
plasmid didn’t exhibit any delay in tumor growth, which suggest that PCI-facilitated 
enhancement of gene delivery was essential to achieve good therapeutic effect. 
  Protein and peptide. Bleomycin is a water-soluble glycopeptidic antibiotic (1.4 
kDa) used in a number of cancer chemotherapies, notably squamous carcinomas and 
malignant lymphomas [55]. As few as 500 bleomycin molecules that translocated to 
cytosol are sufficient to induce cell death in combination with electroporation in vitro 
[55]. However, bleomycin penetrates membrane structures poorly and accumulates in 
endocytic vesicles. Berg et al. [56] demonstrated the in vivo synergistic effect between 
bleomycin and the PCI effect by AlPcS2a on human squamous carcinoma xenograft 
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model, in which curative response was observed in 60% of the tumor bearing mice 
that received PCI of bleomycin, while tumor control was absent in animals receiving 
bleomycin only. In addition, the preclinical data indicated that PCI of bleomycin in 
combination with surgery or external-beam radiotherapy on patients is a promising 
treatment modality that may reduce the need for mutilating surgery or toxic radiation 
effects, and hence improved local tumor control [51]. 
  Nano-delivery vehicles. Nano-delivery vehicles enter cells via endocytosis. 
Except ultra-small gold nanoparticles (2-10 nm) [57], which were identified in nucleus 
and cytoplasm, endolysosomal sequestration and subsequent degradation was 
inevitable if the nano-carriers are not engineered to escape endolysosomes. PCI also 
potentiate the intracellular delivery performance of nano-delivery vehicles. Yen et al. 
[58] reported an augmented anti-tumor efficiency of poly(ethylene glycol)-poly(lysine) 
(PEG-PLys) micelles conjugated with camptothecin via disulfide linkage, when 
endolysosomal escape was achieved from the PCI effect of free photosensitizer 
photofrin. Lu et al. [59] reported PEG-PLys micelles incorporated with zinc 
phthalocyanine dendrimer that exhibited light-facilitated reversal of doxorubicin 
resistance in MCF-7/ADR both in vitro and in vivo. The sequestration of cationic 
doxorubicin hydrochloride in acidic endocytic compartments of MCF-7/ADR cells 
was reported as one the mechanism for doxorubicin resistance in MCF-7/ADR cells, 
and the PCI-facilitated cytosolic release bypass the endolysosomal sequestration of 
doxorubicin, and effectively enhanced the antitumor efficiency compared to the 
groups treated with doxorubicin but not receiving PCI. 
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1.4 Antigen Cross-presentation and cancer immunotherapy 
1.4.1 Antigen processing and presentation 
    Unlike other immune cells, T cells receptor can only recognize antigen in the 
form of peptide binding with MHC (major histocompatibility complex) molecules on 
the surface of antigen presenting cells. To be recognized by T cells, protein antigens 
need to be degraded into peptide intracellularly, and the process is termed as antigen 
processing [60]. The complex assembled from degraded peptide and MHC molecules 
are displayed on the surface of antigen presenting cells such as dendritic cells, 
macrophages, and B cells, etc., and can be recognized by T cells. The process in which 
the complex of peptide /MHC molecules form, translocate to cell surface and 
communicating with T cells, is termed as antigen presentation [60]. The major 
pathways for antigen presentation, including MHC class I presentation and MHC class 
II presentation, are illustrated in Figure 1.7.  
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Figure 1.7. Pathways for antigen presentation [61]. 
 
1.4.2. MHC class I and class II pathway 
    In MHC class I presentation pathway [62], endogenous protein antigens are 
degraded into peptides that can be bounded by MHC class I molecules and presented 
to CD8 T cells. Protein antigens in cytosol are degraded by a large barrel-shaped 
protein complex called the proteasome, which provide several different protease 
activities. The proteasome consists of 28 polypeptide subunits, each of 20-30 kDa. 
Antigenic peptide degraded by proteasome are transported into endoplasmic reticulum 
by transporter associated with antigen processing (TAP). Meanwhile, MHC class I 
heavy chains and β2-mircoglobulin are also translocated to the endoplasmic reticulum, 
where they assembled and bind with the degraded peptide. The peptide-bound MHC 
class I molecules are released from the endoplasmic reticulum and formed closed-
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membrane vesicles before they are transported to the plasma membrane and present to 
CD8 T cells (killer T cells), the major function of which is to kill cells that have been 
infected with virus or pathogens.  
    Alternatively, most exogenous protein antigens are internalized by antigen 
presenting cells via pinocytosis or phagocytosis and presented by MHC class II 
pathway [63]. The internalized exogenous protein antigens are sequestered in endocytic 
vesicles which contains protease and hydrolase, and degraded to produce antigenic 
peptides. Meanwhile, MHC class II α and β chains are assembled with invariant chain, 
before they translocate to the endocytic vesicle, bind with the antigenic peptide and 
dissociated with invariant chain. The peptide-bound MHC class II molecules are 
delivered to plasma membrane by outgoing vesicles, and present to CD4 T cells 
(helper T cells), which help other cells in the immune system to respond to infection. 
 
1.4.3. Cross-presentation for cell-based cancer immunotherapy 
  The protein antigens for the above two are mostly virus-derived protein, infected 
cell bodies, etc. However, antigen presenting cells are also able to process exogenous 
antigen protein such as vaccines, by MHC class I pathway, and this presenting process 
is termed as cross-presentation, and potentiate CD8 T cell response. The cross-
presentation of vaccines [64] also involves the endocytosis of the antigen, degradation 
of the antigen in proteasome, the display of immune complex from the degraded 
antigenic peptide on the surface of antigen presenting cells, and the communication 
with CD8 T cells. The cross-presentation implies some connection between class I 
(degradation of antigen occurs in cytosol, instead of endocytic vesicles) and class II 
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pathways (endocytosis of exogenous antigen), however, the detailed mechanism and 
signaling pathways for cross-presentation is still not clearly defined. Cross-
presentation enables the induction of cytotoxic immunity by vaccine antigens, and 
provides rationale for cell-based cancer immunotherapy. 
  Ovalbumin is the model antigen to study cross-presentation. Cytosolic ovalbumin 
is degraded in proteasome to produce SIINFEKL peptide (OVA 257-264), SIINFEKL 
binds with murine MHC class I molecule H-2Kb and elicit cross-presentation and 
CD8 T cell response [65]. However, ovalbumin in endocytic vesicles is degraded into 
OVA 323-339 peptide, and the subsequent immune response is restricted to MHC 
class II pathway [66].  
  Suppression of immune response is common in tumor local environment [67], and 
cell-based immunotherapy takes advantage of tumor antigens to elicit CD8 T cell 
response in vivo. Many studies [68] have demonstrated that the generation of anti-tumor 
immunity depends on the cross-presentation of tumor antigens by dendritic cells. 
Studies [69] also suggested that dendritic cells can capture tumor antigens, and cross-
present these antigens to T cells in tumor-draining lymph nodes. This results in the 
generation of tumor-specific CD8 T cells, or cytotoxic lymphocytes (CTLs) that 
contribute to tumor depletion. 
 
1.4.4. Protein/peptide vaccines for cancer immunotherapy 
    Epitope peptide and full-length proteins which binds to MHC molecules could 
have the potential to elicit tumor immunity. However, the immunogenicity of 
protein/peptide vaccine are usually low, and adjuvants become necessary component, 
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that functions to activate, mature, and recruit cells of the innate immunity, which in 
turn provide the stimulatory signals essential for the adaptive immune response to 
tumor [70]. For example, vaccination using a full-length recombinant MAGE-A3 
protein with an immune-stimulant adjuvant GSK (a detoxified derivative of the 
lipopolysaccharide of the gram negative bacterium salmonella minnesota R595 strain) 
[71], showed superior induction of humoral and cellular responses in patients with 
resected non-small cell lung cancer and possibly clinical activity in patients with 
metastatic melanoma in phase 2 studies. Another novel vaccine design [72], containing 
a glycosylated Muc1 peptide, and the immuno-adjuvant Pam3CysSk4, a toll-like 
receptor 2 agonist, induced both humoral and cellular responses to glycosylated Muc1, 
and reduced tumor growth was observed in a mouse breast tumor model. 
    Heat shock proteins function as molecular chaperones that assist 
folding/unfolding and transport of proteins across membranes and prevent protein 
aggregation after environmental stress [73]. Extracellularly localized and membrane-
bound heat shock proteins have been found to play key roles in eliciting antitumor 
immune responses by acting as carriers for tumor-derived immunogenic peptides, as 
adjuvants for antigen presentation, or as targets for the innate immune system [74]. The 
interaction of heat shock proteins with receptors on antigen-presenting cells promotes 
the maturation of dendritic cells, results in an upregulation of MHC class I and class II 
molecules, induces secretion of pro- and anti-inflammatory cytokines, chemokines, 
and immune modulatory nitric oxides, and thus integrates adaptive and innate immune 
phenomena [75]. Intratumoral delivery of exogenous heat shock protein Hsp70 in a rat 
glioblastoma model caused a significant inhibition of tumor progression [76], which as 
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accompanied by an increased cytotoxic activity of NK cells and CD8 T lymphocytes. 
A comparable therapeutic efficacy was also reported by Rafiee et al. [77] in which a 
complete tumor eradication following transfection of the hsp70.1 gene sequence into 
mouse tumor cells. 
    Other vaccines are also developed including cell-based vaccines [78] and 
neoantigens [79]. Ex vivo preparation of matured dendritic cells, or gene-modified 
whole tumor cells for improved immune-activation can also be included in 
combination with protein/peptide vaccine. In general, clinical efficacy of cancer 
immunotherapy is still challenged by the following issues [70], such as selection of 
antigen/epitope for optimal binding to MHC molecules; suitable adjuvant for 
immunogenicity and improved immunological outcome; presence of regulatory cells 
that suppress immune activation, etc.   
 
1.4.5 Nano-delivery vehicles for protein based tumor vaccine 
  Good delivery vehicles for protein based tumor vaccine should 1) mimic the 
composition and immunological processing of actual pathogens; 2) actively or 
passively target the antigen presenting cells such as dendritic cells; 3) protect the 
protein vaccine from premature degradation; 4) induce the maturation of antigen 
presenting cells and direct the subsequent immune response. Nanoparticle based 
vaccine delivery system has been developed to overcome limitations that include 
inherent instability of soluble antigens, low internalization efficiency of soluble 
antigens, and insufficient cross-presentation to activate CD8 T cells. Nanoparticle 
based vehicles provided protection against premature degradation of payloads, and 
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exhibited targeted delivery and sustained release of protein antigens, controllable 
interaction with antigen presenting cells, and multivalent presentation, etc.  The 
polymeric based nano-delivery systems for various antigens were summarized in 
Table 1.9, and poly (γ-glutamic acid) (PGA), N-trimethyl chitosan (TMC), 
poly(lactide-co-glycolide) (PLGA) are most extensively studied polymers as 
nanocarriers for vaccine delivery. 
 
Table 1.9. Polymeric nanocarriers as delivery systems for antigens [80]. 
 
 
In the study by Shima et al. [81], nanoparticles from amphiphilic poly (γ-glutamic 
acid)-graft-L-phenylalanine ethyl ester (γ-PGA-Phe) were developed as the delivery 
vehicles for ovalbumin. By modulating the hydrophobicity (the grafting ratio of 
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phenylalanine) of the amphiphilic polymer, optimized encapsulation of ovalbumin was 
achieved and the activation of dendritic cells, as well as the induction of antigen-
specific cellular immunity-based immune responses, were also dependent on the 
chemical/physical properties of the nano-carriers.  γ-PGA-Phe nanoparticles with 
65% to 71% grafting degree of phenylalanine resulted in optimized encapsulation of 
ovalbumin, and stimulated maximum level of cellular immunity in dendritic cells, by 
enhancing the secretion of various cytokines (TNF-α, IL-6, and IL-12, etc). The 
activated cellular immunity by γ-PGA-Phe (65%-71%) was 30-hold higher than the 
free antigen.  Reddy et al. [82] developed ovalbumin loaded polypropylene sulfide 
nanoparticles and reported a size-dependent immunity in mice, in which they proved 
that interstitial flow transported ultra-small nanoparticles (25 nm) highly efficiently 
into lymphatic capillaries and draining lymph nodes, which was much efficient than 
greater nanoparticles (100 nm) in targeting the lymph node residing dendritic cells. In 
addition, the surface functional group also impact the efficiency to induce the 
maturation of dendritic cells and the activation of subsequent immunity. The 25 nm 
nanoparticles with polyhydroxylated surface induced significantly enhanced dendritic 
cell maturation compared to the polymethylated or polycarboxylated counterparts. The 
effect of vaccination of ovalbumin loaded 25-nm polyhydroxylated nanoparticles was 
comparable to that of LPS, which is a typical immunogenic effector and ligand for 
toll-like receptor 4.  Shen et al. [83] developed poly(lactide-co-glycolide) (PLGA) 
nanoparticles encapsulated with ovalbumin which enhanced the cellular uptake of 
ovalbumin and induced T cell responses. While macropinocytosis of soluble 
ovalbumin leads to poor MHC class I presentation by dendritic cells, phagocytosis of 
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ovalbumin-loaded PLGA nanoparticles enhanced cross presentation, leading to potent 
responses of CD8 T cells. The MHC class I presentation of ovalbumin-loaded PLGA 
nanoparticles stimulated T cell interleukin-2 secretion at 1000-fold lower 
concentration than free ovalbumin. 
 
1.5 Conclusions 
  In the design of polymeric delivery carriers for chemotherapeutics, 
photosensitizers or vaccines, it is critical to elucidate the intracellular fate and specific 
interaction between nano-carriers and cells. The cell-vesicles interactions proved 
rationale for the design of environmental responsive and site-specific delivery system 
in response to a series of endogenous cues (enzyme, acidic pH, redox potential, etc.) 
as well as exogenous stimuli (light, temperature, ultrasounds, electric field, etc). 
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CHAPTER 2 
 
A PSEUDO-PROTEIN BASED BIODEGRADABLE MICELLAR PLATFORM 
FOR THE DELIVERY OF ANTI-CANCER DRUG: PHOTO-ENHANCED 
STRUCTURAL STABIITY, UNIQUE INTRACELLULAR TRAFFICKING AND 
IN VITRO THERAPEUTIC EFFECT IN HUMA COLON CANCER CELLS 
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2.1 Abstract 
    Amino acid based poly (ester amide)s (AA-PEA) is a new family of 
biodegradable polymers that exhibits "pseudo-protein" characteristics and the 
structural varieties of AA-PEAs make them hold great potential in multiple biomedical 
applications. In this study, a lysine-phenylalanine based AA-PEA is developed as the 
self-assembled nano-micellar carrier for efficient delivery of doxorubicin (DOX). The 
lysine moieties from the pseudo-protein provided available sites for further 
functionalization, and methylcoumarin was introduced for easy and photo-controllable 
crosslinking, to effectively improve the micellar stability in serum containing 
environment and against dilution. However, photo-crosslinks did not bring in any 
barrier for the intracellular release of DOX. DOX release was significantly accelerated 
by the presence of proteolytic enzyme, due to the biodegradability of pseudo-protein 
micelles. In addition, pseudo-protein delivery system exhibited unique interactions 
with HCT116 human colon cancer cells. DOX loaded in pseudo-protein micelles co-
localized with mitochondria and endolysosomes, while free DOX was distributed only 
in the nuclei. Beside the difference in intracellular trafficking, DOX-loaded pseudo-
protein micelles stimulated increased level of intracellular reactive oxygen species and 
mitochondrial damage. Free DOX induced conditional apoptosis in HCT116 cells 
between 0.5-2 μM, while DOX loaded in pseudo-protein micelles induced apoptosis 
over a higher/broader concentration range (2-10 μM). 
 
2.2 Introduction  
  Polymeric micelles as nano-carriers for chemotherapeutics have gained 
considerable popularity in the study of cancer treatment. The micellar carriers 
provide physical or chemical encapsulation of drugs in their hydrophobic cores, 
and have the potential to improve the pharmacological [1]. However, polymeric 
micelles are facing several practical challenges that significantly limit their 
therapeutic efficacy. One of the major challenge lies in their instability in 
physiological environment [2]. Self-assembled polymeric micelles are 
thermodynamically in equilibrium with their unimers. After intravenous 
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administration, micellar carriers receive instant dilution below their critical 
micelle concentration (CMC), which leads to significant disintegration of the 
micellar structure [3]. In addition, the interaction with blood components, such as 
plasma proteins, is reported to disrupt the thermodynamic equilibrium between 
micelles and unimers, resulting in unwanted micelle collapse [4]. The loss of 
structural integrity causes the premature release of drugs from the carrier, which 
generates toxicity and adverse effects in normal organs.       
  Chemical crosslinking of micelle is one of the most common approaches to 
overcome the physiological destabilization forces. By introducing 
polymerizable moieties, multifunctional reactive agents [5], or functional groups 
for host-guest interactions [6], crosslinking can be established in the shell, core 
or intermediate layer of micelles. Coumarin-based photochemical crosslinking 
is a newly emerged crosslinking technique which takes advantage of the 
reversible photodimerization of coumarin activated by UV irradiation at two 
different wavelengths [7]. As demonstrated by Zhao et al. [8], micelle 
stabilization was achieved by the formation of photo controllable core-
crosslinks between coumarin functionalized poly(methyl methacrylate) chains. 
Other studies [9-12] also incorporated coumarin photo-crosslinks to improve the 
stability of various nanocarriers, including a series of biodegradable or non-
degradable polymers. However, since crosslinking brings in barriers for the 
encapsulated molecules to diffuse out of the micelles, it causes slow/insufficient 
release of payloads inside cancer cells and hinders the potency of micellar 
carriers.  
  The pitfall of the crosslinking approach to stabilize micelles makes the 
concept “stabilization-on-demand” [8] quite appealing, and provides an incentive 
for the development of smart delivery systems that can be destabilized upon 
intracellular signals. By modulating polymer characteristics, such as the 
susceptibility towards intracellular stimuli (acidic pH, redox potential or 
specific enzymes, etc.) [13, 14], rapid release of payloads in cancer cells can be 
achieved, while the extracellular stability is still maintained.  Numerous design 
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concepts and tailor-made polymers have therefore emerged, and biodegradable 
polymeric micelles [15-17] are an attractive option over the non-degradable ones 
due to the unelucidated long term toxicity of the latter.  
  Amino acid based poly (ester amide)s (AA-PEA) is a new family of 
synthetic pseudo proteins recently developed for several biomedical 
applications ranging from synthetic skin, coating for drug-eluting stents, to drug 
delivery vehicles. The details have recently been given in several review articles 
[18-20]. AA-PEA is synthesized from 3 building blocks: amino acids, diols and 
diacids, and has both ester and amide groups on the polymer backbone as 
available sites for enzymatic degradation. AA-PEA exhibits both protein and 
non-protein characteristics, and our previous work have demonstrated the 
unique advantages of AA-PEA, which include reproducible synthetic routes, 
versatile structural design, enzymatic biodegradation, excellent 
biocompatibility, and muted inflammatory response, etc. By selecting different 
types of amino acids, diols, and adjusting the number of hydrocarbons between 
ester and amide groups, AA-PEA materials are tunable in charge density, 
hydrophobicity/hydrophilicity, as well as the reactive sites for further chemical 
functionalization. Chu et al. have demonstrated that arginine or lysine based 
PEAs facilitated the penetration through cell membrane and worked as effective 
delivery systems for therapeutic agents including genes [21-24]. 
    The aim of the study is to develop a novel biodegradable pseudo protein 
micelle as an intracellular drug delivery vehicle. Lysine-phenylalanine PEA is 
chosen based on our preliminary study [21]. And to improve the extracellular 
stability, coumarin functional groups is introduced into the hydrophobic 
segments of the polymer chains so that reversible photo-crosslinking can be 
established. The modified pseudo protein is abbreviated as Lys-Phe-PEAcou-
PEG. Doxorubicin (DOX), one of the most typical anticancer drugs employed in 
the clinical use, is chosen as the model drug for examining the delivery 
performances. Previous work suggested the apoptotic death of HCT116 colon 
cancer cells is conditional with respect to the concentration of DOX [25, 26]. 
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However, of the biodegradable micellar systems investigated so far in the 
literatures, very few studies addressed the dose-dependent interaction between 
DOX-loaded micelles and cancer cells. In this contribution, we not only study 
the effect of photo-crosslinking on the stability of the Lys-Phe-PEAcou-PEG 
micelles, as well as the effect of enzymatic degradation on the in vitro release of 
DOX from the crosslinked micelles. But we also focus on the endocytosis, 
subcellular distribution, and the dose-dependent interaction between DOX-
loaded Lys-Phe-PEAcou-PEG micelles and HCT116 colon cancers cells. 
 
2.3. Experimental  
2.3.1 Chemicals and cells 
    N-Hydroxysulfosuccinimide-polyoxyethylene-maleimide (NHS-PEG-
MAL, MW=2000 Da) was from JenKem Technology (Allen, TX). 7-
(carboxymethoxy)-4-methylcoumarin, thionyl chloride, nile red, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), α-chymotrypsin 
(Type II, from bovine pancreas), methyl-β-cyclodextrin, cobalt chloride, 
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) and QuantiPro BCA Assay 
Kit were from Sigma Aldrich (Milwaukee, WI). Dimethyl sulfoxide (DMSO), 
ethyl acetate and other HPLC grade solvents were from JT Baker (Phillipsburg, 
NJ). Dipeptide cysteine-lysine with amidation at C-terminus of cysteine was 
synthesized by GL Biochem Ltd. (Shanghai, China). Doxorubicin hydrochloride 
was from Lancrix Chemicals (Shanghai, China). Mitotracker deep red FM, 
Mitotracker green, Lysotracker deep red, Lysotraker green, Hoechst 33342, 
SYTOX Red dead cell stain, DiL (1,1'-dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine perchlorate) and DiO (3,3'-
dioctadecyloxacarbocyanine perchlorate) were from Molecular Probes (Eugene, 
OR). Nystatin, chloropromazine, amiloride hydrochloride, JC-1 mitochondrial 
membrane potential assay kit, dihydroethidium (DHE), and calcein AM were 
from Cayman Chemical (Ann Arbour, MI). Annexin V apoptosis detection kit 
was from eBioscience (San Diego, CA). Cleaved caspase 3 western blot kit 
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were from Cell Signaling Technology (Beverly, MA). Snakeskin dialysis tubing 
(MWCO=3.5 kDa or 10 kDa) and NHS-Rhodamine were from Pierce 
(Rockford, IL). Z-LysNCA (ε-(benzyloxycarbonyl)-L-lysine N-
carboxyanhydride), Phe-4 (di-p-toluenesulfonic acid salt of bis-L-phenylalanine 
butane-1, 4-diester) and NA (di-p-nitrophenyl adipate) were synthesized from 
our previous study [21]. 
    HCT116 human colon carcinoma cell line was maintained in McCoy’s 5A 
medium (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum 
(Hyclone, Logan, UT), 2 mM L-glutamine, 100 units/mL penicillin, and 100 
μg/mL streptomycin (Lonza, Walkersville, MD) at 37 °C in 5% CO2.  
 
2.3.2 Characterization 
    1H NMR spectra were recorded on a Varian Unity Inova 400 MHz 
spectrometer (Palo Alto, CA), and deuterated dimethyl sulfoxide (DMSO-d6, 
Cambridge Isotope Laboratories) was used as the solvent. The chemical shifts 
were calibrated against solvent signals. The morphology of micelles was 
observed on a FEI Tecnai Spirit T12 TEM (FEI Co., Hillsboro, OR) at an 
operating voltage of 120 kV. Zeta potential and the size of the micelles were 
characterized at room temperature on a Zetasizer NanoZS system (Malvern, 
UK). UV-vis spectroscopy was performed on a Lambda Bio40 
spectrophotometer (Perkin-Elmer, Norwalk, CT). Fluorescence spectra was 
recorded on a PTI spectrofluorometer (Photon Technology International, South 
Brunswick, NJ). For the microplate assay, the absorbance or relative 
fluorescence units were read on a Synergy HT microplate reader (BioTek, 
Winooski, VT). Cells were visualized with a Zeiss LSM710 confocal 
microscope (Carl Zeiss MicroImaging, Thornwood, NY). Flow cytometry was 
performed on a BD FACSAria fusion fluorescence activated cell sorter (BD 
Biosciences, Franklin Lakes, NJ). 
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2.3.3 Synthesis of Lys-Phe-PEAcou-PEG polymer 
  Synthesis of lysine- phenylalanine based PEA (Lys-Phe-PEA). The 
synthesis of Lys-Phe-PEA with pendent amino groups was based on our 
published studies [21]. Z-LysNCA (1.28 g, 4.14 mmol) was mixed with Phe-4 
(5.78 g, 7.93 mmol) in N, N-dimethylacetamide (DMA, 30 mL) and stirred at 
40 °C for 3 hrs before the temperature was raised to 80 °C and kept for 24 hrs in 
nitrogen atmosphere. The reaction was subsequently cooled to room 
temperature. NA (3.08 g, 7.93 mmol) and trimethylamine (2.41 mL, 17.45 
mmol) were added and stirred at 80 °C for 24 hrs in nitrogen atmosphere. The 
feed ratio between Z-LysNCA, Phe-4 and NA was 1:1.9:1.9 [21]. The resulting 
solution was precipitated into cold ethyl acetate and dried in vacuo. The as 
prepared polymer (5 g) was dissolved in trifluoroacetic acid (20 mL) and stirred 
for 1 hr at room temperature before methanesulfonic acid (1.30 mL) dissolved 
in anisole (2.6 mL) was added. After stirring for additional 1 hr, the solution 
was precipitated into cold diethyl ether. The polymer was dissolved in DMA, 
neutralized with triethylamine, and precipitated into ethyl acetate. The de-
protected polymer, Lys-Phe-PEA, was dialyzed against ethanol for 48 hrs 
(MWCO=3.5 kDa), and dried in vacuo.  
  Synthesis of polyethylene glycol grafted Lys-Phe-PEA (Lys-Phe-PEA-
PEG). Lys-Phe-PEA polymers with various grafting ratio of polyethylene 
glycol were synthesized for PEGylation. To functionalize 45% of the total 
repeating units on Lys-Phe-PEA with PEG, Lys-Phe-PEA (100 mg) was 
dissolved in DMSO (20 mL) containing 178 mg of heterofunctional PEG (NHS-
PEG-MAL, MW=2000) and stirred at room temperature for 24 hrs. The reaction 
mixture was precipitated into ethyl acetate for three times and dried in vacuo. 
  Synthesis of methylcoumarin grafted Lys-Phe-PEA-PEG (Lys-Phe-
PEAcou). 7-(chlorocarbonylmethoxy)-4-methylcoumarin was prepared from 7-
(carboxymethoxy)-4-methylcoumarin and thionyl chloride based on published 
procedure [10]. To functionalize 5% of the total repeating units on Lys-Phe-PEA-
PEG with methylcoumarin, Lys-Phe- PEA-PEG from last step was dissolved in 
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THF (20 mL) with trimethylamine (13 μL). 7-chlorocarbonylmethoxy-4-
methylcoumarin (3 mg) in THF (1 mL) was added and stirred overnight in dark 
at room temperature. The resulted solution was precipitated three times into 
methanol and dried in vacuo. The purified polymer was dissolved in degassed 
DMSO (20 mL). Cysteine-lysine dipeptide (25 mg) in degassed DI water (2 
mL) was added, stirred overnight at room temperature and dialyzed against DI 
water (MWCO=3.5 kDa) for 48 hrs. The purified Lys-Phe-PEAcou-PEG was 
lyophilized.  
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Figure 2.1. Synthesis scheme for A) lysine-phenylalanine based PEA (Lys-Phe-
PEA), B) polyethylene glycol grafted Lys-Phe-PEA (Lys-Phe-PEA-PEG), and 
C) methylcoumarin grafted Lys-Phe-PEA-PEG (Lys-Phe-PEAcou-PEG). 
 
2.3.4 Preparation and characterization of photo-crosslinked Lys-Phe-PEAcou-PEG 
micelles 
    Aqueous dispersion of Lys-Phe-PEAcou-PEG micelles (1 mg/mL) was 
exposed to 365 nm irradiation (model B-100AP; UVP, Upland, CA) for 3 hrs at 
room temperature. The photo-crosslinking process was monitored with UV-vis 
spectroscopy. To prepare the de-crosslinked micelles, aqueous dispersion of 
completely crosslinked Lys-Phe-PEAcou-PEG micelle (1 mg/mL) was exposed 
to 254 nm irradiation (model UVGL-25; UVP, Upland, CA) for 1 hr. The 
critical micelle concentration (CMC) of the Lys-Phe-PEAcou-PEG micelles was 
determined with nile red assay according to previous study [27].   
 
2.3.5 Effect of serum and enzyme on the stability of micelles 
  Lys-Phe-PEAcou-PEG (10 mg) was dissolved in DMSO followed by 
addition of DiO (100 μg) and DiL (100 μg). The mixture was stirred for 30 min 
and dialyzed (MWCO=3.5 kDa) against DI water for 24 hrs.  The dialyzed 
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solution was filtered through a 0.45 µm microfilter and subjected to UV 
irradiation to prepare the crosslinked FRET micelles. 
  To evaluate the effect of serum on micellar stability, the crosslinked or 
uncrosslinked FRET micelles were dispersed in 10 mM PBS (pH=7.4) and 
mixed with fetal bovine serum (FBS) (1:9 v/v, with the final micelle 
concentration of 0.1 mg/mL) at 37°C for up to 48 hrs, 
     To evaluate the effect of proteolytic enzyme on micellar stability, 
crosslinked or uncrosslinked FRET micelles were dispersed in 10 mM PBS 
containing 0.2 mg/mL α-chymotrypsin for up to 48 hrs.  
     The fluorescence emission spectra of FRET micelles after incubation with 
FBS or enzyme was measured (λex=470 nm). And FRET ratio was calculated as 
follows: 
FRET ratio =  
𝐼𝐷𝑖𝐿
𝐼𝐷𝑖𝐿 + 𝐼𝐷𝑖𝑂
 
where IDiL represents the fluorescence intensity at 565 nm and IDiO represents 
the fluorescence intensity at 501 nm. 
       
2.3.6 Preparation of doxorubicin-loaded crosslinked Lys-Phe-PEAcou-PEG 
micelles 
    Doxorubicin hydrochloride (15 mg) was dissolved in DMSO (5 mL) with 
trimethylamine (7.2 µL) and stirred overnight, followed by the addition of Lys-
Phe-PEAcou-PEG (100 mg) in DMSO (10 mL). The mixture was stirred for 
another 2 hrs before DI water (6 mL) was added dropwise. DMSO and unloaded 
drug were removed by dialysis (MWCO=10 kDa) against DI water for 48 hrs. 
The dialyzed solution was filtered through a 0.45 µm microfilter, and subjected 
to UV irradiation at 365 nm as described in section 2.4 to prepare DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles.  
    To determine the drug loading content (DLC) and encapsulation efficiency 
(EE), the solution of crosslinked DOX-loaded Lys-Phe-PEAcou-PEG micelles 
was irradiated by 254 nm UV light for 1 hr to facilitate the photo-cleavage of 
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methylcoumarin dimer. The de-crosslinked micelles were then lyophilized and 
dissolved in DMSO. DOX content was determined by fluorescence 
spectroscopy (λex=480 nm) and calibrated with DOX standard curve.  
 
2.3.7 In vitro DOX release from Lys-Phe-PEAcou-PEG micelles 
    DOX release from Lys-Phe-PEAcou-PEG micelles were examined in 10 
mM phosphate buffer (pH 5.5) with or without the presence of α-chymotrypsin. 
DOX-loaded Lys-Phe-PEAcou-PEG (5 mg, either crosslinked or uncrosslinked) 
dissolved in 10 mM phosphate buffer (pH 5.5, 5mL) with α-chymotrypsin (0.2 
mg/mL) was dialyzed (MWCO=10 kDa) against phosphate buffer (pH 5.5, 30 
mL) at 37 °C under shaking (100 rpm). At pre-determined time intervals, 5 mL 
of buffer outside the dialysis tubing was withdrawn and replaced by 5 mL of 
fresh buffer. Release profile of DOX-loaded micelles dispersed in phosphate 
buffer (pH 5.5) without enzyme was also tested. DOX concentration in collected 
samples was determined by spectrofluorometer (λex=480 nm) and calibrated 
with DOX standard curve. The percentage of cumulatively released DOX was 
plotted vs. time. Each test was performed in triplicate. 
 
2.3.8 Cytotoxicity studies 
    Cytotoxicity of DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles 
was assessed by MTT assay as described previously [28]. HCT116 cells were 
incubated with blank crosslinked micelles, free DOX, or DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles for 48 hrs, with equivalent DOX 
concentration ranging from 0.05 to 20 μM. And the experiments were run in six 
replicates. The absorbance at 570 nm was recorded and normalized to untreated 
control to give the percentage of cell survival.  
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2.3.9 Endocytosis and subcellular localization study  
  Accumulated endocytosis study. HCT116 cells were seeded in 6-well plate 
(3 x 105 cells/well) and pre-incubated for 24 hrs. Free DOX or DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles with 2 μM equivalent DOX 
concentration were added and incubated for 1, 4, 8, 12 or 24 hrs, before the cells 
were harvested for flow cytometry test. The mean fluorescence from cellular 
DOX were plotted vs. time. The tests were performed in triplicate. 
  Endocytosis inhibition assay. HCT116 cells were seeded in 6-well plate (3 
x 105 cells/well) and pre-incubated for 24 hrs. The cells were treated with 
inhibitors that block different endocytic pathways (nystatin, 50 μg/mL; 
chloropromazine, 30 μM; amiloride hydrochloride, 50 μM; or methyl-β-
cyclodextrin, 3 mg/mL) [29, 30] for 0.5 hr before DOX-loaded crosslinked Lys-
Phe-PEAcou-PEG micelles with equivalent DOX concentration of 2 μM was 
added and incubated for another 4 hrs. The cells were harvested for flow 
cytometry test. Cells incubated with DOX-loaded micelles at 37°C but not 
treated with any inhibitor were tested as control. The mean fluorescence 
intensity for each sample was recorded and normalized to control. The tests 
were performed in triplicate. 
    Subcellular distribution. 3 x 105 HCT116 cells were seeded in a 35 mm 
glass bottomed petri dish (3 x 105 cells/well, MaTek, Ashland, MA) and pre-
incubated for 24 hrs. Blank crosslinked micelles labelled with rhodamine, free 
DOX or DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles with 
equivalent DOX concentration of 5 μM was added and incubated for 4 hrs. 
Cells were stained with specific organelle markers including Lysotracker (50 
nM), Mitotracker (500 nM) or Hoechst 33342 (1 μg/mL) and imaged alive by 
confocal microscopy. The Pearson’s coefficient was determined with Fiji 
software (National Institutes of Health). 
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2.3.10 Measurement of cellular reactive oxygen species (ROS) 
    The cellular ROS level was measured by dihydroethidium (DHE) probe 
[31]. HCT116 cells were seeded in black 96-well plate (0.5 x 104 cells/well) and 
pre-incubated for 24 hrs. Blank crosslinked micelles, DOX-loaded crosslinked 
Lys-Phe-PEAcou-PEG micelles, or free DOX with various DOX concentrations 
were added and incubated for 24 hrs. The cells were then stained with 1 μM 
DHE for 20 min [32]. The endpoint relative fluorescence unit was recorded 
(λex=530±25 nm, λem=590±35 nm). Cells treated with DOX only but not DHE 
probe were also tested and the DOX fluorescence was subtracted from the total 
fluorescence. The result was normalized to untreated control and plotted as a 
function of DOX concentration. The experiments were performed in triplicate. 
 
2.3.11 Assessment of MMP and MPTP 
    Mitochondria membrane potential (MMP) assay. HCT116 cells were 
seeded in a 6-well plate (3 x 105 cells/well) and pre-incubated for 24 hrs. Blank 
crosslinked micelles, free DOX or DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles with various DOX concentrations were added and incubated for 
another 24 hrs. The cells were stained with JC-1 probe as per manufacturer’s 
instruction and analysed by flow cytometry. Negative control (untreated cells) 
and positive control (cells treated with mitochondria uncoupler CCCP) were 
also tested. Each experiment was performed in triplicate. The percentage of cell 
population stained with higher level of JC-1 monomer and lower level of J-
aggregates was recorded.  
  Mitochondrial permeability transition pore (MPTP) assay. HCT116 cells 
were seeded in 35 mm glass bottomed petri dish (3 x 105 cells/well) and pre-
incubated for 24 hrs. Blank crosslinked micelles, free DOX or DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles with various DOX concentrations 
were added and incubated for 24 hrs. Cells were then incubated with calcein 
AM (1 μM) for 15 min at 37 °C with the presence of cobalt chloride (1 mM). 
The quenching of mitochondrial calcein fluorescence was visualized by 
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confocal microscopy. The fluorescence intensity normalized to the total number 
of cells was analysed with Fiji software (National Institutes of Health), 
expressed as the percentage to untreated control and plotted as a function of 
DOX concentration.    
  
2.3.12 Caspase assay and annexin V apoptosis assay 
  Caspase 3/7 activity. HCT116 cells were seeded in a black 96-well plate 
(0.5 x 104 cells/well) and incubated for 24 hrs. Blank crosslinked micelles, free 
DOX or DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles with various 
DOX concentrations were added and incubated for another 48 hrs. Caspase 3/7 
activity was assessed by Apo-ONE Homogeneous Caspase-3/7 assay kit 
(Promega, Madison, WI) as per manufacturer’s instruction. The fluorescence 
intensity was recorded (λex=485±20 nm, λem=528±20 nm) and normalized to 
untreated control. Each experiment was performed in triplicate. 
  Western blot for cleaved caspase 3.  HCT116 cells incubated with blank 
crosslinked micelles, DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles, 
or free DOX with various DOX concentrations were harvested, lyzed in RIPA 
buffer. Cell lysates, quantified with BCA assay, were separated by SDS-PAGE 
on tris-glycine gel (4-20%, Novex, San Diego, CA) and transferred to PVDF 
membranes (Bio-Rad Laboratories, Hercules, CA). The protein bands were 
immunostained and visualized with cleaved caspase-3 western detection kit 
(Cell Signaling Technology, Beverly, MA) as per manufacturer’s instruction. 
    Annexin V assay. HCT116 cells were seeded in a 6-well plate (3 x 105 
cells/well) and incubated for 24 hrs. Free DOX or DOX-loaded crosslinked Lys-
Phe-PEAcou-PEG micelles with various DOX concentrations were added and 
incubated for another 48 hrs. Cells (1 x 106) were harvested, stained with 
annexin V-FITC assay reagent (5 μL) in annexin binding buffer (100 μL), and 
further stained with SYTOX Red (5 nM). The percentage of early apoptotic 
cells (annexin V-FITC positive, SYTOX Red negative) was determined by flow 
cytometry. Each experiment was performed in triplicate.  
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2.3.13 Statistical analysis 
    The data are presented as mean values with standard deviations (SD). All 
data were analysed with one-way ANOVA, followed by Tukey’s multiple 
comparison tests, and p < 0.05 is considered statistically significant. 
 
2.4. Results and Discussion 
2.4.1 Synthesis and characteristics of Lys-Phe-PEAcou-PEG micelles  
 
 
 
Figure 2.2. A) Chemical structure and the formation of photo-crosslinked micelles 
from lysine-phenylalanine based poly (ester amide)s grafted with polyethylene glycol 
and methylcoumarin (Lys-Phe-PEAcou-PEG). B) Graphic illustration of the reversible 
photo-crosslinking/de-crosslinking process of DOX-loaded Lys-Phe-PEAcou-PEG 
micelles. 
 
  In the ungrafted Lys-Phe-PEA polymer, the Lys moieties accounts for 33% 
of total amino acid units in the polymer, based on calculation from 1H NMR. 
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And the ratio between the two repeating units (repeating unit A and B as 
indicated in Figure 2.1A) in the polymer chains of Lys-Phe-PEA, was calculated 
to be 50:50 [21]. Molecular weight of Lys-Phe-PEA was determined as Mn=14.1 
kDa, PDI=1.43. The characterization results of Lys-Phe-PEA polymer are 
consistent with our previously published data [21]. Figure 2.2 shows the generic 
chemical structure of the Lys-Phe-PEAcou-PEG with pendant methylcoumarin 
(MCM) in the Lys moiety as well as the schematic illustration of the reversible 
photo-crosslinking process. 
    Figure 2.3 shows the 1H NMR spectrum for Lys-Phe-PEAcou-PEG 
polymer. Typical peak for PEG was observed at 3.3 to 3.5 ppm, and typical 
peaks for methycoumarin functional group were observed at 2.42, 6.23, 6.95 
and 7.73 ppm, which prove the successful grafting of the two molecules into the 
polymer. The PEG content can be roughly calculated by comparing the peak 
area at 3.3 to 3.5 ppm (-CH2CH2O- from PEG) to the peak area at 7.2 to 7.4 
ppm (hydrogens from phenyl groups in Phe moieties). The content of 
methylcoumarin can be calculated by absorption at 320 nm in UV-vis spectrum 
of the sample calibrated with standard curve of 7-(carboxymethoxy)-4-
methylcoumarin. Combining the results from 1H NMR and UV-vis spectrum, 
the molar amount of PEG or methylcoumarin divided by the total molar amount 
of repeating units was calculated, and defined as the grafting ratio. From the 
calculated grafting ratios listed in Table 2.1, the contents of PEG and 
methylcoumarin in the polymer can be controlled by adjusting the feed ratio of 
NHS-PEG-MAL and 7-(chlorocarbonylmethoxy)-4-methylcoumarin to Lys-
Phe-PEA.   
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Figure 2.3. 1H NMR spectrum of Lys-Phe-PEAcou-PEG. 
 
    As shown in Figure 2.1 and 2.2, the Lys-Phe-PEAcou-PEG polymer is 
amphiphilic, and can self-assemble into spherical micellar structure in aqueous 
solution. The influence of grafting ratio on micelle sizes was examined and the 
results are shown in Table 2.1. A higher methylcoumarin content leads to an 
increase in Lys-Phe-PEAcou-PEG micelle size due to the hydrophobicity of 
methylcoumarin molecules.  It’s also reported that excessive amount of 
methylcoumarin could result in interparticle crosslinking [10] and further 
increase the size of assembled structure. The Lys-Phe-PEAcou-PEG micelles 
are designed for the intracellular delivery of chemotherapeutics, and Sakurai et 
al. [33] reported that drug carriers less than 200 nm resulted in more effective 
delivery because they are less likely to be captured by reticuloendothelial 
system (RES) than larger particles. Based on the above consideration, the Lys-
Phe-PEAcou-PEG micelles with 43% grafting ratio for PEG and 5% grafting 
ratio for methylcoumarin is chosen for the rest of the study. 
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Table 2.1. Size data of uncrosslinked (unXL) Lys-Phe-PEAcou-PEG micelles 
with various grafting ratio of PEG and methylcoumarin (MCM). 
Expected grafting ratio Actual grafting ratioa DLS size of unXL Lys-
Phe-PEAcou-PEG 
micelles /nm 
45% PEG + 5%MCM   43%PEG + 5% MCM 197.13 ±7.60 
35% PEG + 15%MCM 31%PEG + 12% MCM 400.22 ± 17.69 
25% PEG + 25%MCM 23%PEG + 29% MCM 592.13 ± 5.90 
15% PEG + 35%MCM 9%PEG + 40% MCM 762.00 ± 11.23 
 
a. Grafting ratio is defined as the molar amount of PEG or MCM divided by the 
total molar amount of repeating units in Lys-Phe-PEA.  
 
 
2.4.2 Characterization of the photo-crosslinked Lys-Phe-PEAcou-PEG 
micelles 
  The process of photo-crosslinking and de-crosslinking of Lys-Phe-
PEAcou-PEG micelles was monitored by UV-vis spectra and shown in Figure 
2.4. Methylcoumarin monomer exhibits a unique absorption peak at 320 nm. A 
decrease in absorbance at 320 nm was observed when the micelle solution was 
subjected to 365 nm irradiation, suggesting the formation of methylcoumarin 
photodimer. After 3 hrs irradiation, no further decrease at 320 nm peak was 
observed, indicating most available methylcoumarin monomers have been 
converted into dimers. The dimerization degree of methylcoumarin in 
crosslinked Lys-Phe-PEAcou-PEG micelles, defined as (1-A320initial/A320end), 
is calculated to be 71%. The recovery of absorbance peak at 320 nm was also 
observed when the micelle solution was subjected to 254 nm irradiation. The 
de-crosslinking process was complete within 1 hr as no further recovery was 
detected, and the degree of dimerization dropped to 7%, which means more than 
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90% of the methylcoumarin photodimer have been photo-cleaved. This 
reversible change of methylcoumarin monomers vs. dimers observed in the UV-
vis spectra in Figure 2.4 demonstrates the successful manipulation of 
crosslinking and de-crosslinking in Lys-Phe-PEAcou-PEG micelle system. In 
addition to being photo-controllable, coumarin-based photo-crosslinking 
technique is easy to apply, and with no need to introduce purification steps to 
remove any by-products. In this research we aim to take advantage of the photo-
crosslinking to improve micellar stability, and the de-crosslinking process was 
only applied in the test of drug loading content to facilitate the complete 
dissolution of DOX-loaded micelles. 
 
 
Figure 2.4. Monitoring the process of photo-crosslinking (irradiated by 365 nm 
UV light) and de-crosslinking (irradiated by 254 nm UV light) of Lys-Phe-
PEAcou-PEG micelles via UV-Vis spectroscopy. The decrease in the 
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absorbance peak at 320 nm represents the formation of methylcoumarin 
photodimer. 
 
    The size characterization for Lys-Phe-PEAcou-PEG micelles after photo-
crosslinking is listed in Table 2.2. The average DLS diameter of the Lys-Phe-
PEAcou-PEG micelles decreased to 157.03 ± 4.5 nm after crosslinking, 
compared to the 191.37 ± 7.6 nm for the uncrosslinked one. The surface charge 
is not affected by crosslinking, as both crosslinked and uncrosslinked Lys-Phe-
PEAcou-PEG were cationic (8.99 ± 0.23 mV and 7.47 ± 0.51mV, respectively), 
due to the covalently attached cysteine-lysine dipeptide. The major purpose for 
introducing dipeptide is to block the unreacted maleimide functional group and 
prevent unwanted interactions with any thiol containing molecules in cells or 
biological fluids. In future applications, the dipeptide can also be replaced by 
other bio-active molecules to introduce functionality.  The critical micelle 
concentration (CMC) of the uncrosslinked Lys-Phe-PEAcou-PEG was detected 
to be 20.4 mg/L. And CMC was non-detectable for the crosslinked Lys-Phe-
PEAcou-PEG micelles with nile red probe. Micelles with lower CMC can better 
maintain structural integrity against dilution, which is a common practice of 
intravenous administration of drugs.  Therefore, we conclude that the photo-
crosslinked Lys-Phe-PEAcou-PEG micelles can effectively improve the 
structural stability of Lys-Phe-PEAcou-PEG micelles against dilution.  
 
Table 2.2. Characterization of Lys-Phe-PEAcou-PEG micelles before and after 
photo-crosslinking.  
 
Micelles DLS 
size/nm 
PDI Zeta 
potential 
/mV 
CMCa  
/ 
mg/L 
DLCb EEb 
unXL 
Lys-Phe-
191.37 ± 
7.6   
0.167±0.009 7.47±0.51 20.4   
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PEAcou-
PEG 
XL Lys-
Phe-
PEAcou-
PEG 
157.03 ± 
3.5 
0.151 ±0.06 8.99±0.23    
unXL 
Lys-Phe-
PEAcou-
PEG/DOX 
168.76 ± 
11.8 
0.209 ±0.05 7.08±0.67  7.6% 65.7% 
XL Lys-
Phe-
PEAcou-
PEG/DOX 
139.08 ± 
11.2 
0.187 ±0.06 7.23±0.69  8.2% 71.2% 
 
a. Critical micelle concentration (CMC) is the lowest concentration for micelle 
formation. 
b. DLC (drug loading content) and EE(encapsulation efficiency) were 
determminded for DOX-loaded crosslinked (XL) or uncrosslinked (unXL) Lys-
Phe-PEAcou-PEG micelles. 
 
 
 
2.4.3 Effect of serum and enzyme on the stability of Lys-Phe-PEAcou-PEG 
micelles 
  TEM morphology of the photo-crosslinked Lys-Phe-PEAcou-PEG 
micelles (Figure 2.5A) further confirmed the formation of spherical assembly 
from the amphiphilic polymer in an aqueous solution.  
  Previous research demonstrated that the presence of serum protein 
impacted the structural integrity of PEGylated micelles [34, 35]. The structural 
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stability of Lys-Phe-PEAcou-PEG micelles in serum-containing environment, 
was determined by measuring the Forster Resonance Energy Transfer (FRET) 
of DiL/DiO pair. When encapsulated in the hydrophobic interior of micelles, the 
FRET pair is close enough to ensure efficient energy transfer. However, upon 
micelle disintegration, the FRET pair is released to the media and the distance 
between them is beyond the permissible range for FRET [36]. The FRET ratio 
reflects the level of micelle disintegration [37]. As shown in Figure 2.5C, in the 
absence of FBS, a slight decrease in FRET ratio (5%-10%) was observed for 
both crosslinked and uncrosslinked micelles, suggesting that both micelles 
retained their stability in phosphate buffer.  However, FRET ratio decreased to 
0.6 when uncrosslinked micelles were incubated with whole FBS for 48 hrs, 
which suggest the leakage of FRET pairs into aqueous media.  The 
disintegration of the uncrosslinked Lys-Phe-PEAcou-PEG micelles in FBS 
containing environment can be attributed to the lack of an internal stabilizing 
force so that the serum protein disrupted the original interactions between 
unimers and pulled the micelles apart. The crosslinked Lys-Phe-PEAcou-PEG 
micelles, on the other hand, remained stable, as FRET ratio was 0.83 after 48 
hrs incubation with FBS. The cross-links between methylcoumarin-containing 
segments help to maintain the structural integrity. 
    We also examined the stability of micelles incubated with α-chymotrypsin, 
an enzyme which preferentially attacks the hydrophobic amino acids such as 
phenylalanine, and cleaves the amide bonds. From Figure 2.5D, FRET ratio 
decreased to 0.64 and 0.61 respectively, for crosslinked and uncrosslinked 
micelles, after incubated with α-chymotrypsin for 48 hrs. The results indicate 
that the crosslinked Lys-Phe-PEAcou-PEG micelles are still sensitive to 
proteolytic enzyme. The destabilization of crosslinked micelles after enzymatic 
degradation is further substantiated by TEM image in Figure 2.5B, as no 
spherical assembled structure was observed. 
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Figure 2.5. A) TEM image of crosslinked Lys-Phe-PEAcou-PEG micelles 
dispersed in phosphate buffer (pH=7.4). B) TEM image of crosslinked Lys-Phe-
PEAcou-PEG micelles after 48 hrs incubation with 0.2 mg/mL α-chymotrypsin. 
C) Stability of crosslinked or uncrosslinked Lys-Phe-PEAcou-PEG micelles incubated 
with FBS. The FRET ratio was measured for micelles after incubation in phosphate 
buffer or whole FBS. D) Stability of crosslinked or uncrosslinked Lys-Phe-PEAcou-
PEG micelles incubated with α-chymotrypsin. The FRET ratio was measured for 
micelles after incubation with phosphate buffer or 0.2 mg/mL α-chymotrypsin. Values 
represent the average ± SD (n=3). 
 
 
2.4.4 In vitro drug release of DOX from Lys-Phe-PEAcou-PEG micelles 
    The Lys-Phe-PEAcou-PEG micelles were then evaluated as the delivery 
vehicles for DOX. The encapsulation efficiency for DOX was 65.7 % in 
crosslinked Lys-Phe-PEAcou-PEG micelles and 71.2 % in uncrosslinked 
micelles (Table 2.2). Effective encapsulation was achieved in the Lys-Phe-
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PEAcou-PEG micelles, and the efficiency is comparable to other biodegradable 
micelle systems [15, 16]. 
 
 
Figure 2.6. A) In vitro release profile of DOX from Lys-Phe-PEAcou-PEG micelles 
in pH 5.5 phosphate buffer with or without the presence of 0.2 mg/mL α-
chymotrypsin. Values represent the average ± SD (n=3). B) Viability of HCT116 cells 
after 48 hrs incubation with blank crosslinked micelles, DOX-loaded crosslinked Lys-
Phe-PEAcou-PEG micelles, or free DOX with various DOX concentrations. Values 
represent the average ± SD (n=6). Statistical significance was compared between 
micellar DOX treated group and free DOX treated control: *, p < 0.05; **, p < 0.01; 
***, p < 0.001. 
 
  To examine the in vitro release of DOX from Lys-Phe-PEAcou-PEG 
micelles, 10 mM phosphate buffer (pH 5.5) with the presence of α-
chymotrypsin was chosen as the release media, which would work as an 
artificial mimic of the endolysosomal environment due to the endolysosomal 
entrapment of of Lys-Phe-PEAcou-PEG micelles (Figure 2.8A). The release 
profiles of DOX are shown in Figure 2.6A. First, at the end of 48 hrs, the 
crosslinked micelles had 70% cumulative DOX release in the presence of α-
chymotrypsin (black curve), while only less than 25% cumulative was achieved 
without any enzyme (red curve). The results indicate that DOX release was 
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effectively accelerated by enzymatic degradation of the crosslinked carrier. 
Second, no significant difference was observed in the release of DOX from 
crosslinked and uncrosslinked micelles with the presence of enzyme. It can be 
concluded that enzymatic degradation has the major impact on the release 
kinetics, and the effect of photo-crosslinking is relatively minor.  
    As demonstrated in section 3.3, the structural stability of the uncrosslinked 
Lys-Phe-PEAcou-PEG micelles is poor in serum containing environment. In 
addition, the uncrosslinked micelles would disassociate when an equivalent 
DOX concentration was lower than 2.7 μM, i.e., inadequate for the proposed 
DOX dose-dependent study. On the other hand, photo-crosslinking significantly 
improved the stability of the Lys-Phe-PEAcou-PEG micelles, and the 
crosslinked micelles maintained their structural stability at DOX concentrations 
lower than 0.5 μM.  Considering the fact that photo-crosslinks did not cause 
any barrier for DOX release when enzyme was present, we decided to focus on 
the crosslinked Lys-Phe-PEAcou-PEG micelles to investigate the dose-
dependent effect at various DOX concentrations in the subsequent studies.   
 
2.4.5 Cytotoxicity of DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles 
in HCT116 cells 
    Cytotoxicity of both blank micelles and DOX-loaded micelles toward both 
HCT116 human colon cancer cells (Figure 2.6B) were examined. From the data 
in Figure 2.6B, no cytotoxicity from the blank crosslinked Lys-Phe-PEAcou-
PEG micelles toward HCT116 cells was observed at all the testing 
concentrations. We concluded that cytotoxicity induced by DOX-loaded 
micelles should be attributed to the released DOX, instead of the carriers.  
    The cytotoxicity of DOX-loaded crosslinked Lys-Phe-PEAcou-PEG 
micelles on HCT116 cells was then tested, and compared with free DOX, with 
equivalent concentrations of DOX ranging from 0.05 to 20 μM. The data in 
Figure 2.6B demonstrates that, at high DOX concentration (10 μM), DOX-
loaded crosslinked Lys-Phe-PEAcou-PEG micelles showed significantly higher 
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cytotoxicity than free DOX. However, at lower DOX concentration (< 2 μM), 
free DOX still statistically outcompeted micellar DOX. No significant 
difference was detected at 2-8 μM or 20 μM. The IC50 was 1.22 μM for DOX-
loaded crosslinked Lys-Phe-PEAcou-PEG micelles and 0.41 μM for free DOX, 
respectively. 
 
2.4.6 Uptake study of DOX-loaded crosslinked Lys-Phe-PEAcou-PEG 
micelles 
    Inhibition study was performed to explore the endocytosis pathway of 
Dox-loaded crosslinked Lys-Phe-PEAcou-PEG micelles, and the data is shown 
in Figure 2.7A.  Incubation of HCT116 cells with DOX-loaded crosslinked 
micelles at 4 °C for 4 hrs resulted in a 40% decrease in the intracellular DOX 
level. Similarly, inhibition of macropinocytosis (by amiloride) and the clathrin-
mediated pathway (by chloropromazine) also resulted in a significant inhibition 
of DOX transmigration. On the other hand, inhibition of caveolae (by nystatin) 
and lipid raft mediated endocytosis (by methyl-β-cyclodextrin), resulted in no 
significant difference in intracellular DOX level compared to control. We 
therefore conclude that the translocation of DOX-loaded crosslinked Lys-Phe-
PEAcou-PEG micelles into HCT116 cells is energy-dependent and involves 
both macropinocytosis and clathrin-mediated endocytosis. This is in contrast to 
the passive diffusion of free DOX across cell membrane [38], which is not 
dependent on either ATP consumption or transport vesicles.  
  To study the intracellular DOX level vs. time, we monitored the uptake of 
DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles or free DOX by 
HCT116 cells within 24 hrs. At the first 4 hrs, average fluorescence from 
HCT116 cells treated with micellar DOX was 50% lower than free DOX, and 
the difference was statistically significant. But after 12 hrs to 24 hrs incubation, 
no statistically significant difference was detected, as shown in Figure 7B. Two 
possible explanations are proposed for this result. First, the endocytosis of 
micellar DOX generally takes longer time than the passive diffusion of free 
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DOX. Second, DOX was located in the hydrophobic interior of micelles and it 
also takes time for the migration of DOX out of the carriers to achieve similar 
level of intracellular fluorescence as free DOX. 
 
 
Figure 2.7. A) Endocytosis inhibition studies. HCT116 cells pre-treated with various 
endocytosis inhibitors were incubated with DOX-loaded crosslinked Lys-Phe-
PEAcou-PEG micelles (2 μM equivalent DOX concentration) for 4 hrs. Mean 
fluorescence from cellular DOX was recorded by flow cytometry and normalized to 
the DOX level in control (cells not treated with any inhibitor). Values represent the 
average ± SD (n=3). Statistical significance was compared between inhibitor treated 
group and control. B) Mean fluorescence of HCT116 cells incubated with free DOX 
or DOX-loaded crosslinked Lys-Phe-PEAcou-PEG (2 μM equivalent DOX 
concentration) vs. incubation time. Values represent the average ± SD (n=3). 
Statistical significance was compared between micellar DOX treated group and free 
DOX treated control: *, p < 0.05; **, p < 0.01. 
 
2.4.7 Subcellular distribution of DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles 
  First, we identified the subcellular distribution of blank crosslinked 
micelles (no DOX loaded). No distinguishable fluorescence from the 
methylcoumarin moieties was detected when exited at 405 nm at regular level 
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of laser power (data not shown). This can be attributed to the low 
methylcoumarin concentration in HCT116 cells. Since methylcoumarin is a 
relatively weak fluorophore compared to other fluorescent dyes used for cell 
imaging, and the formation of photodimer would further quench its 
fluorescence. As a result, we characterized the subcellular distribution of blank 
crosslinked Lys-Phe-PEAcou-PEG micelles labelled with rhodamine, as shown 
in Figure 2.8A and Table 2.3. After 4 hrs incubation with HCT116 cells, a high 
level of co-localization was observed between the blank micelles and 
endolysosomes, with a Pearson’s coefficient of 0.90 ± 0.08, which indicates that 
the blank micelles were largely entrapped in endolysosomes. No significant 
level of co-localization was observed with either nuclei or mitochondria. 
Endolysosomal compartments provide the sequestration of various proteolytic 
enzymes, which can accelerate the intracellular release of DOX from the 
crosslinked Lys-Phe-PEAcou-PEG micelles due to the enzymatic 
biodegradability of the pseudo protein micelles.  
  Co-localization study was performed to identify the intracellular 
distribution of DOX loaded in crosslinked Lys-Phe-PEAcou-PEG micelles. By 
comparing the DOX fluorescence with specific organelle markers for the nuclei 
(Hoechst), mitochondria (Mitotracker) or endolysosomes (Lysotracker), DOX-
loaded crosslinked micelles exhibited different distribution profile than free 
DOX. As shown in Figure 2.8B, a high level of co-localization (yellow) was 
observed between the red fluorescence from DOX loaded in crosslinked 
micelles and the green pseudo-color from Lysotracker or Mitotracker. The 
Pearson’s coefficient was calculated to be 0.63 ± 0.16 for DOX/Lysotracker, 
and 0.89 ± 0.10 for DOX/Mitotracker. The correlation coefficients also confirm 
that DOX from crosslinked micelles was located in both mitochondria and 
endolysosomes. Considering the subcellular distribution of the blank micelles, it 
is reasonable to conclude that the DOX released from the biodegraded micelle 
further migrated out of endolysosomes and co-localized with mitochondria. No 
overlap between DOX and the nuclei was observed, indicating that DOX from 
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crosslinked micelles did not translocate into the nuclei. Free DOX (Figure 
2.8C), on the other hand, significantly co-localized with the nuclei, as the 
Pearson’s coefficient was 0.75 ± 0.11; but not with either mitochondria or 
endolysosomes.  
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Figure 2.8. Subcellular distribution in HCT116 colon cancer cells after 4 hrs 
incubation with A) Rhodamine labeled blank crosslinked Lys-Phe-PEAcou-PEG 
micelles. The nuclei, mitochondria and endolysosomes were labelled with specific 
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organelle markers, Hoechst 33342 (blue), Mitotracker green and Lysotracker green, 
respectively. B) DOX loaded in crosslinked Lys-Phe-PEAcou-PEG micelles. C) free 
DOX. The equivalent concentration of DOX is 5 μM. The nuclei, mitochondria and 
endolysosomes were labelled with specific organelle markers, Hoechst 33342 (blue), 
Mitotracker deep red FM (green pseudo-color) and Lysotracker deep red (green 
pseudo-color), respectively. Scale bar represents 20 μm. 
 
Table 2.3. Pearson’s coefficient for the co-localization of DOX or blank crosslinked 
Lys-Phe-PEAcou-PEG micelles with organelle markers in HCT116 colon cancer cells  
  
 Hoechst Lysotracker  Mitotracker 
Blank XL Lys-Phe 
-PEAcou-PEG micelles 
0.20 ± 0.09 0.90 ± 0.08 0.51 ± 0.10 
DOX loaded in XL 
Lys-Phe-PEAcou-PEG 
micelles 
0.20 ± 0.04 0.63 ± 0.16   0.89 ± 0.10 
Free DOX 0.75 ± 0.11 0.13 ± 0.05 0.21 + 0.13 
 
 
2.4.8 Mitochondria damage and oxidative stress induced by DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles 
  Mitochondria play an important role in signalling and regulation of cell 
death [39, 40]. The opening of mitochondrial permeability transition pore (MPTP) 
as well as the loss of mitochondrial membrane potential (MMP) are crucial 
events in apoptotic cell death. As co-localization was observed between micellar 
DOX and mitochondria, we further characterized the mitochondrial damage in 
HCT116 cells.  
  MPTP is a protein pore that forms in the inner membrane of the 
mitochondria, their opening represents the loss of membrane integrity of 
mitochondria, and will further induce the release of mitochondrial components. 
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As demonstrated in Figure 2.9A and 2.9B, cobalt chloride, a specific quencher 
for calcein fluorescence, only quenched the cytosolic calcein fluorescence in 
untreated cells or blank micelles treated cells. Calcein fluorescence from the 
mitochondria was observed in healthy cells as no MPTP formed and the 
mitochondrial membrane maintained their integrity to prevent the permeation of 
cobalt chloride. However, in HCT116 cells treated with DOX-loaded 
crosslinked Lys-Phe-PEAcou-PEG micelles, the quenching of mitochondrial 
calcein fluorescence was observed, which suggested the opening of MPTP and 
the subsequent permeation of cobalt chloride into mitochondria was significant. 
The DOX concentration that induced mitochondrial calein quenching and 
MPTP opening for micellar DOX was between 2 to 10 μM (as shown in Figure 
2.9C). In the case of free DOX, MPTP opening was detected at lower DOX 
concentrations (0.5 to 2 μΜ).  
 
 
 
Figure 2.9. A) Confocal images of mitochondrial permeability transition pore (MPTP) 
opening in HCT 116 cells incubated with A) DOX-loaded crosslinked Lys-Phe-
PEAcou-PEG/DOX micelles or B) free DOX for 24 hrs with various DOX 
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concentrations. Calcein AM/ cobalt chloride were used to visualize MPTP. Untreated 
cells or cells incubated with blank micelles were also characterized. C) The 
fluorescence intensity of calcein AM normalized to total number of cells, expressed as 
the percentage to untreated control and plotted as a function of DOX concentration. 
Statistical significance was compared between micellar DOX treated group and free 
DOX treated control: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
  As illustrated in Figure 2.10A, when treated with blank crosslinked 
micelles, less than 2% of HCT116 cells were detected with depolarized 
mitochondria (quadrant 3, lower level of J aggregates and higher level of JC-1 
monomer). No significant difference was observed between blank micelles 
treated cells or untreated cells, which demonstrates the biological safety of the 
blank Lys-Phe-PEAcou-PEG micelles to mitochondria. The data in Figure 2.10B 
shows the percentage of HCT116 cells which lost their MMP upon 24 hrs 
incubation with either free DOX, or DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles.  At the DOX concentration between 2 to 10 μM, a significantly 
higher percentage of the HCT116 cells with depolarized mitochondria was 
detected when treated with micellar DOX, compared to free DOX. The loss of 
MMP marks the dysfunction of mitochondria, and can be associated with the 
release of apoptogenic factors, an early event that initiates apoptosis. However, 
it’s also reported that the loss of MMP can be a consequence of apoptotic-
signalling pathway41. So far we can only conclude from the MPTP and MMP 
results that DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles generally 
caused higher level of mitochondria damage, compared to free DOX, at the 
same duration and concentration of drug exposure.  
  Since mitochondria are the major source of ROS generation, we 
subsequently examined the ROS production in HCT116 cells, which is another 
event that closely related to apoptosis. The intracellular ROS induced by 
micellar DOX was comparable to that induced by free DOX at 0.5 and 1 μM 
(Figure 2.10C); but at higher DOX concentrations (2-8 μM), micellar DOX 
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induced significantly higher levels of ROS than free DOX. Although the mean 
ROS level induced by micellar DOX at 10 μM was greater than free DOX, the 
difference was statistically insignificant at p < 0.05.  
  The difference in intracellular ROS level can be attributed to the difference 
in their subcellular distribution. Since mitochondria function as the major 
domain for ROS generation, it is reasonable that micellar DOX interacted with 
mitochondria and produced more ROS at relatively higher DOX concentration 
(2-8 μM). Overproduction of ROS in cells can cause damage to proteins and 
DNA that further initiates apoptosis42. Therefore, the MMP, MPTP and ROS 
data suggest that HCT116 cells treated with DOX-loaded crosslinked Lys-Phe-
PEAcou-PEG micelles, are presumed to be more susceptible to apoptotic cell 
death at higher DOX concentration. 
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Figure 2.10. A) Flow cytometry detection of mitochondrial membrane potential 
(MMP) of HCT116 colon cancer cells by JC-1 assay. HCT116 cells were treated for 
24 hrs with either DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles or free 
DOX with various DOX concentrations, cells incubated with blank crosslinked Lys-
Phe-PEAcou-PEG micelles, or CCCP treated cells were also tested. B) The percentage 
HCT116 cells with depolarized mitochondria (quadrant 3) in JC-1 assay were recorded 
and plotted as a function of DOX concentration. C) The intracellular reactive oxygen 
species (ROS) were probed by dihydroethidium (DHE). HCT116 cells were treated for 
24 hrs with blank crosslinked micelles, DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles or free DOX with various DOX concentrations. The level of ROS was 
normalized to the untreated control. Values represent the average ± SD (n=3). 
Statistical significance was compared between micellar DOX treated group and free 
DOX treated control: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
2.4.9 Dose-dependent apoptosis by DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles 
  To determine whether the overproduction of ROS and mitochondria 
damage could actually lead to increased apoptosis in HCT116 cells treated with 
micellar DOX, we further examined the dose dependent apoptosis.  Figure 
2.11A shows the confocal images of the apoptotic HCT116 cells by annexin-V 
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staining. In the apoptotic HCT116 cells induced by DOX-loaded crosslinked 
Lys-Phe-PEAcou-PEG micelles, the red fluorescence from DOX still distributed 
in the cytoplasm, while apoptotic cells treated with free DOX exhibited DOX 
fluorescence only in the nuclei. Micellar DOX with higher DOX concentration 
(5-10 μM) also exhibited similar distribution in the cytoplasm instead of in the 
nuclei (data not shown). These results suggest that, instead of intercalating in 
nuclear DNA, DOX from crosslinked micelles stayed away from the nuclei 
throughout the apoptotic process, which can be a possible indication of 
potentially different pathway in inducing apoptosis between micellar DOX and 
free DOX. Similar results were also reported by Kopeck et al. [43, 44], in which 
DOX bounded with N-(2-hydroxypropyl) methacrylamide (HPMA) polymer 
showed different distribution pattern and induced apoptosis in ovarian 
carcinoma cells by the disruption of mitochondrial function.  
  The data in Figures 2.11C shows the percentage of early apoptotic cells 
detected with flow cytometry. For DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles, the percentage of apoptotic cells was much lower than free DOX, 
when the DOX concentration is less than 2 μM. The result is consistent with the 
lower cytotoxicity data shown in Figure 2.6B, suggesting that at lower DOX 
concentration, free DOX is more lethal toward HCT116 cells than micellar 
DOX. However, the difference in apoptosis percentage disappeared at 2 μM 
DOX concentration as no statistical difference between free DOX and micellar 
DOX was observed. This trend was reversed when the DOX concentration was 
> 2 μM, as significantly increased percentage of apoptosis was detected in 
HCT116 cells treated with micellar DOX. Free DOX, demonstrated by Yokochi 
et al. [25], induces necrosis at higher dose in HCT116 cells, which explains the 
reduced apoptosis percentage detected in cells treated with free DOX with 
concentration > 2 μM. Micellar DOX, on the other hand, was not observed to 
induce necrotic cell death in the concentration range between 2 to 10 μM. 
    Cleaved caspase 3 (17-19 kDa) is an active enzyme in the execution of 
apoptosis. Western blot data in Figure 2.11B suggest that the cleaved caspase 3 
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was present in HCT116 cells treated with micellar DOX with the DOX 
concentrations of 2 to 8 μM, or free DOX treated cells with the DOX 
concentration of 0.5 to 2 μM. The caspase 3/7 activity was further quantified 
and the data in Figure 2.11D is consistent with the result of apoptosis 
percentage. For HCT116 cells treated with free DOX, increased caspase 3/7 
activity was detected only when DOX concentration was between 0.5-2 μM, 
and was significantly lower than DOX-loaded crosslinked Lys-Phe-PEAcou-
PEG micelles at the DOX concentration > 2 μM. The result of dose-dependent 
apoptosis in HCT116 cells shows the similar trend with the data in Figure 2.9 
and 2.10, which suggests the correlation between apoptosis, MPTP, ROS and 
MMP, and that the concentration range to induce apoptosis in HCT116 cells is 
different between micellar DOX and free DOX. Yokochi et al. [25] reported the 
conditional apoptosis by free DOX in several cancer cell lines, and related the 
dose-dependent behaviour to DNA methyltransferase. However, detailed 
molecular biological characterization are required to further elucidate the 
mechanism of how DOX loaded in crosslinked Lys-Phe-PEAcou-PEG micelles 
translocated to the mitochondria, and their specific signalling pathway in 
inducing apoptosis, which would be the focus of our following study. 
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Figure 2.11. A) Annexin V staining of apoptotic HCT116 cells treated with DOX-
loaded crosslinked Lys-Phe-PEAcou-PEG micelles or free DOX for 48 hrs with 
equivalent DOX concentration of 2 μM. Red fluorescence is from DOX and the green 
fluorescence is from annexin V-FITC. Scale bar represents 20 μm. B) Western blot to 
identify the presence of cleaved caspase 3 (17 – 19 kDa) in the lysate of HCT116 cells 
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after incubation with DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles or free 
DOX. Untreated cells or cells incubated with blank crosslinked micelles were also 
characterized. C) Percentage of early apoptotic HCT116 cells (annexin V positive and 
SYTOX Red negative cells) detected by flow cytometry. HCT116 cells were treated 
with blank crosslinked micelles, DOX-loaded crosslinked Lys-Phe-PEAcou-PEG 
micelles or free DOX with various DOX concentrations for 48 hrs. D) Caspase 3/7 
activity assay for HCT116 cells treated with blank crosslinked micelles, free DOX or 
DOX-loaded crosslinked Lys-Phe-PEAcou-PEG micelles with various concentrations 
of DOX for 48 hrs. Values represent the average ± SD (n=3). Statistical significance 
was compared between micellar DOX treated group and free DOX treated control: *, 
p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
 
2.5 Conclusions 
    A lysine-phenylalanine based pseudo-protein micelles with photo-
crosslinkable methylcoumarin moieties were synthesized for the intracellular 
delivery of DOX. The major conclusions of this study are: A) The crosslinked 
micelles exhibited significantly better structural stability in serum containing 
media and were able to counter the dilution-induced micelle disintegration; B) 
The in vitro release of DOX was not hindered by crosslinking, and can be 
accelerated by enzymatic degradation due to the biodegradability of the pseudo 
protein micelles, suggesting the stabilization-on-demand capability; C) DOX-
loaded crosslinked Lys-Phe-PEAcou-PEG micelles co-localized to a large 
extent with mitochondria and endolysosomes in HCT116 cells, while free DOX 
localized only in the nuclei; D) DOX-loaded crosslinked Lys-Phe-PEAcou-PEG 
micelles induced apoptosis in HCT116 cells at higher and broader drug 
concentration range than free DOX, and the difference in inducing apoptosis 
showed a correlation with mitochondrial depolarization, MPTP opening and 
ROS generation. This research brings a novel perspective in the study of in vitro 
therapeutic effect of micellar drug delivery systems. The pseudo protein 
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micelles also exhibit versatile promise as a “stabilization-on-demand” delivery 
carrier, and can be further functionalized with targeting moieties and other 
bioactive agents. Furthermore, this study provides researchers with new insight 
into the design of micellar delivery vehicles and could have the potential in 
developing new nanocarriers for the mitochondria-targeting delivery of 
payloads.  
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CHAPTER 3 
 
BIODEGRADABLE NANOCOMPLEX FROM HYALURONIC ACID AND 
ARGININE BASED POLY(ESTER AMIDE)S AS THE DELIVERY VEHICLES 
FOR IMPROVED PHOTODYNAMIC THERAPY OF MULTIDRUG RESISTANT 
TUMOR CELLS: AN IN VITRO STUDY OF THE PERFORMANCE OF CHLORIN 
E6 PHOTOSENSITIZER 
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3.1 Abstract 
  Photodynamic therapy (PDT), which enables the localized therapeutic effect by 
the application of light, provides a promising strategy as an alternative and 
complementary modality for the treatment of tumor.  However, the aggregation of 
photosensitizers in acidic microenvironment of tumor and the non-targeted distribution 
of photosensitizers in normal tissues significantly affect the PDT efficiency.  In this 
study, we developed a biodegradable nanocomplex from hyaluronic acid and arginine 
based poly(ester amide)s (HA-Arg-PEA) as the nano-carrier for chlorin e6 (Ce6). 
Hyaluronic acid (HA) in the nanocomplex enhanced the tumor-specific endocytosis 
mediated by the overexpression of CD44 receptor. Arginine-based PEA (Arg-PEA) 
not only provide electrostatic interaction with HA to form self-assembled 
nanostructure, but also improve the monomerization of the loaded Ce6.  HA-Arg-
PEA nanocomplex significantly reduced the aggregation of Ce6 at physiological pH as 
well as mildly acidic pH, compared to free Ce6. The biodegradable characteristic of 
HA-Arg-PEA nanocomplex enabled the intracellular delivery of Ce6, in which its 
release and generation of singlet oxygen can be accelerated by enzymatic degradation 
of the carrier. The in vitro PDT efficiency of Ce6-loaded HA-Arg-PEA nanocomplex 
was examined in CD44 positive MDA-MB-435/MDR multidrug resistant melanoma 
cells. CD44-mediated uptake of Ce6-loaded HA-Arg-PEA nanocomplex significantly 
improved Ce6 level in MDA-MB-435/MDR cells within a short incubation time (4 
hrs), and the PDT efficiency in the inhibition of multidrug resistant tumor cells was 
also enhanced at higher Ce6 concentrations.  
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3.2 Introduction 
  Different from traditional chemotherapy, photodynamic therapy (PDT) offers an 
alternative approach to treat tumor, in which the administration of photosensitizers is 
followed by the application of light irradiation to the tumor site [1]. Upon irradiation, 
photosensitizers generate reactive oxygen species (ROS) and singlet oxygen via 
photon-induced energy transfer, and further induce the localized oxidative damage to 
tumor cells. Most tumor cells with chemotherapy-resistance are not reported to 
develop cross-resistance to PDT photosensitizers including chlorin e6 (Ce6) [2,3], 
chloroaluminum tetrasulfonate phthalocyanine (AlPcS) [4], and protoporphyrin IX 
(PpIX) [5], etc. Many studies have demonstrated the independence of intracellular 
accumulation of these photosensitizers from the overexpression of multidrug 
transporter protein, P-glycoprotein [6,7], and PDT is also reported to have the potential 
to reverse multidrug resistant phenotype [8]. However, current photodynamic 
treatments are still facing several practical challenges that impact their efficacy. Most 
photosensitizers are of poor water solubility and difficult to be directly administered 
via intravenous injection. Besides, the accumulation of photosensitizers in normal 
tissue was also observed [9], and the non-targeted distribution of photosensitizer not 
only affects PDT potency, but also bring in skin photo-sensitivities to patients. 
Patients receiving photodynamic treatment are restricted from sunlight exposure in 
order to minimize side effects [10].  
  Considering the above disadvantages for direct administration of free 
photosensitizers, targeted delivery of photosensitizers to the site of action with a 
suitable delivery vehicle is a promising strategy to improve PDT efficacy, and 
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simultaneously reduce the risk of side effect or toxicity. Various polymeric nano-
vehicles [11] have been reported as the delivery carriers for PDT, and bring in 
additional advantages to PDT, such as protection of photosensitizer from degradation, 
improving their circulating time in blood, selective targeting and controlled release of 
photosensitizer in tumor tissue, etc. Hyaluronic acid (HA) is a natural and 
biodegradable polysaccharide formed by D-glucuronic acid and N-acetyl-D-
glucosamine repetitive units [12]. Identified as the ligand molecule for CD44 receptors 
[13], HA has attracted considerable research interests in the field of tumor-targeting 
delivery, due to the overexpression of CD44 receptors on many types of tumor cells. 
HA-based nano-carriers exhibited enhanced binding and endocytosis by tumor cells, 
and have been developed to improve the potency of various therapeutic agents [14].  
HA was reported as the delivery vehicles for multiple PDT-photosensitizers including 
hematoporphyrin [15], chlorin derivatives [16], phthalocyanine derivatives [17], and 
significantly improved therapeutic efficiency was reported when compared to the 
direct administration of free photosensitizer. However, of the published studies on 
delivery systems for PDT, few of them addressed the aggregation issue of the loaded 
photosensitizer, as aggregation is one of general limitations for PDT efficacy in acidic 
tumor environment [18]. 
    Synthetic amino acid based poly (ester amide)s (AA-PEA) is a new family 
of biodegradable polymers synthesized from 3 building blocks: amino acids, 
dialcohol, diacids. AA-PEAs have been engineered into nanofibrous 
membranes, 3D microporous hydrogels, coating for suture and cardiovascular 
stent, and drug delivery vehicles for multiple biomedical applications. The 
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current research on AA-PEAs have recently been reviewed [19–21]. Previous 
published studies have demonstrated the unique advantages of AA-PEA, which 
includes reproducible synthetic routes, versatile structural design, enzymatic 
biodegradability, excellent biocompatibility, and muted inflammatory response, 
etc. By selecting different types of amino acids, diols, and adjusting the number 
of hydrocarbons between ester and amide groups, AA-PEA materials are 
tuneable in charge density, hydrophobicity/hydrophilicity, as well as the 
reactive sites for further chemical functionalization. Among the amino acids for 
AA-PEA synthesis, arginine (Arg) retains cationic charge over a wide range of 
pH, suitable to form electrostatic complex with other negatively charged 
materials or payloads [22]. Chu et al. have recently demonstrated that cationic 
Arg-PEAs facilitated the penetration through cell membrane and worked as 
effective delivery systems for therapeutic agents including genes [23].  
  In this research, we aim to develop a biodegradable nanocarrier for the targeted 
delivery of photosensitizers, and address the following issues associated with PDT 
treatment of tumor: 1) to improve the selective endocytosis of photosensitizer by 
tumor cells, instead of normal cells.; 2) to reduce the aggregation of photosensitizer in 
an acidic environment. 
   Chlorin e6 (Ce6), a commonly investigated photosensitizer with activation 
wavelength at 660 to 670 nm, is chosen as the payload to be delivered. Three 
peripherally attached carboxylic groups on Ce6 exist in different ionic forms, 
depending on the pH. Prior published studies [24,25] suggested that Ce6 aggregated 
predominantly at acidic pH, which lead to reduced sensitizing efficiency, and 
 89 
adversely impact the therapeutic effect. In this contribution, nano-sized delivery 
carrier is designed from both HA and Arg-PEA, in which HA component provides 
targeting modality to achieve selective endocytosis by CD44 positive tumor cells. The 
cationic Arg-PEA component not only formed electrostatic self-assembled structure 
with HA, but also provided advantages for the improving photosensitizing efficiency 
for Ce6. We focused on investigating the level of Ce6 monomerization in interaction 
with the carrier at both physiological and acidic environment. Intracellular trafficking 
and in vitro PDT efficacy of Ce6-loaded nanocomplex in multidrug resistant MDA-
MB-435/MDR melanoma cells were also studied to investigate its potential as the 
delivery system for PDT. 
 
3.3. Experimental 
3.3.1 Chemicals and cells 
    Sodium hyaluronate (MW= 10 to 20 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN). N-hydroxysuccinimide (NHS), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 
tetrabutylammonium bromide, p-nitrosodimethyl aniline (RNO), methyl-β-
cyclodextrin, ninhydrin, QuantiPro BCA assay kit and hyaluronidase from bovine 
testes were from Sigma Aldrich (Milwaukee, WI). Amberlite IR-120 H+ ion exchange 
resin was from Alfa Aesar (Ward Hill, MA). Dimethyl sulfoxide (DMSO), methanol 
and other HPLC grade solvents were from JT Baker (Phillipsburg, NJ). Chlorin e6 was 
from Frontier Scientific (Logan, UT). Nystatin, chloropromazine, amiloride 
hydrochloride were from Cayman Chemical (Ann Arbor, MI).  Anti-human CD44 
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antibody (clone IM7) and annexin V apoptosis detection kit were from eBioscience 
(San Diego, CA). Lysotracker green was from Cell Signaling Technology (Beverly, 
MA). Snakeskin dialysis tubing (MWCO = 10 kDa) and NHS-rhodamine were from 
Pierce (Rockford, IL). The monomer Arg-4 (tetra-p-toluenesulfonic acid salt of bis-L-
arginine butane-1, 4-diester) and NA (di-p-nitrophenyl adipate) were synthesized 
according to our previously studies [26,27]. 
  MDA-MB-435/MDR multidrug resistant melanoma cells were donated by Dr. 
Robert Clarke (Georgetown University, Washington, D.C.) and MD Anderson Cancer 
Center (Houston, TX). MDA-MB-435/MDR cells were maintained at 37 ºC with 5% 
CO2 in Minimum Essential Medium (Richter’s modification) containing 2mM L-
glutamine, phenol red, 10% fetal bovine serum, and 1% penicillin/streptomycin. NIH 
3T3 fibroblasts were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with phenol red, 10% fetal bovine serum, and 1% 
penicillin/streptomycin. 
   
3.3.2 Synthesis of amine terminated arginine based PEA 
  The synthesis of amine-terminated Arg-PEA was based on our previously 
published study [26]. As depicted in Figure 3.1, excessive amount of Arg-4 (0.82 g, 1.0 
mmol) was mixed with NA (0.31 g, 0.8 mmol) in 1.5 mL DMSO, and heated to 75 ºC 
under stirring to obtain a uniform mixture. Triethylamine (0.31 mL, 2.2 mmol) was 
added under vigorous stirring. The reaction was kept for 12 hrs at 75 ºC. The resulting 
Arg-PEA polymer with amine end groups was precipitated in cold ethyl acetate, 
dissolved in DI water, and repeated concentrated in Macrosep centrifugal device 
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(MWCO=1 kDa, Pall Filtron, Northborough, MA). The purified amine-terminated 
Arg-PEA was lyophilized. Ninhydrin assay was performed as per manufacturer’s 
instruction to estimate the content of primary amine end groups, and calibrated against 
a standard curve from free arginine.  
 
 
Figure 3.1. Synthesis scheme of amine terminated arginine based poly(ester amide)s 
(Arg-PEA). 
 
3.3.3 Preparation of Ce6 loaded HA-Arg-PEA nanocomplex 
    Preparation of blank HA-Arg-PEA nanocomplex. To improve the solubility of 
hyaluronic acid in organic solvents, sodium hyaluronate was converted to tetra-N-
butylammonium hyaluronate (HA-TBA) via ion exchange method [28]. Amberlite IR-
120 H+ resin was washed with methanol and deionized water, neutralized with 1 M 
NaOH, washed with deionized water and then immersed in 0.25 M aqueous tetra-N-
butylammonium bromide solution overnight. The resulting ion exchange resin was 
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then added to an aqueous solution of sodium hyaluronate (20 mg/mL) and stirred 
overnight at room temperature. The resin was then removed by filtration, and the 
aqueous solution was lyophilized to give HA-TBA. To prepare the nanocomplex from 
Arg-PEA and HA-TBA, 100 mg HA-TBA was dissolved in 5 mL DMSO/H2O (1:1 
v/v), the carboxyl groups on HA were activated with NHS/EDC (-COOH: NHS: EDC 
= 1:5:1.2, molar ratio). 100 mg amine terminated Arg-PEA dissolved in 5 mL DMSO 
was then added dropwise. The mixture solution was stirred overnight, dialyzed 
(MWCO = 10 kDa) against DI water for 24 hrs, and repeated concentrated in 
Macrosep centrifugal device (MWCO=100 kDa, Pall Filtron, Northborough, MA).  
Purified HA-Arg-PEA nanocomplex was then lyophilized. The morphology of HA-
Arg-PEA nanocomplex was observed on a FEI Tecnai Spirit T12 TEM (FEI Co., 
Hillsboro, OR) at an operating voltage of 120 kV. Zeta potential and size of the 
nanocomplex were characterized at room temperature on a Zetasizer NanoZS system 
(Malvern, UK). 
    Preparation of Ce6-loaded HA-Arg-PEA nanocomplex. Ce6 (20 mg) and 
amine terminated Arg-PEA (100 mg) were dissolved in 5 mL DMSO and stirred for 
30 min in dark. The mixed solution of Ce6/Arg-PEA was then added dropwise to the 
activated HA-TBA solution as prepared above and stirred overnight in dark. The 
mixture solution was subjected to dialysis and centrifugal concentration, then filtered 
through a 0.45 µm microfilter. The filtered solution was lyophilized. To determine the 
loading content (LC) and encapsulation efficiency (EE) of Ce6, 5 mg lyophilized Ce6-
loaded HA-Arg-PEA nanocomplex was first digested in 0.1 M NaOH (2.5 mL) at 
room temperature overnight, before another 2.5 mL of DMSO was added. The mixed 
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solution was centrifuged at 14000 rcf. The fluorescence intensity (λex=405 nm, 
λem=672 nm) of the supernatant was recorded on a PTI spectrofluorometer (Photon 
Technology International, South Brunswick, NJ).  
 
3.3.4 Detection of monomerization of Ce6 in interaction with Arg-PEA 
    Due to the difficulty to directly probe the UV-Vis spectrum of Ce6 loaded in the 
nanocomplex, the mixture of Arg-PEA and Ce6 in aqueous solution was studied to 
illustrate the monomerization of Ce6 in interaction with Arg-PEA. A mixture of Arg-
PEA and Ce6 (10:1 w/w) was dispersed at an equivalent Ce6 concentration of 50 µM 
in phosphate buffer with various pH ranging from 4.5 to 10.0. Free Ce6 was tested as 
control. UV-Vis spectra were obtained for each sample on a Lambda Bio40 
spectrophotometer (Perkin-Elmer, Norwalk, CT), and the absorbance at 672 nm and 
645 nm were recorded. Absorbance at 672 nm represents the monomeric form of Ce6, 
while absorbance at 645 nm represents the aggregated form of Ce6 [29]. The ratio 
between A672 and A645, an indication of Ce6 monomerization, was calculated and 
plotted vs. pH. 
 
3.3.5 Detection of singlet oxygen generation  
    The generation of singlet oxygen from Ce6 upon irradiation was quantitatively 
evaluated by RNO bleaching assay. Free Ce6 or Ce6-loaded HA-Arg-PEA 
nanocomplex (HA-Arg-PEA/Ce6) was dissolved in a mixed solution of DMSO and 
PBS (1:10 v/v) with or without the presence of 120 unit/mL hyaluronidase, and 
incubated at 37 ºC for 24 hrs. The equivalent concentration of Ce6 in each sample was 
 94 
100 μM. After incubation, 400 μL the above solution was added to 3.6 mL phosphate 
buffer (pH 7.4 or pH 6.5) containing 5.58 mg L-histidine and 0.377 mg RNO. The 
final concentration of Ce6 was 10 μM. Each solution was subjected to light irradiation 
by 120 LED arrays at 660 nm (Elixa, Albuquerque, NM) and the power density was 
25 mW/cm2. The absorbance of RNO in each sample was measured at 440 nm by UV-
Vis spectroscopy as a function of irradiation time. Each test was performed in 
triplicate. 
 
3.3.6 Endocytosis Ce6-loaded HA-Arg-PEA nanocomplex  
    Endocytosis inhibition assay. MDA-MB-435/MDR cells were seeded in a 
6-well plate (3 x 105 cells per well) and pre-incubated for 24 hrs. The cells were 
treated with inhibitors that block different endocytic pathways (nystatin, 50 
μg/mL; chloropromazine, 30 μM; amiloride hydrochloride, 50 μM; methyl-β-
cyclodextrin, 3 mg/mL or anti-CD44 antibody as per manufacturer’s 
instruction) for 0.5 hr before rhodamine labelled blank HA-Arg-PEA 
nanocomplex was added and incubated for another 4 hrs. The cells were then 
washed with PBS, harvested and subjected to flow cytometry assay on 
FACSAria fusion fluorescence activated cell sorter (BD Biosciences, Franklin 
Lakes, NJ). The effect of low temperature (4°C) on endocytosis was also 
studied.  Cells incubated with HA-Arg-PEA nanocomplex at 37°C but not 
treated with any inhibitor were tested as control. The mean fluorescence 
intensity for each sample was recorded and normalized to control. The tests 
were performed in triplicate. 
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    Accumulated endocytosis study. MDA-MB-435/MDR cells were seeded in 
a 6-well plate (3 x 105 cells per well) and pre-incubated for 24 hrs followed by 
the addition of free Ce6 or Ce6-loaded HA-Arg-PEA nanocomplex of an 
equivalent Ce6 concentration 5 μM and incubated for 1, 2, 4, 8, 12 or 24 hrs. 
The cells were washed with PBS, harvested and lysed in 0.4 mL 0.5% Triton-X.  
0.2 mL of the cell lysate was added to 1 mL DMSO and the fluorescence 
intensity (λex = 405 nm, λem = 672 nm) was recorded to quantify the Ce6 level 
in each sample. The other 0.2 mL of cell lysate from the same sample was 
subject to BCA assay to determine the total protein content as per 
manufacturer’s instruction. The fluorescence intensity for each sample was 
normalized to total protein content and each test was performed in triplicate. 
The accumulated endocytosis study on 3T3 fibroblasts (CD44 negative) was 
also performed in the same procedure as described above. 
 
3.3.7 Subcellular distribution of Ce6-loaded HA-Arg-PEA nanocomplex  
  To determine the expression of CD44 in MDA-MB-435/MDR cells, 
immunostaining was performed to untreated MDA-MB-435/MDR cells with anti-
human CD44 antibody, as per manufacturer’s instruction. The expression of CD44 
receptor on MDA-MB-435/MDR cells was visualized on a Zeiss LSM710 confocal 
microscope (Carl Zeiss MicroImaging, Thornwood, NY). 
  To study the subcellular distribution of Ce6-loaded HA-Arg-PEA nanocomplex 
in MDA-MB-435/MDR cells, 3 x 105 MDA-MB-435/MDR cells were seeded in a 
glass bottomed petri dish (P35G-0-10-C, MaTek, Ashland, MA) and pre-incubated for 
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24 hrs. Free Ce6 or Ce6-loaded HA-Arg-PEA nanocomplex with equivalent Ce6 
concentration of 2 μM was added and incubated for 24 hrs. Cells were then washed 
three times with PBS and imaged alive by confocal microscopy.  To study the 
subcellular distribution of blank HA-Arg-PEA nanocomplex labelled with rhodamine, 
MDA-MB-435/MDR cells were incubated with blank nanocomplex for 4 hrs and 
stained with Lysotracker green as per manufacturer’s instruction. The cells were 
imaged alive with confocal microscopy. 
 
3.3.8 Phototoxicity of Ce6 loaded HA-Arg-PEA towards MDA-MB-435/MDR cells  
    MDA-MB-435/MDR cells were seeded in a 96-well plate (5 x 103 cells per 
well) and pre-incubated for 24 hrs. Free Ce6 or Ce6-loaded HA-Arg-PEA 
nanocomplex with various Ce6 concentration were added and incubated for 4 
hrs. The cells were washed three times with PBS and incubated for another 20 
hrs in fresh culture media. Light irradiation was applied by LED arrays for 2 
min at 660 nm with light dose of 3 J/cm2. After a further incubation for another 
24 hrs, the viability of cells was determined by MTT assay. The absorbance at 
570 nm was recorded and normalized to untreated control. Each experiment was 
run in six replicates. 
 
3.3.9 Annexin V assay 
    MDA-MB-435/MDR cells were seeded in a 6-well plate (3 x 105 cells per 
well) and pre-incubated for 24 hrs. Blank HA-Arg-PEA nanocomplex, free Ce6 
or Ce6-loaded HA-Arg-PEA nanocomplex with equivalent Ce6 concentration of 
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2 μM or 10 μM were added and incubated for 4 hrs. The cells were washed 
three times with PBS and incubated for another 20 hrs in fresh culture media. 
Light irradiation was applied by LED arrays at 660 nm for 2 min with light dose 
of 3 J/cm2. Annexin-V/PI double staining was performed 24 hrs post light 
irradiation, as per manufacturer’s instruction. The percentage of dead/apoptotic 
cells were analysed by flow cytometry, and each experiment was performed in 
triplicate.  
 
3.3.10 Statistical analysis  
The data are presented as mean values with standard deviations (SD). All data 
were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison 
tests, and p < 0.05 was used for statistical significance. 
 
3.4 Results and discussion 
3.4.1 Preparation of amine terminated Arg-PEA 
    Amine terminated Arg-PEA was prepared from solution polycondensation, in 
which excess amount of nucleophilic Arg-4 monomer was reacted with electrophilic 
NA monomer to result in free amine groups on both ends of polymer chain. We also 
reported a amine terminated phenylalanine based PEA from the same synthesis 
method [26]. 1H NMR spectrum was obtained to characterize the amine terminated Arg-
PEA, and typical chemical shifts were observed at 8.25 ppm (-NH-CO-), 4.23 ppm (-
CH2-O-CO-) and 3.09 ppm (-NH-CO-CH2-).  The molecular weight of the amine 
terminated Arg-PEA was 6.5 kDa with PDI =1.36, as detected by GPC. The amine-
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terminated Arg-PEA exhibits strong cationic charge when dispersed in pH 7.4 
phosphate buffer, and the zeta potential for the 1 mg/mL solution was + 22.5 ± 3.9 
mV. The content of free amine was 0.25 mmol/g in Arg-PEA, as detected by 
ninhydrin assay. 
 
3.4.2 Characterization of Ce6-loaded HA-Arg-PEA nanocomplex 
  HA-Arg-PEA nanocomplex was formed from electrostatic self-assembly between 
HA (anionic) and Arg-PEA (cationic) as shown in Figure 3.2, and further stabilized 
via covalent crosslinking between -NH2 end groups in Arg-PEA and -COOH groups in 
HA. Negative surface charge (- 17.6 to -22.4 mV) was detected for all HA-Arg-PEA 
nanocomplex with various HA to Arg-PEA ratios, and the size of the nanocomplex 
increased with higher HA contents, e.g., from 114.04 ± 5.92 nm (HA/Arg-PEA= 1:1 
w/w) to 530.58 ± 3.80 nm (HA/ Arg-PEA= 4:1 w/w). In addition, the loading content 
of Ce6 was also affected by HA to Arg-PEA ratio. Increased HA component lead to a 
decrease in the loading content of Ce6, e.g., 9.0% (HA/Arg-PEA= 1:1 w/w) vs. 3.2% 
(HA/ Arg-PEA= 4:1 w/w), which can be attributed to the reduced electrostatic 
interactions between Ce6 and Arg-PEA. Nanocarriers with smaller size resulted in 
more effective delivery because they are less likely to be captured by 
reticuloendothelial system (RES) than larger particles in systemic circulation [30]. HA-
Arg-PEA nanocomplex with HA/Arg-PEA ratio of 1:1 was chosen for the following 
study.  
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Figure 3.2. Chemical structure of tetra-N-butylammonium hyaluronate (HA-TBA), 
amine-terminated arginine based poly(ester amide)s (Arg-PEA) and chlorin e6 (Ce6). 
And the graphic illustration of Ce6-loaded HA-Arg-PEA nanocomplex. 
 
    Electrostatically self-assembled microparticles from HA and unsaturated Arg-
PEA was previously reported by Potuck et al [31]. They reported the assembled 
structure with average feature size of 2.49−15 μm from high molecular weight HA 
(1,000 kDa) and unsaturated Arg-PEA (30 to 60 kDa). In this current study, much 
smaller nanocomplex can be formed by using HA with low molecular weight (10 to 20 
kDa) and amine-terminated Arg-PEA (6.5 kDa).   
    The characteristics of Ce6-loaded HA-Arg-PEA nanocomplex (HA-Arg-
PEA/Ce6) are listed in Table 3.1. The LC and EE for Ce6 were 9.0% and 90.3%, 
respectively. The incorporation of Ce6 into HA-Arg-PEA nanocomplex didn’t 
significantly changed the size and surface charge. The TEM image in Figure 3.3A 
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confirmed the spherical structure of Ce6-loaded HA-Arg-PEA nanocomplex. After 
incubation with hyaluronidase (120 unit/mL) for 24 hrs [32], the spherical morphology 
of Ce6-loaded HA-Arg-PEA nanocomplex disappeared (Figure 3.3B) due to the 
enzymatic breakdown of HA. 
 
Table 3.1. Characteristics of HA-Arg-PEA nanocomplex (HA/Arg-PEA = 1:1 w/w). 
 DLS 
diameter 
(nm) 
PDI Zeta 
potential 
(mV) 
Loading 
Content 
(%) 
Encapsulation 
Efficiency 
(%) 
HA-Arg-PEA 130.58 ± 
7.87 
0.184 ± 
0.055 
-22.4 ± 1.2   
HA-Arg-PEA/ 
Ce6 
114.04 ± 
5.92 
0.159 ± 
0.072 
-20.6 ± 2.5 9.0 90.3 
 
 
 
Figure 3.3. TEM image of A) Ce6-loaded HA-Arg-PEA nanocomplex in pH 7.4 
phosphate buffer, B) Ce6-loaded HA-Arg-PEA nanocomplex after 24 hrs incubation 
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with 120 unit/mL hyaluronidase in pH 7.4 phosphate buffer. 
 
3.4.3 Evaluation of Ce6 monomerization  
    Ce6 aggregates in acidic pH (6.5-6.9) that is common in tumor microenvironment 
[33]. The aggregation can lead to reduced photosensitizing effect, and adversely affects 
the PDT efficiency. To characterize the monomerization level of Ce6, two typical 
absorbance peaks at 672 nm (representing Ce6 in monomer state) and 645 nm 
(representing Ce6 in aggregated state) in the Q-band of UV-vis spectrum were 
investigated and the A672/A645 ratio was evaluated as an index for Ce6 monomerization 
[29].  Due to the difficulty in directly probing the UV-Vis spectra of Ce6 loaded in 
HA-Arg-PEA, as indicated in Figure 3.4A. At the same Ce6 concentration, the 
absorbance peaks of free Ce6 at 672 nm and 645 nm were overlapped and 
indistinguishable from the Ce6 loaded in HA-Arg-PEA, this can be attributed to the 
fact that Ce6 was entrapped in the interior of the nanocomplex which impacted the 
UV-Vis absorbance. Therefore, we studied the A672/A645 ratio of the mixture of Ce6 
and the Arg-PEA component of the HA-Arg-PEA nanocomplex in an aqueous 
solution, as the absorption peaks of Ce6 at 672 nm and 645 nm were more evident and 
clear in Figure 3.4A.  
    As shown in Figure 3.4B, the A672/A645 ratio for free Ce6 reached the highest 
value (i.e., highest level of Ce6 monomerization) at pH 10, then decreased with 
reduced pH, and reached the lowest value at pH 4.5. The monomerization of free Ce6 
as a function of pH are consistent with previous study [34] that Ce6 molecules in 
alkaline aqueous media and polar organic solvents stay predominantly in the 
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monomeric form. An increasing fraction of aggregated Ce6 was observed at acidic pH 
due to the non-ionized carboxylic groups in Ce6 and the formation of intermolecular 
hydrogen bonding [29]. On the other hand, the fraction of Ce6 monomer in complex 
with Arg-PEA was significantly higher than free Ce6 at pH ranging from 4.5 to 7.4. 
No statistical difference between Ce6-loaded Arg-PEA and free Ce6 in the A672/A645 
ratio was found at pH 10.  
  It is suggested that Arg-PEA provided alkaline and polar environment for Ce6, 
and the interaction between Arg-PEA and Ce6 further interrupted the intermolecular 
bonding between Ce6 molecules, which leads to increased fraction of Ce6 monomer. 
In the PDT treatment for tumor, aggregation of Ce6 can be anticipated in acidic 
microenvironment of tumor [35]. Therefore, it’s important to incorporate proper 
delivery carriers that can compensate the disadvantage of Ce6 aggregation. Arg-PEA 
enhanced Ce6 monomerization at a relatively low weight ratio (10:1), which is 
comparable to polyvinylpyrrolidone, an additive used to enhance therapeutic activity 
of Ce6 in the formulation of Pholon® [24,29]. Contrary to the non-biodegradability of 
polyvinylpyrrolidone, Arg-PEAs are enzymatic biodegradable and exhibit excellent 
biocompatibility towards a wide range of cells [36–40].  Therefore, the Arg-PEA 
component in the nanocomplex is expected to provide additional advantages as the 
delivery vehicles for Ce6. 
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Figure 3.4. A) The UV-Vis spectra of free Ce6, mixture of Arg-PEA and Ce6, and 
Ce6-loaded HA-Arg-PEA nanocomplex in an aqueous dispersion (pH 4.5). B) The 
effect of pH on Ce6 monomerization in interaction with Arg-PEA. The ratio between 
the absorbance at 672 nm (representing Ce6 in the monomer state) and 645 nm 
(representing Ce6 in the aggregation state) from UV-Vis spectra obtained from 
mixture of Arg-PEA and Ce6 (with equivalent Ce6 concentration of 50 µM) dispersed 
in phosphate buffer with various pH. Free Ce6 was tested as control. Values represent 
the average ± SD (n=3). Statistical significance: *, p < 0.05; **, p < 0.01, ***, p < 
0.001. 
 
3.4.4 In vitro generation of singlet oxygen  
    To illustrate the effect of enzymatic degradation on photosensitizing effect of Ce6 
in HA-Arg-PEA nanocomplex, the production of singlet oxygen species was probed 
by RNO bleaching assay. RNO bleaching is a consequence of singlet oxygen captured 
by the imidazole ring, resulting in the formation of a trans-annular peroxide 
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intermediate with reduced absorbance at 440 nm [41]. As shown in Figure 3.5A, in the 
absence of hyaluronidase, Ce6 loaded in HA-Arg-PEA nanocomplex (red curve) 
exhibited a delayed release of singlet oxygen when comparing to free Ce6 (blue curve) 
at physiological pH.  The result suggested that when entrapped in the interior of HA-
Arg-PEA nanocomplex, the sensitizing efficiency of Ce6 was suppressed towards 660 
nm light irradiation to produce singlet oxygen. However, after incubation with 
hyaluronidase for 24 hrs, a rapid generation of singlet oxygen was observed for Ce6-
loaded HA-Arg-PEA nanocomplex (black curve) due to the release of Ce6 from the 
nanocomplex, and the rate for singlet oxygen generation was comparable to free Ce6 
(blue curve). Consistent with the morphological changes of HA-Arg-PEA 
nanocomplex in Figure 3.3, Ce6 released from the degraded nanocomplex is 
responsible for the rapid generation of singlet oxygen, and hyaluronidase can provide 
an effective intracellular signal to accelerate the release of Ce6 within tumor cells.  
  At pH 6.5 (Figure 3.5B), slower rate of singlet oxygen generation from free Ce6 
(blue curve) was observed than pH 7.4 (Figure 3.5A), as 74% of RNO was maintained 
after 60 min irradiation. Ce6-loaded HA-Arg-PEA nanocomplex without degradation 
still exhibited a lower level of singlet oxygen generation (red curve) than free Ce6, but 
the difference was significantly reduced at acidic pH. In the case of Ce6-loaded HA-
Arg-PEA nanocomplex after enzymatic degradation (black curve), accelerated RNO 
bleaching was observed (54% of RNO remained after 60 min irradiation), when 
compared to either free Ce6 or Ce6-loaded HA-Arg-PEA without degradation. 
Considering the result of Ce6 monomerization in Figure 3.4, and that singlet oxygen 
generation is positively correlated to the degree of Ce6 monomerization, it is 
 105 
reasonable to attribute the accelerated singlet oxygen generation to the interaction 
between Ce6 and Arg-PEA component in the nanocomplex.  
 
 
Figure 3.5. The production of singlet oxygen from Ce6-loaded HA-Arg-PEA 
nanocomplex after 24 hrs incubation with hyaluronidase, and diluted in phosphate 
buffer with different pH: A) pH 7.4, and B) pH 6.5. The final concentration of Ce6 in 
each sample was 10 μM Light irradiation at 660 nm was applied. The generation of 
singlet oxygen was monitored vs. irradiation time by measuring RNO bleaching at 440 
nm. Values represent the average ± SD (n=3). Statistical significance: ***, p < 0.001. 
 
3.4.5 Subcellular distribution of Ce6-loaded HA-Arg-PEA nanocomplex  
  The expression of CD44 receptor on MDA-MB-435/MDR cells was first 
confirmed by anti-CD44 staining, as shown in Figure 3.6.  The overexpression of 
CD44 receptor on MDA-MB-345 cells was also evidenced by Sun et al. [42].  
Therefore, it is reasonable to select MDA-MB-435/MDR melanoma cells as CD44 
positive in vitro model to examine the antitumor effect of Ce6-loaded HA-Arg-PEA. 
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Figure 3.6A also showed the subcellular distribution of Ce6 loaded in HA-Arg-PEA 
nanocomplex and free Ce6; and both were identified in the cytoplasm of MDA-MB-
435/MDR cells after 4 hrs incubation.  The subcellular distribution of the blank HA-
Arg-PEA nanocomplex was also studied and shown in Figure 3.6B. The red 
fluorescence of rhodamine-labelled nanocomplex was identified to be co-localized 
with endolysosomes, as yellow pixels were observed in the overlay images. The 
results suggested that HA-Arg-PEA nanocomplex was entrapped in endolysosomes 
which have a series of digestive enzymes to be able to accelerate the release of Ce6 
from the nanocomplex due to the biodegradation of the carrier by endolysosomal 
enzymes, as indicated in Figure 3.3 and Figure 3.5. It can be concluded that the 
distribution of the biodegradable HA-Arg-PEA nanocomplex in the endolysosomes 
may lead to release of Ce6 which was accelerated by enzymatic biodegradation of the 
carrier, and Ce6-loaded in the nanocomplex exhibited the same subcellular distribution 
compared to free Ce6, where they can fulfill their biological functions. 
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Figure 3.6.  A) Confocal images of subcellular distribution of Ce6-loaded HA-Arg-
PEA nanocomplex in MDA-MB-435/MDR cells after 24 hrs incubation. Left column: 
MDA-MB-435/MDR cells stained with anti-human CD44 antibody (green), the nuclei 
were counterstained with DAPI (blue). Middle column: intracellular fluorescence from 
MDA-MB-435/MDR cells treated with Ce6-loaded HA-Arg-PEA nanocomplex (red). 
Right column: intracellular fluorescence from MDA-MB-435/MDR cells after treated 
with free Ce6 (red). B) Confocal images of subcellular distribution of blank HA-Arg-
PEA nanocomplex labelled with rhodamine (red) after 4 hrs incubation. The 
endolysosomes of MDA-MB-435/MDR cells were labelled with Lysotracker (green). 
Overlay of green and red fluorescence, and the bright filed (BF) images were 
provided. Scale bar represents 20 μm.  
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3.4.6 Endocytosis of HA-Arg-PEA nanocomplex by MDA-MB-435/MDR cells   
  Inhibition study was performed to probe the endocytosis pathway of the 
blank HA-Arg-PEA nanocomplex in MDA-MB-435/MDR cells, and the data 
are shown in Figure 3.7A. The uptake of HA-Arg-PEA nanocomplex was 
decreased by 38% in MDA-MB-435/MDR cells pre-treated with anti-CD44 
antibody, indicating that the entry of HA-Arg-PEA nanocomplex was mediated 
by CD44 receptor.  Figure 3.7A also suggested that incubation of MDA-MB-
435/MDR cells at 4 °C resulted in 60% decrease in the intracellular 
accumulation of rhodamine labelled nanocomplex, indicating that the 
internalization of HA-Arg-PEA nanocomplex is energy-dependent. The 
inhibition of lipid raft mediated endocytosis by methyl-β-cyclodextrin (methyl-
betaCD) and clathrin mediated endocytosis by chloropromazine lead to the 
reduction of intracellular HA-Arg-PEA nanocomplex by 15% and 22%, 
respectively. The results suggested that both the clathrin mediated and lipid raft 
mediated endocytosis were involved in the internalization of HA-Arg-PEA 
nanocomplex into the MDA-MB-435/MDR cells. The lipid-raft dependent 
endocytosis pathway of was also reported by Qhattal et al. [43]. They suggested 
that HA grafted nanoparticles can rapidly recruit CD44s to the lipid raft 
fraction, and depletion of cholesterol by methyl-betaCD lead to shedding of 
CD44s, which reduced the uptake of HA nanoparticles. 
  However, the inhibition of macropinocytosis and the caveolae-mediated 
pathways by amiloride or nystatin in Figure 3.7A showed no significant 
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reduction in the transmigration of HA-Arg-PEA nanocomplex, indicating that 
the internalization of the blank HA-Arg-PEA nanocomplex was independent of 
macropinocytosis or caveolae pathway. The entry of free Ce6 into tumor cells, 
on the other hand, is a complicated process which involves binding with 
multiple plasma protein and lipoprotein, and LDL(low density lipoprotein) 
receptor mediated endocytosis was also evident for the internalization of free 
Ce6 [44].  
  In addition to the study of endocytosis pathway, the accumulated level of 
intracellular Ce6 were also monitored in both MDA-MB-435/MDR cells (CD44 
positive) and 3T3 fibroblasts (CD44 negative), as shown in Figure 3.7B. When 
MDA-MB-435/MDR cells were incubated with Ce6-loaded HA-Arg-PEA 
nanocomplex, a significantly higher Ce6 level was observed at the first 4 hrs 
(blue curve), the highest among all the testing samples including free Ce6 (black 
curve). But the difference disappeared at longer incubation time (8 hrs and 
thereafter). Therefore, it’s reasonable to conclude that the CD44 receptor 
mediated endocytosis of HA-Arg-PEA nanocomplex was more effective to 
improve the internalization efficiency of loaded Ce6 at a shorter exposure time.  
  In CD44 negative 3T3 fibroblasts, the accumulated level of intracellular 
Ce6 from free Ce6 (red curve) did not exhibit any statistical difference from the 
Ce6 level in MDA-MB-435/MDR cells (blue curve), suggesting no selectivity 
between normal and tumor cells. The lack of selectivity in the endocytosis of 
free Ce6 into cancer cells was also reported by Yoon et al. [45] in their study of 
HT29 colorectal tumor cells. In the case of Ce6-loaded HA-Arg-PEA 
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nanocomplex, the intracellular Ce6 level in MDA-MB-435/MDR cells (blue 
curve) was 1.8 fold higher than 3T3 fibroblasts (green curve) after 24 hrs 
incubation. HA-Arg-PEA remarkably enhanced the selectivity of Ce6 
internalization by CD44 overexpressed tumor cells, and provides promising 
potential as the tumor-targeted delivery vehicles in PDT treatments. 
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Figure 3.7. A) Endocytosis pathway inhibition studies. MDA-MB-435/MDR cells 
pre-treated with various endocytosis inhibitors or low temperature were incubated 
with rhodamine labelled HA-Arg-PEA nanocomplex for 4 hrs. Mean cellular 
fluorescence was recorded by flow cytometry and normalized to control (cells 
incubated with nanocomplex but not treated by any inhibitor). Values represent the 
average ± SD (n=3). Statistical significance was compared with control. B) Mean 
fluorescence of MDA-MB-435/MDR cells (CD44 positive) or 3T3 fibroblasts (CD44 
negative) incubated with free Ce6 or Ce6-loaded HA-Arg-PEA nanocomplex (5 μM 
equivalent Ce6 concentration) was plotted vs. incubation time. Values represent the 
average ± SD (n=3). Statistical significance was compared between free Ce6 and Ce6-
loaded HA-Arg-PEA nanocomplex treated groups, *, p < 0.05; **, p < 0.01, ***, p < 
0.001. 
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3.4.7 Phototoxicity of Ce6-loaded HA-Arg-PEA nanocomplex  
    Cytotoxicity of blank HA-Arg-PEA nanocomplex (without loaded Ce6) was first 
examined in MDA-MB-435/MDR cells to determine the biocompatibility of the 
carrier.  As shown in Figure 3.8A, no significant cytotoxicity from the blank 
nanocomplex was observed at the concentration range from 1 to 100 μg/mL，which 
correlated to equivalent Ce6 concentration between 0.15 to 15 μM that was used in 
cytotoxicity study in Figure 3.8B. Therefore, the phototoxicity of Ce6-loaded HA-
Arg-PEA nanocomplex can be solely attributed to the loaded Ce6 photosensitizer, 
instead of the carrier.  
    The phototoxicity of Ce6-loaded HA-Arg-PEA nanocomplex toward MDA-MB-
435/MDR cells was then studied and the results are given in Figure 3.8B. The light 
dose of 3 J/cm2 was selected based on the previous research on chlorin PDT. Chung et 
al. [46] and Luo et al. [47] suggested the range of light dose (1 – 5 J/cm2) in both 
HCT116 human colon cancer cells and Tca8113 human tongue squamous cancer cells. 
In our preliminary study, we tested different light doses of 1 J/cm2, 3 J/cm2 and 5 
J/cm2, and only 3 J/cm2 (120 sec) light dose resulted in a gradual increase in cellular 
toxicity as a function of the concentration of Ce6. At a lower light dose (1 J/cm2, 40 
sec) the cytotoxicity induced by both free Ce6 and Ce6-loaded nanocomplex was not 
significant (MDA-MB-435/MDR viability was greater than 70%) throughout the 
tested concentration range of Ce6 (1 – 10 µM). At a higher light dose (5 J/cm2, 200 
sec), the phototoxicity effect by free Ce6 and Ce6-loaded nanocomplex dominated 
from 0.5 to 10 µM, and the difference between free Ce6 and Ce6-loaded nanocomplex 
was not detectable due to the overdose of light irradiation that masked the difference.  
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    When a light dose of 3 J/cm2 was applied at 660 nm, enhanced toxicity was 
observed for both free Ce6 and Ce6-loaded HA-Arg-PEA nanocomplex, due to the 
production of singlet oxygen by photosensitizer shown in Figure 3.5B.  Ce6-loaded 
HA-Arg-PEA nanocomplex induced significantly enhanced toxicity towards MDA-
MB-435/MDR cells than free Ce6 at higher Ce6 concentrations (5-15 μM). However, 
the difference in phototoxicity between the two treatments disappeared at 
concentrations lower than 2 μM. The IC50 was calculated to be 4.3 μM for free Ce6 
and 2.6 μM for Ce6-loaded HA-Arg-PEA nanocomplex, respectively.  
  The enhanced cytotoxicity towards MDA-MB-435/MDR cells by Ce6-loaded 
nanocomplex at higher Ce6 concentrations can be attributed to the enhanced level of 
Ce6 monomerization and efficiency in generating singlet oxygen as indicated in 
Figure 3.4 and 5B.  As Ce6 monomerization positively correlated to the 
photosensizting effect which induced phototoxicity [48], the interaction between Arg-
PEA and Ce6, which is favorable for Ce6 monomerization, lead to the improved PDT 
efficiency of Ce6-loaded HA-Arg-PEA nanocomplex. At diluted condition (less than 2 
μM), Ce6 maintained their monomeric form and the interaction with nanocomplex had 
less impact on their therapeutic efficiency. 
  The enhanced phototoxicity by Ce6-loaded HA-Arg-PEA nanocomplex is also 
closely related to the accumulated cellular Ce6 level described in Figure 3.7B.  In 
addition, CD44 mediated endocytosis of HA-Arg-PEA nanocomplex facilitated the 
internalization of Ce6 by MDA-MB-435/MDR cells within a shorter incubation time 
(Figure 3.7B), and the higher intracellular Ce6 level also contributed to the improved 
phototoxicity of Ce6-loaded HA-Arg-PEA nanocomplex. 
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  Phototoxicity of free Ce6 and Ce6-loaded HA-Arg-PEA nanocomplex was also 
detected on wild type MDA-MB-435 cells without multidrug resistance. At a light 
dose of 3 J/cm2, the IC50 was 5.0 μM for free Ce6 and 2.4 μM for Ce6-loaded HA-
Arg-PEA nanocomplex. Comparing the IC50 values between wild type vs. multidrug 
resistant phenotype, MDA-MB-435/MDR cells did not exhibit cross-resistance to 
photodynamic treatment in the case of both free Ce6 and Ce6-loaded HA-Arg-PEA 
nanocomplex. Since the presence of drug efflux pump does not adversely affect the 
therapeutic performance of Ce6-loaded HA-Arg-PEA nanocomplex, it can be applied 
as an alternative/complementary treatment for multidrug resistant tumor with 
improved therapeutic efficiency.  
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Figure 3.8. A) Viability of MDA-MB-435/MDR cells treated by blank HA-Arg-PEA 
nanocomplex.  B) Viability of MDA-MB-435/MDR cells treated by Ce6-loaded HA-
Arg-PEA nanocomplex and free Ce6 at various Ce6 concentrations with and without 
irradiation.  The MDA-MB-435/MDR cells were incubated with Ce6 for 4 hrs, 
washed and further incubated for another 20 hrs in fresh media, before light irradiation 
was applied (660 nm, 3 J/cm2). Cell viability was determined 24 hrs post-irradiation. 
Values represent the average ± SD (n=6).  Statistical significance: *, p < 0.05; **, p < 
0.01, ***, p < 0.001. 
  
3.4.8 Apoptosis study on PDT-treated MDA-MB-435/MDR cells 
    To further characterize cell death in PDT-treated MDA-MB-435/MDR cells, flow 
cytometry results for annexin V/PI assay were shown in Figure 3.9A. The percentages 
of cell population in each quadrant were obtained as: live cells (PI-/annexin V-, the 
lower left quadrant), dead cells (PI+/annexin+ and PI+/annexin V-, both the upper right 
and upper left quadrant), early apoptotic cells (PI-/annexin V+, the lower right 
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quadrant), and listed in Figure 3.9B. Blank HA-Arg-PEA nanocomplex didn’t induce 
significant cell death, as 83.6% of cells was alive. The result suggested the 
biocompatibility of the blank nanocomplex. Cell death induced by two different Ce6 
concentrations (2 μM and 10 μM) was then detected for both free Ce6 and Ce6-loaded 
HA-Arg-PEA nanocomplex. It can be concluded that any cytotoxicity should be 
attributed to the loaded Ce6 instead of the carrier. 
  At a higher Ce6 concentration (10 μM), neither Ce6-loaded nanocomplex nor 
free Ce6 induced early apoptosis. When treated with Ce6-loaded HA-Arg-PEA 
nanocomplex, the majority of the cell population (79.6 %) was detected as dead cells, 
and a minor population of live cells was detected (20.0%). These results suggest a 
trend of necrotic death of MDA-MB-435/MDR cells when treated with a higher dose 
of Ce6-loaded HA-Arg-PEA nanocomplex. Free Ce6 at a similar concentration (10 
μM) induced a significantly lower level of cell death, as 46.7% of cells were alive. 
These results further suggest that the Ce6-loaded HA-Arg-PEA nanocomplex was 
more potent than free Ce6 at a higher Ce6 concentration. 
  At a lower Ce6 concentration (2 μM), the Ce6-loaded HA-Arg-PEA 
nanocomplex did not induce cell death as effectively as free Ce6, i.e., 64.3% of cells 
were alive in the Ce6-loaded nanocomplex treatment vs. 56.7% live cells treated with 
free Ce6. However, 16.7% of cells were subjected to early apoptosis in the Ce6-loaded 
HA-Arg-PEA nanocomplex treatment, the highest among all 4 testing groups, 
indicating a potentially different cell death mechanism at this particular treatment 
condition.  
  At higher Ce6 concentration (10 μM), Ce6-loaded HA-Arg-PEA nanocomplex 
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outperformed than free Ce6. Higher Ce6 concentration lead to a greater tendency to 
form Ce6 aggregates in the absence of a proper carrier.  At diluted condition, Ce6 
monomer would dominate irrespective of the carrier, and bring in therapeutic 
effectiveness.  In general, the annexin V/PI assay provided consistent results with the 
phototoxicity data in Figure 3.8, in which enhanced PDT efficiency was observed for 
Ce6-loaded HA-Arg-PEA nanocomplex at higher Ce6 concentrations (5 to 15 μM). 
The in vitro cell work was performed at physiological pH, and it’s reasonable to 
predict that Ce6-loaded HA-Arg-PEA can exhibit enhanced potency than free Ce6 in 
acidic microenvironment of tumor in the in vivo study.  
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Figure 3.9. Photosensitizer-induced apoptosis of MDA-MB-435/MDR cells by 
Annexin V/PI Staining. A) Flow cytometry plots of annexin V/PI staining of MDA-
MB-435/MDR cells.  Blank HA-Arg-PEA nanocomplex, free Ce6 or Ce6-loaded 
HA-Arg-PEA nanocomplex with equivalent Ce6 concentrations (2 and 10 μM) were 
incubated with MDA-MB-435/MDR cells for 4 hrs before the photosensitizer was 
washed off and cells were incubated for another 20 hrs in fresh media. Light 
irradiation was then applied (660 nm, 3 J/cm2). Annexin-V/PI double staining was 
performed 24 hrs post irradiation. B) The percentage of cell population in each 
quadrant was determined by flow cytometry, values represent the average ± SD (n=3).  
Statistical significance: ***, p < 0.001. 
 
3.5 Conclusions 
  Self-assembled nanocomplex was formed from anionic HA and cationic Arg-
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PEA, and further stabilized via covalent bonding. The Arg-PEA component in the 
nanocomplex facilitated the formation of Ce6 monomer with enhanced 
photosensitizing efficiency, while the HA component achieved targeted delivery of 
Ce6 in CD44 positive tumor cells. The monomerization of loaded Ce6 was maintained 
in acidic environment compared to free Ce6, and the efficiency of singlet oxygen 
generation was also improved. The biodegradability of HA-Arg-PEA nanocomplex 
enabled enzymatic-triggered release of Ce6. The CD44-mediated endocytosis of Ce6-
loaded nanocomplex significantly improved the selectivity and the intracellular Ce6 
level in CD44 positive MDA-MB-435/MDR cancer cells within a shorter incubation 
time.  The PDT efficiency in tumor cell inhibition was also enhanced compared to 
free Ce6, especially at higher Ce6 concentrations. Therefore, the biodegradable HA-
Arg-PEA nanocomplex could be a promising delivery vehicle in the application of 
photodynamic therapy for tumors.  
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CHAPTER 4 
 
LIGHT-FACILITATED REDUCTION-RESPONSIVE DRUG DELIVERY SYSTEM 
FROM BIODEGRADABLE PSEUDO PROTEIN/HYAURONIC ACID 
NANOCOMPLEX WITH IMPROVED ANTI-TUMOR EFFECT 
  
 124 
 
4.1 Abstract 
    Reduction-sensitive nanomedicine is a promising strategy to achieve controlled 
release of payloads in response to intracellular reductive milieu. However, 
endolysosomal sequestration of internalized carriers and insufficient redox potential in 
endolysosomes may delay the release of payloads and impact their therapeutic 
efficacy. Photochemical internalization (PCI), which takes advantage of light-induced 
endolysosomal rupture, is an effective technique for endosomal escapes and cytosolic 
release of cargos. In this study, a biodegradable and reduction-sensitive nanocomplex 
was developed from arginine based poly(ester amide)s and hyaluronic acid (HA), and 
the PCI-photosensitizer AlPcS2a was conjugated to the surface of the nanocomplex 
(ArgPEA-ss-HA(AP)). The PCI effect of ArgPEA-ss-HA(AP) nanocomplex was 
validated in both monolayers and 3D spheroid models of MDA-MB-231 breast cancer 
cells. Synergism was detected between PCI effect and doxorubicin-loaded 
nanocomplex in the inhibition of MDA-MB-231 cells. In addition, the ArgPEA-ss-
HA(AP) nanocomplex also provided enhanced intratumoral penetration in 3D 
spheroids compared to free AlPcS2a. The in vivo results suggested that the 
conjugation of AlPCs2a in the nanocomplex enabled the consistent and preferential 
accumulation of both doxorubicin and AlPcS2a in tumor site. Light-enhanced anti-
tumor effect was observed for doxorubicin-loaded nanocomplex at well-tolerable 
dosage. ArgPEA-ss-HA(AP) nanocomplex, as a reduction-responsive delivery vehicle, 
can hold great potential to achieve spatio-temporally controllable anti-tumor effect. 
 
4.2 Introduction 
    Stimuli-responsive nanomedicine with controlled release profile and minimal 
side effect have gained considerable popularity in the study of anti-cancer drug 
delivery [1]. Smart nano-carriers enable the site-specific release of payloads in 
response to a series of biological cues in tumor local environment (enzyme, acidic pH, 
redox potential, etc.) as well as other physical stimuli (light, temperature, ultrasounds, 
electric field, etc) [2]. Among various smart nanomedicines, reduction-sensitive nano-
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vehicles provide a promising strategy for intracellular drug delivery, in which the 
release of payloads is predominantly triggered by thiol/disulfide exchange induced by 
the intracellular reducing agent such as glutathione[3]. 
    The internalization of nanomedicine by tumor cells involves transporter-mediated 
endocytosis [4]. The nanoparticles are wrapped around by the plasma membrane, and 
closed-vesicle structures are formed, followed by fusion with endolysosomes. Except 
ultra-small gold nanoparticles (2-10 nm), which were identified in nucleus and 
cytoplasm [5,6], endolysosomal sequestration and subsequent degradation was 
inevitable if the nano-carriers are not engineered to escape endolysosomes [7]. For 
reduction-responsive nanomedicine, the therapeutic potency can be challenged due to 
the absence of reductive milieu in endolysosomes [8]. Augmentation in therapeutic 
effect resulted from endolysosomal escape of reduction-sensitive nanomedicine were 
reported [9,10]. 
    Photochemical internalization (PCI), developed by Berg and colleagues [11], is a 
highly efficient technology which takes advantage of photochemical rupture of 
endocytic vesicles and enables the cytosolic release of therapeutic agents [12]. PCI-
photosensitizers are amphiphilic molecules which contain hydrophobic fused rings and 
hydrophilic sulfonate groups, and exhibit specific affinity with the membrane of 
endocytic vesicles where they generate singlet oxygen upon irradiation to induce the 
permeabilization of endocytic vesicles. PCI-photosensitizers are non-toxic in the 
absence of light, and spatio-temporally controlled tumoricidal effect can be achieved 
by the application of light irradiation. PCI has been demonstrated to enhance the 
efficacy of various therapeutic agents, such as macromolecular [11]. In addition, PCI 
was also documented to enhance the delivery performance of polymer-based nano-
carriers[13]. Yen et al. [14] reported an augmented anti-tumor efficiency of poly(ethylene 
glycol)-poly(lysine) (PEG-PLys) micelles conjugated with camptothecin via disulfide 
linkage, when endolysosomal escape was achieved from the PCI effect of free 
photosensitizer photofrin.  
    The concentration of PCI-photosensitizers and therapeutic agents, light dosage, 
the time interval between the administration of drug and the application of light are the 
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key factors that contribute to the efficacy of PCI [15]. In the current research, PCI-
photosensitizers and the therapeutics were administered separately. The discrepancy in 
their biodistribution and pharmacokinetic profiles can impact the efficiency of PCI-
facilitated treatment. It is of particular interest to develop a biodegradable vehicle for 
the co-delivery of both PCI-photosensitizer and therapeutic agents. 
    Amino acid based poly (ester amide)s (AA-PEA) is a family of biodegradable 
pseudo-proteins synthesized from 3 building blocks: amino acids, dialcohol, diacids. 
By selecting different amino acids, AA-PEAs are tunable in their chemical/physical 
properties and have been engineered into coatings for cardiovascular stent, nanofibers, 
nanoparticles, hydrogels for multiple biomedical applications.  The advantages for 
AA-PEAs include biodegradability, biocompatibility, and muted inflammatory 
response, etc., and current research on AA-PEAs have recently been reviewed [16–19]. 
Among the amino acids for AA-PEA synthesis, arginine retains cationic charge over a 
wide range of pH, suitable to form electrostatic complex with other negatively charged 
materials such as hyaluronic acid (HA) [19–21]. HA-based nanomedicine provided 
considerable therapeutic potency in the field of tumor-targeting delivery, due to the 
overexpression of CD44 receptors on many types of tumor cells [22]. Choi et al [23] 
suggested that low degree of PEGylation on HA nanoparticles improved their blood 
circulation time, resulted in an enhanced retention of the nanoparticles in tumor site. 
    In this contribution, we aimed to develop a biodegradable and reduction-
responsive nanocomplex from arginine based PEA and hyaluronic acid, and 
functionalized the surface of the nanocomplex with PCI-photosensitizer AlPcS2a 
(aluminum phthalocyanine disulfonate) via PEG (polyethylene glycol) spacer. 
AlPcS2a is one of the most commonly studied PCI-photosensitizers with activation 
wavelength of 660 -670 nm. As evidenced by previous studies, phthalocyanine 
derivatives maintained the photosensizting effect after being conjugated with PEG [24] 
or small molecules [25], which provides rationale for the PCI-effect induced by 
conjugated AlPcS2a. However, efficiency for the endocytosis of free AlPcS2a by 
tumor cells or the penetration in solid tumor can challenge the therapeutic efficacy, as 
the general incubation time of free AlPcS2a and various 2D tumor cells was reported 
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[16] at 12-18 hrs before PCI effect was achieved. It is important to develop a delivery 
system with improved endocytosis/penetration of AlPcS2a. In this study, the AlPcS2a-
cojugated nano-carriers exhibited enhanced uptaken efficiency on both 2D monolayer 
of MDA-MB-231 breast cancer cells, and 3D multicellular spheroids, compared to 
free AlPcS2a. The PCI effect in combination with doxorubicin(DOX)-loaded 
nanocomplex was investigated to illustrate the impact of endosomal escape on the 
anti-tumor efficacy of reduction-sensitive nanomedicine both in vitro and in vivo.  
 
 
4.3 Experimental 
4.3.1 Chemicals and cells 
    Sodium hyaluronate (MW= 10 to 20 kDa) was from Lifecore Biomedical 
(Chaska, MN). Tetrabutylammonium bromide, thionyl chloride, cystamine 
dihydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC), 1-hydroxybenzotriazole (HOBT), dithiothreitol (DTT), and glutathione (GSH) 
were from Sigma Aldrich (Milwaukee, WI). Amberlite IR-120 H+ ion exchange resin 
was from Alfa Aesar (Ward Hill, MA). Dimethyl sulfoxide (DMSO), methanol and 
other HPLC grade solvents were from JT Baker (Phillipsburg, NJ). Lysotracker green 
and Hoechst 33342 were from Molecular Probes (Eugene, OR). Aluminum 
phthalocyanine disulfonate (AlPcS2a) was from Frontier Scientific (Logan, UT). 
Doxorubicin hydrochloride was from Lancrix Chemicals (Shanghai, China). 
Maleimide-polyoxyethylene-amine (MAL-PEG-NH2, MW= 5 kDa) was from JenKem 
Technology (Allen, TX). Snakeskin dialysis tubing (MWCO = 10 kDa), SPDP (N-
succinimidyl 3-(2-pyridyldithio) propionate) crosslinker were from Pierce (Rockford, 
IL). Arg-2 (tetra-p-toluenesulfonic acid salt of bis-L-arginine ethane diester) and NSu 
(di-p-nitrophenyl succinate) were synthesized from our previous study [26]. 
    MDA-MB-231 cancer cells were maintained in Dulbecco's modified Eagle 
medium (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum 
(Hyclone, Logan, UT), 2 mM L-glutamine, 100 unit/mL penicillin, and 100 
μg/mL streptomycin (Lonza, Walkersville, MD) at 37 °C in 5% CO2.  
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4.3.2 Synthesis of polymers 
    Synthesis of AlPcS2a dichloride. AlPcS2a (50mg, 63.6 µM) was dissolved in 
thionyl chloride (5 mL); the mixture was refluxed for 8 hrs [25,27]. The excess of 
thionyl chloride was evaporated under vacuum and the residue was washed with 
dichloromethane and dried to give dichlorosulfonyl phthalocyanine. 
    Synthesis of HA-SH conjugated with PEG and AlPcS2a (HA-SH(AP)). HA-SH  
with degree of thiolation of 23% was synthesized according to the published 
procedures [28]. Tetrabutylammonium salt of HA-SH (HA-SH-TBA) was prepared as 
previously described [29]. As illustrated in Figure 4.1B, MAL-PEG-NH2 (70 mg) and 
triethylamine (5.6 mg) was dissolved in DMF (5 mL), AlPcS2a dichloride (11 mg) 
was added and reacted overnight at a room temperature. Ethanol (0.5 mL) was then 
added and the reaction mixture was purged with nitrogen for 1 hr before it was added 
to a solution of HA-SH-TBA (165 mg) in DMF (10 mL) under nitrogen protection. 
The reaction was stirred at room temperature overnight, dialyzed (MWCO=3.5 kDa) 
against DMF/H2O (3:7, v/v) for 24 hrs and DI water for another 24 hrs. The resulted 
aqueous solution of HA-SH(AP) was stirred with 25 mM DTT for 2 hrs, precipitated 
in ethanol, re-dissolved in 10 mL DI water and lyophilized. The above procedures 
were performed in dark. UV-Vis spectra of HA-SH(AP) in aqueous solution was 
examined on a Lambda Bio40 spectrophotometer (Perkin-Elmer, Norwalk, CT). 
  Preparation of NH2-ArgPEA-NH2. The synthesis of amine-terminated Arg-PEA 
was according to published study [30]. As illustrated in Figure 4.1A, an excessive 
amount of monomers Arg-2 (1.0 mmol) was mixed with monomer NSu (0.8 mmol) in 
DMSO (1.5 mL), and heated to 75 ºC under stirring. Triethylamine (0.31 mL) was 
added until the monomers were completely dissolved. The reaction was kept for 12 hrs 
at 75 ºC. The resulting NH2-ArgPEA-NH2 was precipitated in cold ethyl acetate twice, 
re-dissolved in DI water, and repeatedly concentrated in Macrosep centrifugal device 
(MWCO=1 kDa, Pall Filtron, Northborough, MA) for purification. Ninhydrin assay 
was performed to estimate the content of primary amine, calibrated with a standard 
curve obtained from free arginine. 
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Figure 4.1. Synthesis scheme for A) arginine based poly(ester amide)s (ArgPEA) with 
amino end groups (NH2-ArgPEA-NH2), and activation of amino groups with SPDP 
crosslinker; B) thiolated hyaluronic acid (HA-SH) functionalized with polyethylene 
glycol (PEG) and AlPcS2a photosensitizer (HA-SH (AP)); and C) A) the formation of 
reduction-sensitive nanocomplex ArgPEA-ss-HA(AP) from NH2-ArgPEA-NH2 
activated by SPDP and HA-SH(AP) via disulfide linkage. 
 
 
4.3.3 Preparation and characterization of DOX-loaded ArgPEA-ss-HA (AP) 
nanocomplex 
  To prepare the DOX-loaded ArgPEA-SS-HA(AP) nanocomplex (Figure 4.1C), 
NH2-ArgPEA-NH2 (50 mg) was dissolved in DMSO (5 mL), SPDP (13 mg) was 
added and stirred for 2 hrs at room temperature.  HA-SH(AP) in DI water (176 mg, 
20 mg/mL) was further added and stirred for 2 hrs. 20 mg doxorubicin hydrochloride 
was then added and stirred overnight.  The resulted nanocomplex was dialyzed 
against DI water (MWCO=10 kDa) for 48 hrs, repeatedly concentrated in Macrosep 
centrifugal filter (MWCO=100 kDa), and lyophilized. To determine the contents of 
AlPcS2a in the nanocomplex, ArgPEA-ss-HA (AP) nanocomplex (10 mg) was 
digested in 0.1 M NaOH (1 mL) overnight. The fluorescence of AlPcS2a was 
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determined on a PTI spectrofluorometer (Photon Technology International, South 
Brunswick, NJ) at λex=605 nm, λem=660-790 nm, and calibrated with an AlPcS2a 
standard curve. 
  To determine the loading contents of DOX in the nanocomplex, 10 mg of DOX-
loaded ArgPEA-ss-HA (AP) nanocomplex was dissolved in 25 mM aqueous solution 
of DTT and stirred overnight. The solution was centrifuged at 14000 rcf and DOX 
concentration was determined by spectrofluorometer at λex=480 nm, λem=590 nm 
and calibrated with a DOX standard curve. Drug loading content (DLC) and 
encapsulation efficiency (EE) were calculated. 
    The morphology of the nanocomplex was observed on a FEI Tecnai Spirit T12 
TEM (FEI Co., Hillsboro, OR) at an operating voltage of 120 kV. Zeta potential and 
the size profile were characterized on a NanoZS Zetasizer (Malvern, UK). 
 
4.3.4 Oxygen consumption rate of ArgPEA-ss-HA(AP) nanocomplex 
    The oxygen consumption rate of blank ArgPEA-ss-HA(AP) nanocomplex was 
measured using a Clark-type oxygen electrode (Hansatech Instruments Ltd, UK) as 
previously described [31]. The microelectrode was inserted into the PBS solution of 
free AlPcS2a or blank ArgPEA-ss-HA(AP) with equivalent AlPcS2a concentration. 
10% FBS was also present in each sample as receptor for reactive oxygen species. 
LED arrays (660 nm, 25 mW/cm2, Elixa Ltd, Albuquerque, NM) was used for light 
irradiation. Before each measurement, the system was calibrated in PBS bubbled with 
air. Fold of oxygen consumption was acquired by normalizing the measured oxygen 
pressure in each sample to untreated PBS bubbled with air, and the result was plotted 
as a function of irradiation time. Oxygen consumption rate of non-irradiated solution 
of free AlPcS2a or blank ArgPEA-ss-HA(AP) were also tested. 
 
4.3.5 In vitro release of DOX from ArgPEA-ss-HA(AP) nanocomplex 
    In vitro release profiles of DOX from the ArgPEA-ss-HA(AP) 
nanocomplex were examined in 10 mM phosphate buffer (pH 7.4) with or 
without the presence of 10 mM glutathione(GSH) for 48 hrs at 37 °C. The 
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DOX-loaded ArgPEA-ss-HA(AP) nanocomplex in PBS (5mg/mL, 5mL) with 
10 mM GSH was placed in dialysis tubing (MWCO = 10 kDa) and immersed 
against same buffer (30 mL) at 37 °C under shaking (100 rpm). At pre-
determined time intervals, buffer outside the dialysis tubing (5 mL) was 
withdrawn and replaced by fresh buffer. DOX concentration in collected 
samples were determined on spectrofluorometer at λex=480 nm, λem=590 nm, 
the percentage of released DOX was plotted vs. time. Each test was performed 
in triplicate. 
 
4.3.6 In vitro endocytosis and endosomal escape of ArgPEA-ss-HA(AP) 
nanocomplex 
    Endocytosis. MDA-MB-231 cells incubated with blank ArgPEA-ss-HA(AP) 
nanocomplex or free AlPcS2a for predetermined time intervals. Flow cytometry was 
performed on FACSAria fusion fluorescence activated cell sorter (BD Biosciences, 
Franklin Lakes, NJ), and each test was run in 3 replicates. 
  Endosomal escape. MDA-MB-231 cells were seeded in a 35 mm glass-bottomed-
dish (3 x 105 cells/well, MaTek, Ashland, MA) and incubated for 24 hrs. Blank 
ArgPEA-ss-HA(AP) nanocomplex (c(AlPcS2a) = 5 µM) was added and incubated for 
4 hrs. The cells were washed and labeled with Lysotracker green (50 nM) as per 
manufacturer’s instruction, and imaged alive by confocal microscopy (Zeiss LSM710, 
Carl Zeiss MicroImaging, Thornwood, NY). Light irradiation was then applied by 
LED arrays at 660 nm with light dosages of 0 J/cm2, 0.5 J/cm2, 1.5 J/cm2 or 3 J/cm2. 
The Pearson’s coefficient for co-localization between the blank ArgPEA-ss-HA(AP) 
nanocomplex and Lysotracker before and 0.5 hr after irradiation was determined with 
Fiji software (National Institutes of Health), 30 images were analyzed for each group. 
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4.3.7 Cytotoxicity of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex in MDA-MB-
231 monolayers 
  MDA-MB-231 cells were seeded in 96-well plate (5 x 103 cells/well) and 
pre-incubated for 24 hrs. Blank ArgPEA-ss-HA(AP) nanocomplex, DOX-
loaded ArgPEA-ss-HA(AP) nanocomplex, free DOX with various DOX 
concentration were added and incubated for 4 hrs. The cells were washed with 
PBS and incubated for another 4 hrs in fresh DMEM. Light irradiation was 
applied by LED arrays (120 arrays, 25 mW/cm2, Elixa Ltd, Albuquerque, NM) 
at 660 nm with light dosages of 0, 0.5, 1.5 or 3 J/cm2. After further incubation 
for another 24 hrs, the cell viability was determined with WST-1 assay (Roche 
Diagnostics, Mannheim, Germany). The results were normalized to the viability 
of untreated cells to give the percentage of viability.  Each experiment was run 
in 6 replicates. Factor α [32] was calculated from the survival fraction (SF) of 
different groups to evaluate the level of synergism (α>1 synergistic; α=1 simply 
additive; α<1 antagonistic).  
 
α =
𝑆𝐹(𝑓𝑟𝑒𝑒 𝐷𝑂𝑋) × 𝑆𝐹 (𝐴𝑟𝑔𝑃𝐸𝐴 − 𝑠𝑠 − 𝐻𝐴(𝐴𝑃))
𝑆𝐹 (𝐴𝑟𝑔𝑃𝐸𝐴 − 𝑠𝑠 − 𝐻𝐴(𝐴𝑃)/𝐷𝑂𝑋)
 
 
 
4.3.8 Anti-tumor effect of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex in MDA-
MB-231 spheroids 
  MDA-MB-231 multicellular spheroids were developed from the published 
protocols [33]. MDA-MB-231 cells were harvested and resuspended in DMEM 
containing 2.5% matrigel (BD Bioscience, San Jose, CA). Cells were seeded in ultra-
low-attachment 96-well plate (CellCarrier, Perkin Elmer, Waltham, MA) at 0.5 x 104 
cells/well, centrifuged at 1000 rcf for 10 min and incubated for 3 days. Spheroids were 
treated with blank ArgPEA-ss-HA(AP) nanocomplex, DOX-loaded ArgPEA-ss-
HA(AP) nanocomplex, free DOX or free AlPcS2a for 8 hrs, (with equivalent c(DOX) 
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= 5 μM, c(AlPcS2a) = 2.55 μM). Light irradiation was applied at 660 nm, 1.5 J/cm2. 
Confocal Z-stack images were obtained with 20 μm interval between slices. The total 
fluorescence intensity for each Z-stacks was analyzed with Fiji software (National 
Institutes of Health) and normalized to the cross-sectional area of the spheroid. Each 
test was performed in 10 replicates. 
    Spheroid viability assay. MDA-MB-231 spheroids were treated with blank 
ArgPEA-ss-HA(AP) nanocomplex, DOX-loaded ArgPEA-ss-HA(AP) nanocomplex, 
free DOX or free AlPcS2a (with equivalent c(DOX) = 1 μM, c(AlPcS2a) = 0.51 μM) 
for 8 hrs The spheroids were then washed, chased for another 4 hrs, and light 
irradiation was applied at 660 nm, 1.5 J/cm2. 7 days post irradiation, the viability of 
spheroids was determined with WST-1 assay. The results were normalized to the 
viability of untreated spheroids to give the percentage of viability, and each test was 
run in 10 replicates. 
 
4.3.9 Ex-vivo examination of biodistribution of ArgPEA-ss-HA(AP) nanocomplex 
  The female BALB/c nude mice were provided by the Vital Laboratory Animal 
Center (Beijing, China). All care of the animals was performed under specific 
pathogen free (SPF) conditions with free access to standard food and water, and all the 
animal experiments were conducted with the approval of the Ethics Committee of 
Shanghai University of Traditional Chinese Medicine.  
  To establish MDA-MB-231 xenograft model, MDA-MB-231 cells were 
harvested from confluent culture and re-suspended in DMEM containing 30% 
matrigel. 3×10 6 cells (100 μL) were injected subcutaneously into right flank area of 
each mouse. When tumors grew to 500 – 1000 mm3 in volume, blank ArgPEA-ss-
HA(AP) or free AlPcS2a was injected into the mice via tail vein (with equivalent 
AlPcS2a dose of 10 mg/kg). Mice were sacrificed 24 hrs post-injection, major organs 
and tumors were excised and observed with IVIS imaging system (Caliper Life 
Science, Hopkinton, MA). The protocol reported by Lee et al. [34] was used to 
determine the fluorescence intensity of AlPcS2a in each organ. Major organs and 
tumors were washed with saline and blotted dry, digested with 0.1 M NaOH (10 mL/ 
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0.l g tissue) for 4 hrs at 50 °C and centrifuged. The fluorescence intensity of AlPcS2a 
in supernatant was determined with spectrofluorometer (λex=605 nm, λem=660-790 
nm). The results were expressed as fluorescence intensity per unit mass of organs, and 
each test was run in 4 replicates. 
 
4.3.10 In vivo antitumor effect of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex 
    The in vivo antitumor efficacy of the DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex was evaluated on the MDA-MB-231 xenograft model. 3×10 6 cells (100 
μL) were injected subcutaneously into right flank area of each BALB/c nude mice. 
When the tumor sizes reached approximately 100 mm3, the mice were randomly 
divided into 5 groups (n=6) and intravenous (i.v.) injection was given with saline, free 
DOX (1.5 mg/kg/week), blank ArgPEA-ss-HA(AP) nanocomplex with irradiation, 
DOX-loaded ArgPEA-ss-HA(AP) nanocomplex (with equivalent DOX dosage of 1.5 
mg/kg/week) with or without light irradiation. 3 injections were given at day 1, day 8 
and day 15. 24 hrs post-injection, tumor tissues were irradiated by 671 nm He-Ne laser 
(100 mW/cm2, 30 J/cm2). Tumors were measured with a caliper, and tumor volume 
was calculated as following: Vtumor = (a × b 2)/2, where a is the maximum length and 
b is the minimal width. The weight of tumor-bearing nude mice was also monitored. 
At day 28, all mice were sacrificed and the weight of the tumor was measured.  
 
4.3.11 Statistical analysis 
    The data are presented as mean values with standard deviations (SD). All data 
were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison 
tests, and p < 0.05 was considered statistically significant. 
 
 
4.4 Results and discussion 
4.4.1 Characterization of ArgPEA-ss-HA(AP) polymers 
  The amine terminated Arg-PEA (NH2-ArgPEA-NH2) was prepared from a 
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solution polycondensation, in which excess amounts of nucleophilic Arg-2 monomer 
reacted with electrophilic NSu monomer to result in free amine groups at both ends of 
the Arg-PEA chain. 1H NMR spectrum (Figure 4.2A) was obtained to characterize the 
amine terminated Arg-PEA, and typical chemical shifts were observed at 8.25 ppm (-
NH-CO-), 4.23 ppm (-CH2-O-CO-) and 3.09 ppm (-NH-CO-CH2-).  The molecular 
weight of the amine-terminated Arg-PEA by GPC was 6.5 kDa with PDI =1.36. The 
amine-terminated Arg-PEA exhibits strong cationic charge, and the zeta potential for 
the 1 mg/mL solution was + 22.5 ± 3.9 mV. The content of free -NH2 was 0.25 
mmol/g in Arg-PEA, as detected by ninhydrin assay.   
  Conjugation with polyethylene glycol (PEG) was reported [23] to elongate the 
blood circulation time of HA nanoparticles, prevent the nanoparticles from being 
captured by reticuloendothelial system, and still maintain the CD44-mediated tumor-
targeting property of HA. The optimized PEGylation ratio was reported to be 5% [35]. 
In this study, PEGylation was also introduced to HA via thiol-maleimide chemistry. 
As shown in Figure 4.2B, the typical peaks for methylene protons in PEG chain (-
CH2CH2O-) was observed at 3.4 to 3.9 ppm. The integral for methylene groups from 
PEG and methyl groups from HA was calculated. The grafting ratio of PEG, defined 
as the ratio between the molar amount of PEG and the molar amount of hyaluron 
repeating units, was estimated to be 5.8% which is in line with the optimized 
PEGylation ratio reported by Choi et al.[23] PEGylation of HA not only provides 
enhanced tumor-specific delivery property, but also introduces available -NH2 groups 
for further functionalization. AlPcS2a was converted to its sulfonylchloride form by 
reaction with thionyl chloride [25,27] before it was reacted with the -NH2 groups on 
PEG and resulted in thiolated HA conjugated with AlPcS2a (HA-SH(AP)). The 
chemical reaction between PEG and AlPcS2a was evidenced by centrifugation 
method. AlPcS2a conjugated with PEG or AlPcS2a physically mixed with PEG were 
dispersed in ethanol and centrifuged at 10, 000 rcf for 20 min. Due to the poor 
solubility of free AlPcS2a in ethanol, significant precipitation was observed in the 
physical mixture. However, uniform solution was observed after centrifugation in the 
case of AlPcS2a conjugated with PEG, as PEG improved the solubility of the 
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photosensitizer. Absorbance peaks were also observed at 667 nm and 605 nm in the 
UV-vis spectrum of HA-SH(AP), which corresponded to the Q-bands of 
phthalocyanine, and further proved the presence of AlPcS2a in the modified HA-
SH(AP) polymers.  
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Figure 4.2. 1H NMR spectra of A) NH2-ArgPEA-NH2; B) HA-SH functionalized with 
PEG and AlPcS2a (HA-SH(AP)). 
 
4.4.2 Characterization of ArgPEA-ss-HA(AP) nanocomplex 
  ArgPEA-ss-HA(AP) nanocomplex was formed from self-assembly between HA 
and ArgPEA, as shown in Figure 4.1C and Figure 4.3A, and further stabilized via the 
disulfide linkage between the pyriyldithiol groups in SPDP-activated Arg-PEA and -
SH groups in HA. Since amphiphilic AlPcS2a localized specifically in the lipid bilayer 
in the endolysosomes [15], the light-induced photochemical rupture should be limited to 
the endolysosomal membrane, instead of other subcellular compartments. The 
conjugation of AlPcS2a on the surface of ArgPEA-ss-HA(AP) nanocomplex via PEG 
spacer enabled the close contact between AlPcS2a and endolysosomal membrane, as 
illustrated in Figure 4.3B.  
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Figure 4.3.  Illustration of A) dissociation of reduction-sensitive ArgPEA-ss-
HA(AP) nanocomplex triggered by glutathione (GSH); and B) endosomal escape of 
ArgPEA-ss-HA(AP) nanocomplex and cytosolic release of payloads. 
 
  Spherical assembled structure was observed for ArgPEA-ss-HA(AP) 
nanocomplex, as suggested by the transmission electron microscope (TEM) image in 
Figure 4.4A.  For ArgPEA-ss-HA(AP) nanocomplex with HA/ArgPEA = 2:1 (w/w) 
in feed, the average DLS (dynamic light scattering) diameter was detected as 109.9 ± 
5.7 nm, with a PDI of 0.135. We also synthesized a series of ArgPEA-ss-HA(AP) 
nanocomplex with various HA to ArgPEA feed ratios, and a higher HA to ArgPEA 
ratio led to an increased size of the nanocomplex, i.e., 286.2 ± 7.9 nm for 
HA/ArgPEA=4:1 (w/w) vs. 109.9 ± 5.7 nm for HA/ArgPEA=2:1 (w/w).  
  The UV-Vis spectrum of the ArgPEA-ss-HA(AP) in an aqueous solution was 
shown in Figure 4.4C. The Q-bands of phthalocyanine groups in the nanocomplex 
were observed at 667 nm and 605 nm, respectively, with similar peak profile as free 
AlPcS2a. Brasseur et al. [24] suggested that the absorbance peak at 667 nm (A667) 
represents the monomeric form of AlPcS2a, while the peak at 605 nm (A605) 
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represents the aggregated form of AlPcS2a. The ratio of A667/A605 was calculated to 
be 4.45 for free AlPcS2a and 5.92 for the ArgPEA-ss-HA(AP) when the equivalent 
concentration of AlPcS2a in PBS was 10 μM. Aggregation was reported [36] as one of 
the challenges in photosensitizer-related cancer therapy, because it can reduce the 
photochemical sensitizing efficiency of the photosensitizer. Therefore, the higher 
A667/A605 ratio in the ArgPEA-ss-HA(AP) nanocomplex can be an indication of 
enhanced monomerization level of AlPcS2a in ArgPEA-ss-HA(AP), hence enhanced 
its photosensitizing efficiency. In Figure 4.4C, we also compared the UV-Vis spectra 
of ArgPEA-ss-HA(AP) (chemical conjugation of AlPcS2a) vs. AlPcS2a loaded in the 
ArgPEA-ss-HA nanocomplex (physical encapsulation of AlPcS2a). With equivalent 
concentration, AlPcS2a physically encapsulated in the interior of the nanocomplex 
exhibited significantly reduced absorbance at 667 nm, compared to the chemically 
conjugated counterpart. The absorbance of encapsulated AlPcS2a can be shielded by 
the carriers, however, AlPcS2a conjugated to the nanocomplex exhibited similar 
absorbance profile as the free ones, which provided evidence that AlPcS2a was 
localized on the surface of the nanocomplex, instead of the interior. 
  Oxygen consumption rate. As the photosensitizing effect of AlPcS2a involves the 
photo-induced generation of free radical, and further interact with oxygen molecules 
to form ROS. The rate of oxygen consumption positively correlates with the efficiency 
of ROS generation by ArgPEA-ss-HA nanocomplex. As shown in Figure 4.4D, 
oxygen consumption by ArgPEA-ss-HA(AP) increased with irradiation time, and the 
fold of oxygen consumption was 0.98 (with light dose of 0.5 J/cm2), 0.91 (1.5 J/cm2), 
and 0.79 (3 J/cm2), respectively. In addition, the oxygen consumption profile by 
ArgPEA-ss-HA nanocomplex was almost identical to that of free AlPcS2a at the first 
120 sec of irradiation at 660 nm (25 mW/cm2). The results suggested that ArgPEA-ss-
HA(AP) complex was as competent as free AlPcS2a in ROS generation, and could 
provide equivalent potential to initiate PCI. With longer irradiation time, ArgPEA-ss-
HA(AP) exhibited higher rate of oxygen consumption than free AlPcS2a, which could 
be attributed to the enhanced monomerization level of the photosensitizer when 
conjugated with the nanocomplex (Figure 4.4C). Low level of oxygen consumption 
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was observed for non-irradiated groups in Figure 4.4D, which further validated the 
light-induced consumption of oxygen and generation of ROS by ArgPEA-ss-HA(AP) 
nanocomplex. Aluminum phthalocyanine conjugated with PEG and polyvinyl alcohol 
was previously reported [24] and the generation of reactive oxygen species by light 
irradiation was not affected by conjugation, which lead to similar conclusions as the 
oxygen consumption profile in Figure 4.4D, and provided the rationale for our 
following study. 
 
 
 
Figure 4.4. A) TEM images of blank ArgPEA-ss-HA(AP) nanocomplex, scale bar 
represents 200 nm. B) Distribution histogram of blank ArgPEA-ss-HA(AP) 
nanocomplex or AlPcS2a encapsulated in the interior of ArgPEA-ss-HA 
nanocomplex. C) UV-vis spectra of blank ArgPEA-ss-HA(AP) nanocomplex, free 
AlPcS2a or AlPcS2a encapsulated in the interior of ArgPEA-ss-HA nanocomplex in 
PBS with c(AlPcS2a) = 10 μM. D) Oxygen consumption vs. irradiation time for 
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ArgPEA-ss-HA(AP) nanocomplex or free AlPcS2a in PBS containing 10% FBS under 
irradiation (660 nm, 25 mW/cm2), the fold of oxygen consumption was obtained by 
normalizing the oxygen pressure of testing samples to that of untreated PBS. 
Irradiation time that result in light dose of 0.5, 1.5 or 3 J/cm2 were marked as dotted 
lines. 
 
4.4.3 Characterization of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex     
  The DOX-loaded ArgPEA-ss-HA(AP) nanocomplex of various HA/ArgPEA feed 
ratio were characterized and the data are shown in Table 1. Slightly negative surface 
charge (-4.31 to -5.89 mV) was observed for all DOX-loaded nanocomplex. 
HA/ArgPEA ratio also affected the size of the self-assembled nanocomplex, and a 
higher HA content in feed lead to an increased size of the nanocomplex, i.e. 272.7 nm 
for HA/ArgPEA=4:1(w/w) vs. 97.2 nm for HA/ArgPEA=2:1 (w/w). Nano-carriers of 
smaller size (< 200 nm) were found to be more effective in drug delivery because they 
are less likely to be captured by reticuloendothelial system than larger particles during 
systemic circulation [37].  
  At the same feed ratio of DOX, the DOX loading content (DLC) was 9.2% for 
the nanocomplex at the HA/ArgPEA=2:1 (w/w), while the DLC of DOX decreased to 
5.1% for the nanocomplex at HA/ArgPEA=1:1 (w/w). The reduced DLC in 
nanocomplex of a lower HA/ArgPEA ratio can be attributed to the fact that 
doxorubicin hydrochloride is cationic and binds preferentially with anionic hyaluronic 
acid. Therefore, ArgPEA-ss-HA(AP) nanocomplex with the HA/ArgPEA ratio of 2:1 
(w/w) was chosen for the following studies. The content of conjugated AlPcS2a in this 
DOX-loaded ArgPEA-ss-HA(AP) nanocomplex was detected as 5.9 wt%.      
  The release of DOX from ArgPEA-ss-HA(AP) nanocomplex with the presence of 
glutathione (GSH) was studied to investigate the sensitivity of the nanocomplex to 
reductive condition. As demonstrated in Figure 4.5, the cumulative percentage of 
DOX release in the presence of GSH was consistently and significantly higher than in 
the phosphate buffer saline (PBS, pH 7.4) over the whole duration of study. The 
accelerated release of DOX from the nanocomplex triggered by GSH provided 
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possibilities for PCI-enhanced therapeutic performances.  
 
Table 1. Characterization of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex with 
various HA to ArgPEA ratio. 
 
HA to ArgPEA ratio (w/w) a 1:1 2:1 4:1 
DLS diameter / nm 90.8 ± 4.29 97.25 ± 8.42 272.7 ± 6.78 
PDI 0.152 ± 0.03 0.147 ± 0.04 0.144 ± 0.04 
Zeta potential / mV - 4.3 ± 0.78 -3.62 ± 0.99 -5.89 ± 1.27 
AlPcS2a content / %wt 2.9 4.7 6.2 
DOX DLC /% 5.1 9.2 10.4 
DOX EE /% 57.4 83.5 82.6 
 
a. The weight ratio here indicated the feed ratio between HA-SH and NH2-ArgPEA-
NH2 in the formulation of the nanocomplex. 
 
 
 
Figure 4.5. In vitro release of DOX from DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex dispersed in PBS with or without the presence of 10 mM GSH. All the 
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results were obtained from ArgPEA-ss-HA(AP) nanocomplex with HA/ArgPEA=2:1 
(w/w). Statistical significance: *** p < 0.001. 
 
4.4.4 Light-facilitated endosomal escape of ArgPEA-ss-HA(AP) nanocomplex  
  To optimize the incubation time of ArgPEA-ss-HA(AP) nanocomplex with 
MDA-MB-231 monolayers, we studied the endocytosis of the nanocomplex as a 
function of time. As illustrated in Figure 4.6A, a distinct difference in intracellular 
AlPcS2a fluorescence was observed between ArgPEA-ss-HA(AP) nanocomplex and 
free AlPcS2a at the first 12 hrs, and the fluorescence intensity from the nanocomplex-
treated MDA-MB-231 cells was 3-fold higher than the free AlPcS2a at 4 hrs. The 
fluorescence signals from the free AlPcS2a, however, gradually increased with time 
until the difference in intracellular fluorescence between the two treatments narrowed 
at 18-20 hrs. Free AlPcS2a contains two sulfonate groups and exhibits negative charge 
in biological environment due to the low pKa value, resulting in a slower rate of 
internalization [38]. ArgPEA-ss-HA(AP) nanocomplex significantly enhanced the 
internalization efficiency of AlPcS2a in MDA-MB-231 cells especially at the first 4 
hrs. Subsequent incubation didn’t result in significant increase in the intracellular level 
of the nanocomplex, and 4 hrs was hence chosen for the following study in MDA-MB-
231 monolayers.  
    Co-localization study was performed to investigate the endosomal escape of 
ArgPEA-ss-HA(AP) nanocomplex in MDA-MB-231 monolayers. First, in the absence 
of light irradiation, MDB-MB-231 cells were incubated with blank ArgPEA-ss-
HA(AP) nanocomplex for 4 hrs and stained with Lysotracker green before cells were 
imaged alive with confocal microscopy (Zeiss LSM710, Carl Zeiss MicroImaging, 
Thornwood, NY). The red pixels of ArgPEA-ss-HA(AP) nanocomplex overlapped 
with the green pixels of endolysosomes (Figure 4.6B), and Pearson’s coefficient 
between green and red fluorescence, was determined as 0.63 (Figure 4.6C), indicating 
the endolysosomal sequestration of the nanocomplex. After another 0.5 hr incubation 
in dark, no significant change in fluorescence profile or Pearson’s coefficient were 
observed. The results demonstrated that without irradiation, the blank ArgPEA-ss-
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HA(AP) nanocomplex was largely entrapped inside endolysosomes.  
    When 660 nm irradiation at 1.5 J/cm2 was applied with LED arrays (25 mW/cm2, 
Elixa Ltd, Albuquerque, NM), the confocal image before and 0.5 hr post irradiation 
were recorded. The endosomal escape of the nanocomplex was evident, as less level of 
yellow pixels was observed, and non-overlapping red pixels from ArgPEA-ss-HA(AP) 
nanocomplex was observed to be diffused into cytosol. Significant difference in 
Pearson’s coefficient was also observed before and 0.5 hr post irradiation, which 
further proved the endosomal escape of the nanocomplex induced by 660 nm 
irradiation.  The effect of light dose on the endosomal escape in the ArgPEA-ss-
HA(AP) nanocomplex was also investigated, as shown in Figure 4.6C. At a lower 
light dose (0.5 J/cm2), the difference in Pearson’s coefficient before and after 
irradiation was not statistically significant, which suggested that 0.5 J/cm2 was not 
sufficient to result in endosomal escape of the nanocomplex. However, at higher light 
doses of 1.5 J/cm2 and 3 J/cm2, distinct endosomal escape was observed. The results 
also correlated well with Figure 4.4D, in which the oxygen consumption by 0.5 J/cm2 
was minor, while significant oxygen consumption was observed in the case of 1.5 
J/cm2 and 3 J/cm2.  In general, the light-induced translocation of ArgPEA-ss-HA(AP) 
from endolysosomal compartments into the reductive cytosol may result in enhanced 
intracellular release of DOX, as suggested in Figure 4.5, and we further studied the 
impact of light dose on the in vitro inhibition of MDA-MB-231 cells. 
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Figure 4.6. A) Mean fluorescence of free AlPcS2a and blank ArgPEA-ss-HA(AP) 
nanocomplex (c(AlPcS2a) = 5 μM) in MDA-MB-231 cells over incubation time in 
hrs. Values represent the average ± SD (n=3). B) Confocal images of MDA-MB-231 
cells incubated with blank ArgPEA-ss-HA(AP) nanocomplex (c(AlPcS2a) = 5 μM) 
for 4 hrs before and after light irradiation at 660 nm (1.5 J/cm2), Cells were labelled 
with Lysotracker green for lysosome, Intracellular fluorescence of Lysotracker 
(green), ArgPEA-ss-HA(AP) nanocomplex (red), and nuclei (blue) was recorded 
before irradiation and 0.5 hr post irradiation at 660 nm (1.5 J/cm2). C) Pearson’s 
coefficient for co-localization degree between blank ArgPEA-ss-HA(AP) 
nanocomplex and Lysotracker before and 0.5 hr after irradiation was applied at 
various light dose.  Values represent the average ± SD (n=30). Statistical 
significance: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
4.4.5 Light-enhanced anti-tumor effect of DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex in MDA-MB-231 monolayers   
   The dosage of light and drug, intervals between drug administration and light 
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application, contributed to the anti-tumor efficiency of PCI-facilitated treatments. As 
described in the endocytosis rate of the ArgPEA-ss-HA(AP) nanocomplex (Figure 
4.6A), 4 hrs incubation lead to significantly enhanced intracellular level of the 
nanocomplex, and was chosen as incubation time of DOX-loaded nanocomplex. 
Cytotoxicity in MDA-MB-231 monolayers treated with DOX-loaded ArgPEA-ss-
HA(AP) nanocomplex were then studied for screening the proper light dose and DOX 
concentration that could enable maximum level of synergism. The results are shown in 
Figure 4.7. Based on the weight content of conjugated AlPcS2a and the DLC of DOX 
in the nanocomplex, the equivalent concentration of both DOX and AlPcS2a was 
indicated in Figure 4.7.  
    In the absence of light irradiation (Figure 4.7A), blank ArgPEA-ss-HA(AP) 
nanocomplex didn’t induce significant toxicity. Cytotoxicity was observed in MDA-
MB-231 cells treated with DOX-loaded ArgPEA-ss-HA(AP) nanocomplex, with an 
IC50 of 2.3 μM. However, The DOX-loaded nanocomplex was still less potent than 
free DOX in the inhibition of tumor cells. The IC50 for free DOX was determined as 
1.1 μM. 
    In the absence of light irradiation (Figure 4.7A), blank ArgPEA-ss-HA(AP) 
nanocomplex didn’t induce significant toxicity. Cytotoxicity was observed in MDA-
MB-231 cells treated with DOX-loaded ArgPEA-ss-HA(AP) nanocomplex, with an 
IC50 of 2.3 μM. However, The DOX-loaded nanocomplex was still less potent than 
free DOX in the inhibition of tumor cells. The IC50 for free DOX was determined as 
1.1 μM. 
    When light irradiation was applied (Figure 4.7B, C and D), no variation was 
observed in the cytotoxicity induced by free DOX, as the IC 50 of free DOX was 
detected between 1.1 to 1.3 μM. In addition, cytotoxicity was observed in the case of 
blank ArgPEA-ss-HA(AP) nanocomplex, at higher AlPcS2a concentration and higher 
light dose. When 3 J/cm2 irradiation was applied (Figure 4.7D), MDA-MB-231 cell 
survival was less than 50% at c(AlPcS2a) = 1 to 5.1 μM. Cytotoxicity induced by 
irradiated blank nanocomplex can be related to the overproduction of reactive oxygen 
species by the conjugated AlPcS2a, which lead to oxidative damage and cell death. 
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However, PCI-facilitated drug delivery highlighted the photosensitizing effect to 
enhance the therapeutic effect of delivered payloads, instead of the photosensitizer 
itself taking the lead in the inhibition of tumor.  
    The IC50 for DOX-loaded nanocomplex at 1.5 J/cm2 and 3 J/cm2 was 0.71 μM 
and 0.62 μM, respectively, suggesting that light irradiation significantly enhanced the 
cytotoxicity of DOX-loaded nanocomplex. Factor α [32] was evaluated from the 
survival fraction (SF) to distinguish whether this augment was from simple addition, 
or from synergism induced by PCI (α>1 synergistic; α=1 simply additive; α<1 
antagonistic).  
    At all testing groups, we only observed α >1 (synergism) for DOX-loaded 
ArgPEA-ss-HA(AP) with c(DOX) = 0.5 μM (with equivalent c(AlPcs2a) = 0.26 μM), 
and c(DOX) = 1 μM (with equivalent c(AlPcS2a) = 0.51 μM), when 660 nm 
irradiation was applied at 1.5 J/cm2. The finding was consistent with the study by 
Matthew et al. [32] in which the optimized level of synergism was observed between 
bleomycin (0.25 µg/mL) and non-conjugated AlPcS2a (1.37 µM, 1 J/cm2, 670 nm) in 
MDA-MB-231 cells. And we focused on DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex with c(DOX) = 1 μM (equivalent c(AlPcS2a) = 0.51 μM), and irradiated 
by 660 nm light at 1.5 J/cm2 for the following in vitro study. 
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Figure 4.7. MDA-MB-231 cells were incubated with blank ArgPEA-ss-HA(AP) 
nanocomplex, DOX-loaded ArgPEA-ss-HA(AP) nanocomplex or free DOX with 
various DOX concentration for 4 hrs, washed off, chased for another 4 hrs before 660 
nm irradiation was applied at A) no irradiation; B) 0.5 J/cm2; C) 1.5 J/cm2; D) 3 J/cm2. 
Viability of cells was determined 24 hrs post irradiation and normalized to untreated 
control. Values represent the average ± SD (n=6). The equivalent concentration of 
AlPcS2a in DOX-loaded nanocomplex was also indicated in each diagram. Factor α 
was evaluated for the level of synergism. 
 
4.4.6 Enhanced penetration and anti-tumor effect of DOX-loaded ArgPEA-ss-
HA(AP) nanocomplex in MDA-MB-231 spheroids  
    In addition to 2D monolayer, we extended our studies to 3D multicellular 
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spheroids, which correlated closely with in vivo outcomes [39]. To evaluate the ability 
of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex to access the intratumoral space, 
confocal Z-stack was acquired from MDA-MB-231 spheroids after 8 hrs incubation 
with the blank ArgPEA-ss-HA(AP) nanocomplex or free AlPcS2a with equivalent 
concentration. Total fluorescence intensity was calculated and normalized to the cross-
sectional area of the spheroids. As shown in Figure 4.8A and 4.8C, free AlPcS2a 
displayed the weakest fluorescence intensity, and the fluorescence disappeared at 100 
to 120 μm from the top of the spheroids, suggesting free AlPCs2a was incompetent in 
penetration. The less efficient intratumoral migration of free AlPcS2a correlated with 
the endocytosis results in Figure 4.6A and can be attributed to its negative charge. In 
the case of blank ArgPEA-ss-HA(AP) nanocomplex without irradiation, the 
fluorescence from conjugated AlPcS2a disappeared 140 to 160 μm from the top of the 
spheroids, and significantly enhanced fluorescence intensity was also detected, 
comparing to free AlPcS2a. When 660 nm irradiation was applied at 1.5 J/cm2, both 
the fluorescence intensity and penetration depth of the blank nanocomplex was 
significantly higher than free AlPcS2a; however, no significant difference was 
observed between irradiated vs. non-irradiated nanocomplex.  
    We further studied the distribution of DOX in the spheroids. Free DOX 
penetrated easily into the spheroids, as suggested in Figure 4.8B and 8C, the 
fluorescence from free DOX was observed as 160 to 180 μm into the spheroids, and 
the fluorescence intensity outcompeted the DOX-loaded nanocomplex with or without 
irradiation. DOX-loaded ArgPEA-ss-HA(AP) exhibited an effective level of 
penetration depth and fluorescence intensity in the absence of irradiation. When 1.5 
J/cm2 irradiation was applied, significantly increased fluorescence intensity was 
observed for DOX-loaded nanocomplex comparing to the non-irradiated counterpart. 
The released DOX was reported by Zhu et al. and Zheng et al.[40,41] to exhibit stronger 
fluorescence intensity than DOX entrapped in the carriers. Therefore, the increase in 
DOX fluorescence intensity after irradiation could be attributed to the translocation of 
the nanocomplex into the cytosol and the liberation of DOX from the carrier.  
    Blank ArgPEA-ss-HA(AP) nanocomplex, DOX-loaded nanocomplex, free DOX 
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or free AlPcS2a were incubated with MDA-MB-231 spheroids for 8 hrs, and the 
equivalent concentration of DOX (1 µM) and AlPcS2a (0.51 µM) was derived from 
the inhibition study in Figure 4.7. The nanocomplex was then washed off, chased for 4 
hrs, before 660 nm irradiation was applied at 1.5 J/cm2. Viability assay was performed 
6 days post irradiation. As shown in Figure 4.8D, blank ArgPEA-ss-HA(AP) 
nanocomplex and free AlPcS2a didn’t exhibit significant toxicity with or without 
irradiation, as more than 80% viability was detected. In the case of DOX-loaded 
nanocomplex, remarkably enhanced toxicity was observed in irradiated group when 
comparing to the non-irradiated counterpart. The therapeutic efficiency of irradiated 
DOX-loaded ArgPEA-ss-HA(AP) nanocomplex was equivalent to free DOX.  
    The enhanced therapeutic effect from DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex in both monolayer and spheroid suggested the potency of the PCI effect 
to overcome the sequestration of internalized carriers in endocytic compartments. The 
PCI-facilitated delivery of chemotherapeutics was also reported for other drug carriers. 
For example, Lu et al.[42] reported the use of dendrimer phthalocyanine to enhance the 
therapeutic effect of free DOX in multidrug resistant breast tumor MCF-7/ADR. Yen 
et al. [14] reported reduction-sensitive PEG-PLys conjugated with camptothecin, and 
the chemotherapy on AY27 urothelial carcinoma was augmented by co-administration 
of photofrin. However, in both studies, the photosensitizer and chemotherapeutics 
were administered separately, and the different blood circulation profiles might lead to 
a discrepancy in their biodistribution. We further investigate the in vivo distribution of 
ArgPEA-ss-HA(AP) nanocomplex, as a co-delivery system for both DOX and 
AlPcS2a. 
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Figure 4.8. MDA-MB-231 multicellular spheroids incubated with A) blank ArgPEA-
ss-HA(AP) nanocomplex or free AlPcS2a; B) DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex or free DOX for 8 hrs. The nanocomplex was then washed off, chased 
for 4 hrs, before 660 nm irradiation was applied at 1.5 J/cm2. Confocal Z-stacks from 
0 to 200 μm was obtained before and 4 hrs post irradiation, to evaluate the penetration 
depth of nanocomplex in tumor spheroids. AlPcS2a was pseudo-colored as green and 
DOX fluorescence was pseudo-colored as red. Scale bar represents 500 μm.  C) Total 
DOX fluorescence or AlPcS2a fluorescence from Z-stacks was quantified and 
normalized to the cross-sectional area of the spheroid. Values represent the average ± 
SD (n=10). D) MDA-MB-231 multicellular spheroids incubated with blank ArgPEA-
ss-HA(AP) nanocomplex, DOX-loaded ArgPEA-ss-HA(AP) nanocomplex, free DOX 
for 8 hrs, washed off, before 660 nm light irradiation was applied (1.5 J/cm2. The 
equivalent concentration in each group: c (DOX) = 1 μΜ, and c(AlPcS2a) = 0.51 μΜ. 
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Viability of spheroids was determined 6 days post irradiation, and normalized to 
untreated control. Values represent the average ± SD (n=10). Statistical significance 
was compared: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
4.4.7 Biodistribution of ArgPEA-ss-HA(AP) nanocomplex in mice xenograft model  
    Blank ArgPEA-ss-HA(AP) nanocomplex or free AlPcS2a (5 mg/kg) was 
intravenously (i.v.) injected in BALB/c nude mice with MDA-MB-231 tumor 
xenograft. 24 hrs post-injection, tumor and other major organs were harvested and ex-
vivo examination was performed as shown in Figure 4.9A and 4.9B. Chemical 
extraction of AlPcS2a in homogenized tissues were also performed, and the 
fluorescence intensity per unit mass of tissue was shown in Figure 4.9C. Free AlPcS2a 
was identified largely in liver and spleen, and this trend was also reported in previous 
study [43]. The normalized fluorescence intensity of free AlPcS2a in liver and spleen 
was 5-fold higher than tumor tissue, which suggested the efficiency for direct 
administration of free photosensitizer was incompetent.  The distribution of the blank 
ArgPEA-ss-HA(AP) nanocomplex in tumor, on the other side, was more than 4-fold 
higher when comparing to free AlPcS2a, when equivalent dose was applied. 
Therefore, the ArgPEA-ss-HA(AP) nanocomplex exhibited enhanced tumor-specific 
accumulation of photosensitizer, and is expected to induce PCI effect in the tumor site. 
The level of free AlPcS2a in skin tissue was 6-fold higher compared to ArgPEA-ss-
HA(AP) nanocomplex. The reduced distribution of conjugated AlPcS2a in skin could 
result in reduced risk of skin photosensitivity. 
    Distribution of DOX in different organs was also examined 24 hrs post i.v. 
injection. As the data shown in Figure 4.9D, kidney was the only organ that had the 
higher drug concentration from free DOX compared to DOX-loaded nanocomplex, 
which is consistent with the prior study that free DOX can be rapidly eliminated from 
blood circulation and excreted via kidney [44]. The concentration of free DOX was 
generally lower in other major organs including liver and spleen when comparing to 
DOX-loaded ArgPEA-ss-HA(AP) nanocomplex. The difference was the most 
significant in the tumor tissue, in which DOX-loaded nanocomplex exhibited 3.7-fold 
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higher concentration than free DOX. The enhanced distribution of both DOX and 
AlPcS2a in tumor site delivered by the nanocomplex can be attributed to the tumor-
specific circulating properties of based nanocarriers [35], and could provide substantial 
advantages in the in vivo therapeutic effect.   
 
 
Figure 4.9.  A) Ex-vivo examination of the biodistribution of A) blank ArgPEA-ss-
HA(AP) nanocomplex and B) free AlPcS2a in different organs 24 hrs post i.v. 
injection. C) Normalized AlPcS2a fluorescence in the extraction of homogenized 
organs 24 hrs post i.v. injection of blank ArgPEA-ss-HA(AP) nanocomplex or free 
AlPcS2a (5 mg/kg). D) DOX concentration in the extraction of homogenized organs 
24 hrs post i.v. injection of DOX-loaded ArgPEA-ss-HA(AP) nanocomplex or free 
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DOX (5 mg/kg). Values represent the average ± SD (n=4). Statistical significance: *, p 
< 0.05; **, p < 0.01, *** p< 0.001. 
 
 
4.4.8 Light-enhanced anti-tumor effect by DOX-loaded ArgPEA-ss-HA(AP) 
nanocomplex in vivo  
    The PCI effect on in vivo anti-tumor efficiency of DOX-loaded nanocomplex 
was further evaluated on MDA-MB-231 mice xenografts.  i.v. injection of blank 
nanocomplex, DOX-loaded nanocomplex or free DOX were performed on day 1, 8 
and 15, with equivalent DOX dosage of 2 mg/kg/week. The light dose of 50 J/cm2 by 
671 nm He-Ne laser (100 mW/cm2) was used, and the time interval between i.v. 
injection and light irradiation was chosen as 24 hrs, according to the in vivo study of 
PCI on mice xenograft by Berg et al [45]. The growth of tumor was monitored over 28 
days, and the results were illustrated in Figure 4.10A. Free DOX didn’t exhibit any 
antitumor effect, as the tumor growth curve was almost identical to saline-treated 
control. Minor tumor suppression was observed in the group treated with blank 
ArgPEA-ss-HA(AP) nanocomplex with irradiation. Major anti-tumor effect was 
observed in groups treated with DOX-loaded ArgPEA-ss-HA(AP) nanocomplex both 
without or with irradiation. The final volume of tumor on day 28 by irradiated DOX-
loaded nanocomplex was 180 mm3(normalized to the tumor volume on day 0), which 
suggested an 78% of reduction in tumor volume compared to saline-treated control. In 
addition, the rate of tumor suppression was significantly higher for the irradiated 
DOX-loaded nanocomplex, compared to the non-irradiated counterpart. The 
treatments were well tolerated as no statistically significant loss in body weight was 
observed in any of the groups (Figure 4.10B).  
    Skin photosensitivity [46] is an important challenge associated with 
photosensitizer-related treatment. As indicated in Figure 4.10B, free AlPcS2a resulted 
in 6-fold higher distribution in skin than AlPcS2a conjugated with the nanocomplex. 
The result can be attributed to the unique circulating properties [47] of the nano-carriers 
and the preferential accumulation in tumor tissues. The significantly reduced level of 
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AlPcS2a by ArgPEA-ss-HA(AP) in skin is expected to reduce the risk of light-induced 
disorder, damage or immune response in skin tissue [48]. In the groups treated by 
DOX-loaded ArgPEA-ss-HA(AP), minor edema and erythema were observed right 
after irradiation was applied, but was reversed in 2-3 days. No wound or scar was 
observed by the end of the treatment (day 28), which positively related to the low 
distribution of photosensitizer in skin tissue, and further proved the biosafety of the 
PCI-facilitated ArgPEA-ss-HA(AP) delivery vehicles.  
    It is worth pointing out that the reduction in weight/size of the exercised tumors 
(Figure 4.10C and 10D) occurred in groups treated with both irradiated non-irradiated 
DOX-loaded ArgPEA-ss-HA(AP) nanocomplex. The difference in tumor inhibition 
between irradiated and non-irradiated groups was statistically significant, which 
suggested that PCI effectively enhanced the anti-tumor activity of the reduction-
sensitive DOX-loaded nanocomplex.  
    The advantages of light-facilitated delivery of chemotherapeutics were also 
discussed in previous literature [42,49], in which the photosensitizer DPc/m or Photofrin 
was administrated separately with the chemotherapeutics. The major improvement in 
this study was the covalent conjugation of the aluminum phthalocyanine disulfonate 
(AlPcS2a) photosensitizer on the reduction-responsive nano-vehicles, which enabled 
the preferential distribution of the photosensitizer in tumor site, and provided an 
effective tumor suppression at a low dosage of DOX (2 mg/kg/week). In addition to 
the current in vivo results, screening for the optimized treatment in vivo models would 
be the focus of our future study, including the dosage of light and DOX, the time 
interval between drug administration and light irradiation, etc., to further enhance the 
therapeutic effect and to achieve more precise manipulation of the spatio-temporally 
controllable anti-tumor effect.  
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Figure 4.10. In vivo anti-tumor effect of blank ArgPEA-ss-HA(AP) nanocomplex, 
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DOX-loaded ArgPEA-ss-HA(AP) nanocomplex or free DOX (with equivalent DOX 
dosage of 1.5 mg/kg/week) treated female BALB/c nude mice. Light irradiation at 660 
nm was applied 24 hrs post i.v. injection at 30 J/cm2.  A) Tumor volume was 
monitored vs. time.  B) Body weight of tumor-bearing mice was monitored vs. time. 
C) Representative tumor images from different treatment group at day 28. D) Tumor 
weight from different treatment group at day 28. Statistical significance was 
compared: * p < 0.05; ** p < 0.01. 
 
4.5 Conclusions 
    A biodegradable and reduction-sensitive nanocomplex was developed from 
hyaluronic acid and arginine based PEA, and crosslinked with disulfide linkage. 
Photosensitizer, AlPcS2a, was conjugated via PEG spacer, and enabled the light-
enhanced therapeutic effect of DOX-loaded nanocomplex. The data from both in vitro 
and in vivo studies lead to the following conclusions: A) The conjugated AlPcS2a 
induced endolysosomal rupture in MDA-MB-231 monolayers upon light 
irradiation, the sequestered nanocomplex was translocated into cytosol so that 
the release of DOX was accelerated by cytosolic GSH. B) PCI enhanced the in 
vitro inhibition of MDA-MB-231 cells by DOX-loaded nanocomplex, and 
synergism was detected at lower concentrations of DOX and AlPcS2a, with a 
moderate level of light irradiation. C) The AlPcS2a conjugated nanocomplex 
exhibited enhanced penetration in MDA-MB-231 spheroids compared to free 
AlPcS2a, and PCI-enhanced DOX release as well as augmented therapeutic 
effect were also observed in the spheroid model. D)  In vivo results suggested a 
consistent and preferential accumulation of both AlPcS2a and DOX in tumor tissues, 
as delivered by the nanocomplex. PCI amplified the efficiency of the nanocomplex in 
tumor suppression, with a well-tolerable dosage of drug and light irradiation. This 
study provided insights in designing reduction-sensitive nano- carriers, and suggested 
the potential to develop smart nanomedicine responsive to both endogenous and 
exogenous cues to achieve spatio-temporal manipulation of the therapeutic effect. 
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CHAPTER 5 
 
INCLUSION COMPLEX FROM CYCLODEXTRIN-GRAFTED HYALURONIC 
ACID AND PSEUDO PROTEIN AS A BIODEGRADABLE NANO-DELIVERY 
VEHICLES FOR GAMBOGIC ACID 
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5.1 Abstract 
    β-Cyclodextrin can form inclusion complex with a series of guest molecules 
including phenylalanine, and has gained considerable popularity in the study of 
supramolecular nanostructure. In this study, a biodegradable nano-delivery vehicle 
was developed from β-cyclodextrin grafted hyaluronic acid and phenylalanine based 
pseudo protein (HA(CD)-4Phe4 nanocomplex). Gambogic acid (GA), a naturally-
derived chemotherapeutics from Garcinia hanburyi tree resin, was loaded in the 
nanocomplex and the delivery performance was evaluated in vitro. The 4Phe4 pseudo 
protein provided hydrophobic interaction with GA for efficient encapsulation of drug, 
while the HA component enabled the targeting delivery to CD44 positive tumor cells. 
In the presence of hyaluronidase, the release of GA from the nanocomplex was 
significantly accelerated, due to the enzymatic biodegradation of the carrier. The 
internalization of the nanocomplex in MDA-MB-435/MDR cells was mediated by 
both the overexpression of CD44 receptor, and clathrin-dependent pathway. GA-
loaded nanocomplex exhibited significant cytotoxicity toward MDA-MB-435/MDR 
multidrug resistant melanoma cells, and induced enhanced level of apoptosis and 
mitochondrial depolarization, at low concentration of GA. Suppressed matrix 
metalloproteinase activity was also detected in MDA-MB-435/MDR melanoma cells 
treated by GA-loaded nanocomplex. The in vitro data suggested that GA-loaded 
HA(CD)-4Phe4 nanocomplex can provide the potential as a tumor-targeting delivery 
system to induce toxicity in CD44 positive tumor cells, and simultaneously inhibiting 
the tumor metastasis.  
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5.2 Introduction 
    Cyclodextrin (CD), a family of macrocyclic oligosaccharides linked by α-1,4 
glycosidic bonds, has been extensively studied in the field of drug delivery [1].  CD 
and their derivatives have been successfully employed to construct supramolecular 
functional materials, and the biomedical applications of CDs are attractive due to the 
low toxicity and low immunogenicity.  β-cyclodextrin (β-CD), composed of 7 
glucose units, is a truncated cone-shaped molecule with top and bottom diameters of 
0.60 nm and 0.65 nm, respectively [2].  β-CD can form inclusion complex with 
various guest molecules based on complementary stereoelectronic arrangement of 
binding sites between host and guest [3].  The guest molecules include poly(propylene 
oxide) [4], poly(dimethylsiloxane)s [5], aliphatic polyesters [6], polyacrylate with 
adamantyl pendant group [7], and poly(β-benzyl L-aspartate) [8], etc. The wide range of 
guest molecules enables the versatile structural design for the supramolecular 
assembled nanostructure of β-CD, and can be developed as the nano-sized drug 
delivery vehicles. Zhang et al. [9] developed a nanostructure assembled form β-CD-
grafted-polyethylene glycol and polyaspartatamide as the delivery vehicles for 
docetaxel. Fan et al. [10] developed a nano-assembly from β-CD grafted 
polyethyleneimine and adamantine-doxorubicin for the co-delivery of both 
doxorubicin and therapeutic gene pTRAIL. 
    Hyaluronic acid (HA) is a natural and biodegradable polysaccharide formed by 
D-glucuronic acid and N-acetyl-D-glucosamine repetitive units [11]. Identified as the 
ligand molecule for CD44 receptors, HA has attracted considerable research interests 
in the field of tumor-targeting delivery, due to the overexpression of CD44 receptors 
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on many types of tumor cells including breast tumors, colon cancers, and myeloma, 
etc [12]. HA-based nano-carriers exhibited enhanced selective binding and uptake by 
tumor cells, and have been developed to improve the potency of various therapeutic 
agents [13], such as chemotherapeutics, nucleic acids and proteins.  HA has been 
studied as the nano-delivery vehicles for anti-cancer drug delivery [14].  However, 
very few literatures reported the inclusion complex from hyaluronic acid and other 
polymers via cyclodextrin functional groups. In the work by Kulkarni et al. [15], 
nanoparticles were prepared from the inclusion complex between PEI grafted with β-
cyclodextrin and hyaluronic acid with adamantine groups, and developed as the 
delivery vehicles for plasmid DNA in HeLa cells. 
    Biodegradable amino acid based poly(ester amide)s (AA-PEAs), a new family of 
synthetic pseudo proteins, are synthesized from 3 building blocks: amino acids, 
dialcohol and diacids. The choice of different amino acids, and the hydrocarbons 
between the amide and ester groups, provides a versatile structural design of AA-
PEAs and makes them tunable in hydrophilicity/hydrophobicity, charge density, and 
reactive sites for expanded properties and functionality.  AA-PEAs have been studied 
for various biomedical applications and have also been hybridized with other polymers 
like polysaccharides and synthetic aliphatic polyesters to form unique hybrids 
with broadened properties and applications [16–18]. The current status of AA-PEAs 
have recently been reviewed [19,20]. 
    Gambogic acid (GA), a natural compound from gamboge resin that produced by 
Garcinia hanburyi trees, has been reported [21–23] to exhibit significant cytotoxic 
activity against multiple tumor cells. Several mechanisms were proposed for 
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elucidating its anti-tumor effect [24,25], which include the inhibition of the expression of 
telomerase, telomerase reverse transcriptase mRNA and VEGF receptor signaling, 
downregulation of the Bcl-2,4 activating tumor necrosis factor (TNF)-induced cell 
death, etc. GA has been approved for the phase II clinical trial for cancer therapy by 
the Chinese Food and Drug Administration (CFDA) [26,27]. However, GA is still facing 
several challenges, such as low bioavailability due to its poor water solubility (< 1 
μg/mL) and the lack of adequate tumor targeting due to the wide distribution of GA in 
normal tissues, which can limit its therapeutic efficacy. Nano-delivery vehicles can 
provide the advantage to solve the challenges associated with the direct administration 
of GA. Saxena et al. [28] developed poloxamers/TGPS mixed micelles to for the 
delivery of GA in MCF-7 breast carcinoma, resulting in 1.6-fold higher toxicity 
compared to free GA. Zhang et al. [29] developed lactoferrin based nanoparticles for 
the delivery of GA to S180 mice sarcoma, and they reported a significantly enhanced 
in vivo therapeutic effect. It is of particular interest to develop a tumor-specific nano-
delivery system for GA, while simultaneously improve its water solubility and 
bioavailability.  
    The aim of this study was to develop a biodegradable nanocomplex from the 
inclusion complex between β-cyclodextrin and phenylalanine based poly(ester amide)s, 
and incorporate hyaluronic acid on the surface of the complex for the specific delivery 
of GA to CD44 positive tumor cells. The phenylalanine based poly(ester amide)s in 
the nanocomplex  provided hydrophobic interaction with GA to improve its 
encapsulation capacity. MDA-MB-435/MDR multidrug resistant melanoma cells with 
overexpression of CD44 receptors were chosen for the in vitro examination of the GA 
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delivery system. In vitro characterization of the endocytosis and tumor cell inhibition 
by the GA-loaded nanocomplex was performed. Mitochondrial damage, cell death 
assay and the activity of matrix metalloproteinases were also investigated to further 
validate the potency of the GA-loaded nanocomplex.  
 
5.3 Experimental 
5.3.1 Chemicals and cells  
   Sodium hyaluronate (MW= 10 to 20 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN). Tetrabutylammonium bromide, β-cyclodextrin (β-CD), 4-
toluenesulfonyl chloride, succinic dihydrazide (SDH), N-hydroxysuccinimide (NHS), 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC·HCl), 2-(N-
morpholino)ethanesulfonic acid buffer (MES buffer, 0.5 M in water), hyaluronidase 
from bovine testes were from Sigma Aldrich (Milwaukee, WI). Amberlite IR-120 H+ 
ion exchange resin was from Alfa Aesar (Ward Hill, MA). Gambogic acid (GA) was 
from BroadPharm (San Diego, CA). Lysotracker green was from Cell Signaling 
(Beverly, MA). Dimethyl sulfoxide (DMSO), methanol and other HPLC grade 
solvents were from JT Baker (Phillipsburg, NJ). JC-1 mitochondrial membrane 
potential assay kit was from Cayman Chemical (Ann Arbour, MI). Annexin V 
apoptosis detection kit was purchased from eBioscience (San Diego, CA). Snakeskin 
dialysis tubing (MWCO = 3.5 kDa or 10 kDa) and NHS-Rhodamine were from Pierce 
(Rockford, IL). Phenylalanine based poly(ester amide)s  4Phe4 was synthesized from 
our previous study [30].  
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    MDA-MB-435/MDR multidrug resistant melanoma cells were donated by Dr. 
Robert Clarke (Georgetown University, Washington, D.C.) and MD Anderson Cancer 
Center (Houston, TX). MDA-MB-435/MDR cells were maintained at 37 ºC with 5% 
CO2 in Minimum Essential Medium (Richter’s modification) containing 2mM L-
glutamine, phenol red, 10% fetal bovine serum, and 1% penicillin/streptomycin. NIH 
3T3 fibroblasts were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with phenol red, 10% fetal bovine serum, and 1% 
penicillin/streptomycin. 
 
5.3.2 Synthesis  
    Synthesis of 6-monotosyl β-cyclodextrin. To introduce amine-reactive functional 
groups into β-cyclodextrin (β-CD), 6-monotosyl-β-CD was prepared from previously 
published study [31]. β-CD (17.22 g) was dissolved in 1% NaOH solution (200 mL). 
Toluene sulfonyl chloride (2.9 g) dissolved in acetonitrile (11 mL) was added 
dropwise. The reaction was stirred at room temperature for another 2 hrs. The pH of 
the filtered solution was adjusted to 2-3 with 0.1 M HCl solution and precipitated 
overnight at 4 °C. The white precipitate was filtered and re-crystalized twice in water 
to give purified 6-monotosyl β-CD. 
    Synthesis of succinic acid dihydrazide grafted HA. HA (300 mg) and succinic 
dihydrazide (SDH, 587 mg) were first dissolved in MES buffer (60 mL, 50 mM), and 
the pH was adjusted to 5.5 with 0.1 M hydrochloric acid. EDC·HCl (43 mg) and NHS 
(26 mg) were added and the reaction was stirred at room temperature overnight. The 
reaction mixture was dialyzed (MWCO = 3.5 kDa) against DI water for 48 hrs to give 
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the aqueous solution of HA grafted with succinic acid dihydrazide (HA-SDH). To 
improve the solubility of HA-SDH in organic solvents, HA-SDH was converted to its 
tetrabutylammonium salt (HA-SDH-TBA) via ion exchange method. Amberlite IR-
120 H+ resin was neutralized with NaOH, washed with deionized water and immersed 
in 0.25 M aqueous tetra-N-butylammonium bromide solution overnight. The resulting 
ion exchange resin was added to the dialyzed solution of HA-SDH and stirred 
overnight at room temperature. The resin was removed by filtration, and the aqueous 
solution was lyophilized to give HA-SDH-TBA.  
    Synthesis of β-CD grafted HA. HA functionalized with β-CD was prepared as 
indicated in Figure 5.1. HA-SDH-TBA (100 mg) was dissolved in DMSO with 
triethylamine (30 µL), 6-monotosyl β-CD (91 mg) was added and stirred for 24 hrs at 
40 °C. The solution was dialyzed against DI water for 48 hrs, the pH of the solution 
was adjusted to 4.0 with 0.1 M HCl, kept at 4 °C overnight and filtered to remove 
unreacted 6-monotosyl β-CD. The filtered solution was converted to the TBA salt via 
ionic exchange method and lyophilized to give HA(CD)-TBA.  The 1H-NMR was 
examined on a Varian Unity Inova 400 MHz spectrometer (Palo Alto, CA). 
Synthesis of rhodamine-labeled HA(CD)-TBA. HA-SDH (100 mg) was dissolved in DI 
water (5 mL) and mixed with NHS-rhodamine (3 mg). The reaction was stirred 
overnight at room temperature, and dialyzed (MWCO=3.5 kDa) against DI water. The 
resulted rhodamine-labeled HA-SDH was converted to its TBA salt (rhodamine 
labeled HA-SDH-TBA) via ionic exchange method. The preparation of β-CD grafted 
HA-SDH-TBA labeled with rhodamine was the same as the preparation of HA(CD)-
TBA.  
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Figure 5.1. Synthesis scheme for tetrabutyl ammonium salt of β-CD grafted 
hyaluronic acid (HA(CD)-TBA). 
 
5.3.3 Preparation of GA-loaded HA(CD)-4Phe4 nanocomplex 
    Inclusion complex from HA(CD)-TBA and phenylalanine based poly(ester 
amide)s (4Phe4) was prepared via  the host-guest interaction between β-CD and the 
phenyl groups of 4Phe4. 4Phe4 was synthesized based on published procedures [30], 
and had an average molecular weight of 20.6 kDa and PDI of 1.27.  
    To prepare GA-loaded HA(CD)-4Phe4 nanocomplex, HA(CD)-TBA (200 mg) 
was dissolved in DMSO (20 mL), DMSO solution of 4Phe4 (50 mg, 5 mL) was added 
and stirred overnight. Gambogic acid (GA, 25 mg) was then added and stirred for 
another 4 hrs. The resulting solution was dialyzed (MWCO = 3.5 kDa) against DI 
water for 48 hrs and filtered with 0.22 µm PVDF microfilter to remove unloaded drug 
or free 4Phe4. The filtered solution was lyophilized. 
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The GA loading content (LC) and encapsulation efficiency (EE) was determined by 
extracting GA from GA-loaded HA(CD)-4Phe4 nanocomplex in ethanol for 24 hrs at 
40 °C [32] and the filtered with 0.22 µm PVDF microfilter. The GA-ethanol solution 
was dried in vacuo, and the resulting GA was re-dissolved in DMSO. The 
concentration of GA in DMSO was determined by the absorption at 360 nm on 
Lambda Bio40 spectrophotometer (Perkin-Elmer, Norwalk, CT), and calibrated with a 
standard GA curve.  
    The morphology of GA-loaded HA(CD)-4Phe4 nanocomplex was observed on a 
FEI Tecnai Spirit T12 TEM (FEI Co., Hillsboro, OR) at an operating voltage of 120 
kV. Zeta potential and size of the nanocomplex were characterized at room 
temperature on a Zetasizer NanoZS system (Malvern, UK). 
 
5.3.4 In vitro release profile of GA-loaded HA(CD)-4Phe4 nanocomplex  
    GA-loaded HA(CD)-4Phe4 nanocomplex (10 mg) was dissolved in phosphate 
buffer (pH 7.4, 5mL) with or without the presence of 120 unit/mL hyaluronidase 
(Hyal). The solution was placed in dialysis tubing (MWCO = 10 kDa) and dialyzed 
against pH 7.4 phosphate buffer (30 mL) at 37 °C under shaking (100 rpm). At 
predetermined time intervals, 5 mL of the solution outside the dialysis tubing was 
retrieved and replaced by fresh media. The concentration of GA in each sample was 
determined by the absorption at 360 nm in UV-Vis spectra and calibrated against a 
standard curve of GA. The percentage of released GA was plotted vs. time. Each test 
was performed in triplicate. 
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5.3.5 Endocytosis and subcellular distribution of HA(CD)-4Phe4 nanocomplex 
    To study the accumulated endocytosis of blank HA(CD)-4Phe4 nanocomplex, 
MDA-MB-435/MDR (CD44 positive) or NIH 3T3 cells (CD44 negative) were 
incubated with blank HA(CD)-4Phe4 nanocomplex labeled with rhodamine for 1, 2, 4, 
8, 12 or 24 hrs. The cells were washed with PBS, harvested and the cellular 
fluorescence intensity was analyzed on FACSAria fusion fluorescence activated cell 
sorter (BD Biosciences, Franklin Lakes, NJ).  5 x 104 cells were analyzed for each 
sample, and the average fluorescence intensity was plotted vs. time. 
Subcellular distribution of blank HA(CD)-4Phe4 nanocomplex was visualized on a 
Zeiss LSM710 confocal microscope (Carl Zeiss MicroImaging, Thornwood, NY). 
MDA-MB-435/MDR were incubated with blank HA(CD)-4Phe4 nanocomplex labeled 
with rhodamine (0.1 mg/mL) for 4 hrs. Cells were then stained with Lysotracker green 
as per manufacturer’s instruction, washed with PBS and imaged alive by confocal 
microscopy. 
    To study the pathway of endocytosis, MDA-MB-435/MDR cells treated 
with inhibitors that block different endocytic pathways (nystatin, 50 μg/mL; 
chloropromazine, 30 μM; amiloride hydrochloride, 50 μM; methyl-β-
cyclodextrin, 3 mg/mL or anti-CD44 antibody as per manufacturer’s 
instruction) for 0.5 hr, before rhodamine labelled blank HA(CD)-4Phe4 
nanocomplex was added and incubated for another 4 hrs. The cells were then 
washed with PBS, harvested and subjected to flow cytometry assay. The effect 
of low temperature (4°C) on endocytosis was also studied.  Cells incubated 
with the blank nanocomplex at 37°C but not treated with any inhibitor were 
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tested as control. The mean fluorescence intensity for each sample was recorded 
and normalized to control. The tests were performed in triplicate. 
 
5.3.6 Cytotoxicity of GA-loaded nanocomplex 
    MDA-MB-435/MDR cells were incubated with blank nanocomplex, free GA or 
GA-loaded HA(CD)-4Phe4 nanocomplex (c(GA) =0.1 to 20 μM) for 24 hrs. The 
viability of cells were determined by MTT assay, and each experiment was run in six 
replicates. The absorbance at 570 nm was recorded and normalized to the results of the 
untreated cell control to give the percentage of cell survival. Each test was run in 6 
replicates. 
 
5.3.7 Mitochondrial membrane potential assay 
    MDA-MB-435/MDR cells were incubated with blank nanocomplex, free GA or 
GA-loaded HA(CD)-4Phe4 nanocomplex (c(GA) =1 μM) for 24 hrs. The cells were 
stained with JC-1 probe as per manufacturer’s instruction and analyzed by flow 
cytometry. The experiments were performed in triplicate. The percentage of cell 
population stained with higher degree of JC-1 monomer and lower degree of J-
aggregates was recorded. 5 x 104 cells were analyzed for each sample. 
 
5.3.8 Apoptosis study 
    MDA-MB-435/MDR cells were incubated with blank nanocomplex, free GA or 
GA-loaded HA(CD)-4Phe4 nanocomplex (c(GA) =1 μM) for 24 hrs. The cells were 
washed and harvested. For apoptosis assay, Annexin-V/PI double staining was 
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performed as per manufacturer’s instruction. The percentage of dead/apoptotic cells 
were analysed by flow cytometry. 5 x 104 cells were analyzed for each sample and 
each experiment was performed in triplicate. For the assay of caspase 3/7 activities, 
the cells were incubated with Apo-ONE Homogeneous Caspase-3/7 assay reagents 
(Promega, Madison, WI) as per manufacturer’s instruction. The fluorescence intensity 
was recorded on a microplate reader (λex = 485 ± 20 nm/λem = 528 ± 20 nm). The 
untreated cells were tested as control. The fluorescence for each sample was 
normalized to control to give the fold of caspase 3/7 activities. Each experiment was 
performed in triplicate. 
 
5.3.9 Gelatin zymography 
    MDA-MB-435/MDR cells were incubated in serum free medium with free GA, 
GA-loaded HA(CD)-4Phe4 nanocomplex or blank HA(CD)-4Phe4 nanocomplex 
(c(GA) =1 μM) for 24 hrs.  The media were centrifuged (400 rcf, 5 min, 4 ºC), and 
gelatin zymography for the supernatant was performed as described previously [33]. In 
brief, SDS-PAGE gels were prepared containing 1% type B gelatin (w/v). After 
electrophoresis, the gels were washed with 2.5% Triton X-100 to remove SDS and 
incubated with developing buffer (50 mM Tris-HCl, 10 mM CaCl2, 0.02% NaN3, pH 
7.6) at 37 °C for 16 hrs. The gels were stained with 0.25% Coomassie Brilliant Blue 
R-250 solution and destained with destaining solution (10% methanol, 5% acetic acid 
in DI water). Regions digested by matrix metalloproteinases (MMP) were observed as 
white bands against a dark background. 
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5.3.10 Statistical analysis  
    The data are presented as mean values with standard deviations (SD). All data 
were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison 
tests, and p < 0.05 was used for statistical significance. 
 
5.4 Results and discussion 
5.4.1 The characterization of polymers 
   β-Cyclodextrin-grafted HA (HA(CD)) was prepared from the reaction between 6-
monotosyl-β-CD and succinic dihydrazide functionalized HA (HA-SDH). The tosyl 
groups in the 6-monotosyl-β-CD was reacted with the amine groups on HA-SDH to 
obtain HA(CD). As indicated in the 1H NMR spectra of HA(CD) in Figure 5.2, the 
typical peak for the methyl groups in HA was observed at 1.73 ppm, and the typical 
peak for the 1H proton from the glucose residue in β-CD was observed at 4.75 to 5.05 
ppm. Based on the integral of these two peaks, the grafting ratio of β-CD onto HA, 
defined as the molar amount of β-CD divided by the total molar amount of HA 
repeating units, was calculated to be 13%. The 1H-NMR spectra suggested the 
effective grafting of β-CD onto HA, and the β-CD pendant groups provides available 
sites to form inclusion complex with the phenylalanine moiety of 4Phe4.  
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Figure 5.2. 1H NMR spectra of β-cyclodextrin-grafted HA (HA(CD)). 
 
5.4.2 The characterization of GA-loaded HA(CD)-4Phe4 nanocomplex 
   The scheme for the formation of HA(CD)-4Phe4 nanocomplex was illustrated in 
Figure 5.3. In aqueous environment, HA provided the hydrophilic component as the 
outer layer of the nanocomplex, and 4Phe4 provided the hydrophobic component in 
the interior. The hydrophobic and hydrophilic segments were held together via the 
host-guest interaction between β-CD side groups on HA(CD) and phenyl side groups 
on 4Phe4.  The impact of the feed ratio between HA(CD) and 4Phe4 on the yield and 
size of the nanocomplex was shown in Table 1. When the weight ratio between 
HA(CD)/4Phe4 was 1:2, significant precipitate was obtained, which can be attributed 
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to the excessive amount of the hydrophobic 4Phe4 that didn’t formed the inclusion 
complex with HA(CD), and the lack of stabilizing effect by the HA lead to the direct 
precipitation of 4Phe4. As the feed ratio between HA(CD)/4Phe4 increased, the 
HA(CD)-4Phe4 nanocomplex was effectively formed, and the average diameter of the 
nanocomplex decreased with an increase in the HA(CD) component, i.e.  732.63 ± 
38.2 nm (yield 13.6%) for HA(CD)/4Phe4=1:1, and 148.5 ± 21.2 nm (yield 65.1%) for 
HA(CD)/4Phe4=2:1. When the HA(CD)/4Phe4 ratio increased further to 4:1, no 
significant change in diameter was detected, but the yield reduced to 27.5%, due to the 
fact that the excessive amount of HA(CD) which didn’t form the nanocomplex was 
removed in the purification process. Negative zeta potential ranging from -19.5 ± 2.7 
mV to -26.23 ± 3.2 mV was detected for the nanocomplex, which can be attributed to 
the presence of HA at the surface of the nanocomplex. Nano-carriers of smaller size (< 
200 nm) were found to be more effective in drug delivery because they are less likely 
to be captured by reticuloendothelial system than larger particles during systemic 
circulation [34]. Based on the result of size and yield, the nanocomplex from 
HA(CD)/4Phe4=2:1 was selected for the following studies.  
    The hydrophobic interior of the HA(CD)/4Phe4 nanocomplex provided the 
loading capacity for GA due to the hydrophobic interaction. The loading content (LC) 
and encapsulation efficiency (EE) for GA in the nanocomplex were 12.5% and 88.6%, 
respectively. The loading of GA did not impact the size (diameter = 184.16 ± 16.3 nm, 
PDI = 0.169 ± 0.042) and surface charge (-20.2 ± 2.8 mV) of the HA(CD)-4Phe4 
nanocomplex, when compared to the blank counterpart.   
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Figure 5.3. Chemical structures of β-cyclodextrin grafted HA (HA(CD)), 
phenylalanine based poly (ester amide)s (4Phe4), and gambogic acid (GA). HA(CD)-
4Phe4 was formed from the inclusion complex between β-cyclodextrin moieties on 
HA(CD) and the phenyl groups from 4Phe4.  
 
Table 5.1. Characterization of HA(CD)-4Phe4 nanocomplex with different HA(CD) 
to 4Phe4 ratios. 
HA(CD) to 4Phe4 / 
(w/w) in feed ratio 
DLS diameter/nm PDI  Zeta potential 
(mV) 
Yield a  
1:2 Precipitate b NA NA NA 
1:1 732.63 ± 38.2 0.171 ± 
0.061 
-26.23 ± 3.2 13.6% 
2:1 161.57 ± 11.2 0.176 ± 
0.053 
-21.4 ± 1.7 65.1% 
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4:1 148.5 ± 21.2 0.181 ± 
0.021 
-19.5 ± 2.7 27.5% 
 
a. Yield was calculated from the mass of purified nanocomplex divided by the total 
mass of HA(CD) and 4Phe4 in feed. 
b. Formation of significant precipitate; the PDI, zeta potential and yield were non-
detectable. 
 
5.4.3 In vitro release of GA-loaded HA(CD)-4Phe4 nanocomplex  
    The morphology of GA-loaded HA(CD)-4Phe4 nanocomplex was shown in 
Figure 5.4A. Spherical assembled structure was observed for GA-loaded HA(CD)-
4Phe4 nanocomplex in aqueous dispersion. However, the assembled structure 
disappeared when a competing guest, 1-adamantane carbonyl acid (2 molar equivalent 
to cyclodextrin moieties), was added to the DMSO solution of HA(CD)-4Phe4 
nanocomplex and dialyzed for 48 hrs. Significant precipitation was observed after 
dialysis, and no assembled structure was observed in the filtered solution, as suggested 
in Figure 5.4B. The replacement of phenyl groups from 4Phe4 with the competing 
guest lead to the dissociation of the nanocomplex, which further confirmed that the 
nanocomplex was formed form the host-guest inclusion complex between HA(CD) 
and 4Phe4. 
    After 48 hrs incubation with hyaluronidase, which is a specific enzyme that 
breaks down HA into oligosaccharide [35], the destabilization of the HA(CD)-4Phe4 
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nanocomplex was evidenced  in Figure 5.4C, as no spherical assembled structure was 
observed. 
    The in vitro release profile of GA were shown in Figure 5.4D. At the end of 48 
hrs, 61% cumulative GA was released in the presence of hyaluronidase (black curve), 
while only less than 20% cumulative release was detected in PBS (red curve). The 
release profiles of GA correlated directly with the morphological changes of HA(CD)-
4Phe4 nanocomplex after incubation with hyaluronidase (Figure 5.4C), and the 
accelerated GA release can be attributed to the disintegration of the nanocomplex 
induced by enzymatic biodegradation.  
 
 
Figure 5.4. A) TEM image of GA-loaded HA(CD)-4Phe4 nanocomplex in aqueous 
dispersion (0.5 mg/mL). B) TEM image of GA-loaded HA(CD)-4Phe4 nanocomplex 
incubated with 1-adamantane carbonyl acid. C) TEM image of GA-loaded HA(CD)-
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4Phe4 nanocomplex after 48 hrs incubation with 120 unit/mL hyaluronidase. D) 
Percentage of accumulated release of GA from HA(CD)-4Phe4 nanocomplex with or 
without the presence of 120 unit/mL hyaluronidase in phosphate buffer (pH = 7.4). 
Statistical significance: *** p< 0.001. 
 
5.4.4 Endocytosis and subcellular distribution of blank HA(CD)-4Phe4 
nanocomplex 
   MDA-MB-435/MDR cell was selected as the in vitro model to study the 
endocytosis and subcellular distribution of the blank HA(CD)-4Phe4 nanocomplex, 
due to the overexpression of CD44 receptor [36]. 3T3 fibroblast, which is CD44 
negative, was also included as the negative control. The endocytosis of the HA(CD)-
4Phe4 nanocomplex as a function of time in both MDA-MB-435/MDR cell (CD44 
positive) and 3T3 fibroblast (CD44 negative) were given in Figure 5.5. Significant 
difference in the intracellular level of the rhodamine-labelled nanocomplex between 
MDA-MB-435/MDR cells and 3T3 cells was observed throughout the 24 hrs 
incubation, as demonstrated in Figure 5.5B. HA(CD)-4Phe4 nanocomplex exhibited 
significantly enhanced endocytosis by CD44 overexpressed MDA-MB-435/MDR cells, 
and could be developed as the tumor-targeted delivery vehicles.  
    The subcellular distribution of the blank HA(CD)-4Phe4 nanocomplex after 4 hrs 
incubation was also studied and shown in Figure 5.5A. The red fluorescence from the 
rhodamine-labelled nanocomplex in 3T3 fibroblasts is weaker than in MDA-MB-
435/MDR cells, which correlated well with the accumulated endocytosis results in 
Figure 5.5B. In MDA-MB-435/MDR cells, the red fluorescence of the rhodamine-
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labelled HA(CD)-4Phe4 nanocomplex was identified to be co-localized with 
endolysosomes, as yellow pixels (combined from red nanocomplex with Lysotracker 
Green) were observed in the overlay images. The results suggested that HA(CD)-
4Phe4 nanocomplex was entrapped inside endolysosomes which have a series of 
digestive enzymes to break down the nanocomplex and accelerate the release of GA, 
as indicated in Figure 5.4.  
    To identify the pathway for the entry of HA(CD)-4Phe4 nanocomplex into MDA-
MB-435/MDR cells, inhibition study was performed and the results were shown in 
Figure 5.5C. The uptake of the HA(CD)-4Phe4 nanocomplex was decreased by 31% 
in MDA-MB-435/MDR cells pre-treated with anti-CD44 antibody, indicating 
that the entry of HA(CD)-4Phe4 nanocomplex was mediated by the CD44 
receptor. Incubation of MDA-MB-435/MDR cells at 4 °C resulted in a reduction 
of 38% in the intracellular accumulation of the nanocomplex, indicating that the 
internalization of the nanocomplex is energy-dependent. Inhibition of clathrin-
mediated pathway by chloropromazine resulted in 17% reduction in intracellular 
fluorescence, which suggested the endocytosis is also dependent on clathrin 
pathway. However, the inhibition of macropinocytosis, caveolae-mediated or 
lipid-raft mediated pathways by amiloride, nystatin or methyl-betaCD showed 
no significant reduction in the transmigration of HA(CD)-4Phe4 nanocomplex, 
which suggested that the internalization was independent of lipid raft, 
macropinocytosis or caveolae pathway. In general, the CD44-mediated 
endocytosis of the HA(CD)-4Phe4 nanocomplex in MDA-MB-435/MDR cells lead 
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to the selectivity between CD44 positive cells versus CD44 negative cells, which 
provide the rationale for the tumor-targeting delivery of GA. 
    Saxena et al. [28] reported the enhanced internalization rate of GA when loaded in 
Poloxamer 407/TPGS micelles compared to free GA. The internalization of free GA 
involved binding with transferrin receptor [37], and is less competent as the endocytosis 
of GA-loaded nano-delivery system. The HA(CD)-4Phe4 nanocomplex is expected 
to improve the intracellular availability of GA, and further impact its therapeutic 
efficiency. 
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Figure 5.5. Endocytosis and subcellular distribution of blank HA(CD)-4Phe4 
nanocomplex in MDA-MB-435/MDR cells (CD44 positive) or NIH 3T3 cells (CD44 
negative).  A) The confocal image of MDA-MB-435/MDR cells or NIH 3T3 
fibroblasts incubated with blank HA(CD)-4Phe4 nanocomplex (0.1 mg/mL) for 4 hrs. 
Green (Lysotracker); red (rhodamine-labelled nanocomplex); the overlay of green and 
red pixels; and bright field (BF) image of the cells. Scale bar represented 20 µm. B) 
Accumulated endocytosis of blank HA(CD)-4Phe4 nanocomplex (0.1 mg/mL) in 
MDA-MB-435/MDR cells (CD44 positive) or NIH 3T3 cells (CD44 negative). The 
average cellular fluorescence from rhodamine-labelled nanocomplex was determined 
via flow cytometry. (n=3). Statistical significance: *** p< 0.001. 
 
5.4.5 Cytotoxicity of GA-loaded HA(CD)-4Phe4 nanocomplex 
    Cytotoxicity against MDA-MB-435/MDR cells after 24 hrs incubation with free 
GA, blank HA(CD)-4Phe4 and GA-loaded HA(CD)-4Phe4 nanocomplex was shown 
in Figure 5.6A. No significant cytotoxicity from the blank nanocomplex was observed 
at the concentration range from 1 to 100 μg/mL which correlated to equivalent GA 
concentration between 0.1 to 20 μM. Therefore, the cytotoxicity of GA-loaded 
HA(CD)-4Phe4 nanocomplex can be solely attributed to the loaded GA instead of the 
carrier. 
    Free GA and GA-loaded HA(CD)-4Phe4 nanocomplex exhibited concentration-
dependent toxicity towards MDA-MB-435/MDR cells. Significantly higher toxicity 
from GA-loaded nanocomplex than free GA was detected at c(GA) =1 μM. However, 
GA-loaded nanocomplex exhibited similar cytotoxicity as free GA toward MDA-MB-
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435/MDR cells at the rest of the tested GA concentrations. The IC50 was calculated as 
1.14 μM for GA-loaded nanocomplex, and 1.63 μM for free GA, respectively.  
    Cytotoxicity of free GA and GA-loaded HA(CD)-4Phe4 nanocomplex was also 
detected on MDA-MB-435/WT cells (without multidrug resistance) as shown in 
Figure 5.6B. After 24 hrs incubation, the IC50 values of the wild type MDA-MB-435 
cells were 0.45 μM for free GA and 0.37 μM for GA-loaded HA(CD)-4Phe4 
nanocomplex. Comparing the IC50 values between wild type vs. multidrug resistant 
phenotype, MDA-MB-435/MDR cells did not exhibit significant cross-resistance to 
GA treatment in the case of both free GA and GA-loaded HA(CD)-4Phe4 
nanocomplex. As reported by Wang et al. [38], free GA showed good potency in the 
inhibition of docetaxel resistant BGC-823 gastric cancer cells, and could further 
reverse the drug resistance the presence of drug efflux pump on MDA-MB-435/MDR 
cells does not adversely affect the therapeutic performance of GA-loaded HA(CD)-
4Phe4 nanocomplex, it may be the beneficial as a complementary treatment for multi-
drug resistant tumors. 
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Figure 5.6. Viability of A) MDA-MB-435/MDR cells and B) MDA-MB-435/WT 
cells incubated with blank HA(CD)-4Phe4 nanocomplex, free GA or GA-loaded 
HA(CD)-4Phe4 nanocomplex with various GA concentrations for 24 hrs. Statistical 
significance was compared between free GA and GA-loaded nanocomplex treated 
groups: *, p < 0.05.    
 
5.4.6 Mitochondrial depolarization 
    The change in the mitochondrial membrane potential of MDA-MB-435/MDR 
cells was detected after treated by blank HA(CD)-4Phe4 nanocomplex, GA-loaded 
HA(CD)-4Phe4 nanocomplex or free GA (c(GA) = 1 µM) for 24 hrs. The percentage 
of cells with depolarized mitochondria can be identified as the population that stained 
with a higher level of green fluorescence (JC-1 monomer) and lower level of red 
fluorescence (J-aggregates), which is the population in quadrant 3 from flow 
cytometry results (Figure 5.7A). The quantitative results were also shown in Figure 
5.7B.   
    In the case of blank HA(CD)-4Phe4 nanocomplex, only 3.91% of total cells were 
observed in quadrant 3 (with depolarized mitochondria), which was consistent with the 
untreated MDA-MB-435/MDR cells (i.e. 3.67% in quadrant 3). The result 
demonstrated the biosafety of the blank nanocomplex, which correlated directly with 
the low cytotoxicity of the blank HA(CD)-4Phe4 nanocomplex in Figure 5.6. 
    A significant loss of mitochondrial membrane potential was observed in MDA-
MB-435/MDR cells treated by both free GA and GA-loaded HA(CD)-4Phe4 
nanocomplex. At c(GA) =1 µM, GA-loaded HA(CD)-4Phe4 nanocomplex induced 
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greater level of mitochondrial depolarization, as 16.6% of cells were detected with 
depolarized mitochondria, compared to 10.3% of cells in quadrant 3 treated by free 
GA. The results suggested that the cytotoxicity induced by either free GA or GA-
loaded HA(CD)-4Phe4 nanocomplex was related to mitochondria, and was also 
consistent with the study by Qiang et al. [39], in which 21% of Rat C6 glioma cells 
were detected with depolarized mitochondrial when treated by 1 µM free GA. The 
loss of mitochondrial membrane potential marks the dysfunction of 
mitochondria [40], and can be associated with the release of apoptogenic factors 
in the signaling of cell death. Further studies were performed to probe the cell 
death induced by GA-loaded HA(CD)-4Phe4 nanocomplex.  
 
 
Figure 5.7. A) Mitochondrial membrane potential in MDA-MB-435/MDR cells 
incubated with blank HA(CD)-4Phe4 nanocomplex, free GA or GA-loaded HA(CD)-
4Phe4 (c(GA) = 1 µM) for 24 hrs. B) The percentage of MDA-MB-435/MDR cells 
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with depolarized mitochondria (quadrant 3) in JC-1 assay were recorded. Statistical 
significance: *, p < 0.05.    
 
5.4.7 Annexin-V and caspase 3/7 assay 
    Flow cytometry results for the annexin V/PI assay were shown in Figures 5.8A 
and 5.8B. The percentages of cell population in each quadrant were obtained as: live 
cells (PI-/annexin V-, quadrant 4), dead cells (PI+/annexin+ and PI+/annexin V-, 
quadrant 1 and 2), and early apoptotic cells (PI-/annexin V+, quadrant 3). The blank 
HA(CD)-4Phe4 nanocomplex didn’t induce significant cell death, as 81.5% of MDA-
MB-435/MDR cells was alive. In both untreated group and blank nanocomplex treated 
group, minor cell population was detected as early apoptotic cells (6.73% and 6.76%, 
respectively). For MDA-MB-435/MDR cells treated by GA-loaded HA(CD)-4Phe4 
nanocomplex (c(GA) = 1 µM), significantly higher population of dead cells was 
observed in quadrants 1 and 2, and only 51.0% of cells were identified as alive. The 
percentage of live cells treated by GA-loaded nanocomplex was also significantly 
lower than cells treated by free GA, in which 70.5% cells were detected alive. In 
addition, 33.2% of cells treated by GA-loaded HA(CD)-4Phe4 nanocomplex were 
subjected to early apoptosis, which was also significantly greater than cells treated by 
free GA (16.2%).  
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Figure 5.8. A) Annexin-V/PI staining of MDA-MB-435/MDR cells incubated with 
blank HA(CD)-4Phe4 nanocomplex, free GA or GA-loaded HA(CD)-4Phe4 
nanocomplex (c(GA) = 1 µM) for 24 hrs. B) The percentage of live cells, early 
apoptotic cells and dead cells was recorded. Statistical significance: **, p < 0.01. 
 
  To further characterize apoptosis induced by GA-loaded nanocomplex, assay of 
caspase 3/7 activities were performed and the result was shown in Figure 5.9A.  The 
activation of caspase marks the execution-phase of apoptosis, and subsequently result 
in the disassembly of cells. In MDA-MB-345/MDR cells treated by GA-loaded 
nanocomplex (c(GA) = 1 µM) for 24 hrs, significantly increased activities of caspase 3 
and caspase 7 was observed, comparing to free GA. The detection of caspase activities 
was in line with the results from annexin V/PI assay in Figure 5.8A, which suggested 
that at relatively low GA concentration (1 µM), GA-loaded nanocomplex was more 
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potent in inducing apoptotic cell death to MDA-MB-435 melanoma cells, comparing 
to free GA.  
Apoptotic death was reported in multiple cancer cells with drug resistance, such as 
doxorubicin resistant leukemia P388 cells [21], docetaxel-resistant gastric carcinoma 
BGC-823 cells [38], doxorubicin-resistant breast cancer cell line MCF-7/ADM [41], etc. 
In these researches, GA inhibited the growth of tumor cells which were resistant to 
common chemotherapeutics, and GA further provided the potential to reverse the 
chemo-resistance. GA-loaded HA(CD)-4Phe4 nanocomplex exhibited enhanced level 
of apoptosis and cytotoxicity in MDA-MB-435/MDR cells at lower concentration, 
which can be related to the effective endocytosis (Figure 5.5) and enzyme-accelerated 
release of GA (Figure 5.4). The GA-loaded nanocomplex could be developed as the 
complementary therapeutic treatment for tumor resistance.  
 
5.4.8 Gelatin zymography 
    Matrix metalloproteinases (MMPs) are a family of zinc-dependent 
endopeptidases that are involved in tumor invasion and metastasis. Due to the 
metastatic characteristics of MDA-MB-435 melanoma cells [42], it’s of particular 
importance to address the impact of GA-loaded HA(CD)-4Phe4 nanocomplex on the 
MMP activities and further inhibiting the metastasis and invasion of tumor cells. 
Gelatin zymography was performed to examine the activities of MMP-2 and MMP-9 
in MDA-MB-435/MDR cells treated by free GA or GA-loaded HA(CD)-4Phe4 
nanocomplex (c(GA) = 1 µM).  
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    As shown in Figure 5.9B, the zymography of either untreated cells or cells treated 
by the blank HA(CD)-4Phe4 nanocomplex showed broader bands digested by MMP, 
indicating a high level of MMP activity and that MDA-MB-435/MDR cells 
maintained strong tendency of metastasis. However, after being treated by free GA or 
GA-loaded HA(CD)-4Phe4 nanocomplex, smaller band area than the untreated control 
was observed, suggesting significantly suppressed MMP activities. No difference was 
observed between the free GA and GA-loaded HA(CD)-4Phe4 nanocomplex treated 
groups, and it can be concluded that the delivery of GA by HA(CD)-4Phe4 
nanocomplex didn’t hinder the pharmaceutical potency of GA in controlling tumor 
invasion.  
    In addition to exhibiting significant cytotoxicity, inducing mitochondrial 
depolarization and apoptotic cell death in MDA-MB-435/MDR melanoma cells, GA-
loaded HA(CD)-4Phe4 nanocomplex also provide the potential to inhibit the invasion 
and metastasis of MDA-MB-435/MDR cells. As we demonstrated in vitro, the HA 
component of the HA(CD)-4Phe4 nano-carrier could introduce the tumor-targeting 
delivery property, which could further improve the therapeutic potency of this delivery 
system. To extend the current in vitro study to in vivo models, and further investigate 
the anti-tumor performance of GA-loaded HA(CD)-4Phe4 nanocomplex, would also 
be the focus of our future work. 
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Figure 5.9. A) Caspase 3/7 activities of MDA-MB-435/MDR cells incubated with 
GA-loaded HA(CD)-4Phe4, free GA, or blank HA(CD)-4Phe4 nanocomplex for 24 
hrs (c(GA) = 1 µM). Statistical significance: *, p < 0.05. B) Gelatin zymography of 
MDA-MB-435/MDR cells incubated with blank HA(CD)-4Phe4 nanocomplex, free 
GA or GA-loaded HA(CD)-4Phe4 (c(GA) = 1 µM) in serum-free media for 24 hrs. 
The area of bright band correlated to the activities of matrix metalloproteinases MMP-
9 and MMP-2. 
 
5.5 Conclusions 
    In this study, biodegradable nano-delivery vehicles for GA was developed from 
the inclusion complex between cyclodextrin grafted HA and phenylalanine based 
pseudo protein. The 4Phe4 component provide hydrophobic interaction and loading 
capacity for GA, while the HA component of the nanocomplex targeted the 
overexpressed CD44 receptor on MDA-MB-435/MDR melanoma. The 
biodegradability of the HA(CD)-4Phe4 nanocomplex enabled an enzymatic-
accelerated release of GA. The CD44-mediated internalization of GA-loaded 
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HA(CD)-4Phe4 nanocomplex significantly improved the selective endocytosis in the 
CD44 positive MDA-MB-435/MDR melanoma cells. Compared to free GA at 1 µM, 
GA-loaded HA(CD)-4Phe4 nanocomplex induced significantly enhanced 
mitochondrial depolarization and apoptotic cell death in MDA-MB-435/MDR cells, 
and effectively inhibited the MMP activity which is responsible for tumor metastasis. 
It is expected that the CD44-medicated tumor targeting from the HA component on 
the HA(CD)-4Phe4 nanocomplex could introduce more advantages in the in vivo 
performance in the future study Therefore, the HA(CD)-4Phe4 nanocomplex could 
hold a promising potential as the tumor-targeting delivery platform for gambogic acid 
or other hydrophobic drugs. 
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CHAPTER 6 
 
LIGHT-FACILITATED DELIVERY OF OVALBUMIN WITH BIODEGRADABLE 
POLY(ESTER AMIDE)S NANOPARTICLES FOR MHC-I ANTIGEN 
PRESENTATION IN VITRO 
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6.1 Abstract 
    The generation of CD8 T cells is crucial in the adaptive immunity against cancer 
and many infectious diseases. Vaccine aimed to stimulate CD8 T cell response 
typically became ineffective because the antigens are primarily subject to 
sequestration by endocytic compartment, instead of being delivered cytosolically for 
MHC-I processing and presentation to elicit CD8 T cell responses. In this study, a 
biodegradable nano-carrier for ovalbumin (OVA) was developed from arginine and 
phenylalanine based poly(ester amide)s, and formed electrostatic complex with 
photosensitizer AlPcS2a (Arg-Phe-PEA(AP) nanoparticles). The enzymatic 
biodegradability of the nano-carrier enabled enzyme-accelerated release of OVA, and 
significantly enhanced the internalization rate by dendritic cells, compared to free 
OVA. The photochemical interruption of endocytic compartments by the AlPcS2a in 
the Arg-Phe-PEA(AP) nanocarrier enabled the light-facilitated endosomal escape of 
the OVA-loaded nanoparticles into cytosol, and hence to facilitate the process of 
MHC-I presentation of CD8 T cell response. The MHC-I response by OVA-loaded 
Arg-Phe-PEA(AP) nanoparticles was dependent on the light dose, as well as the 
concentration of the photosensitizer. The proper dose of both photosensitizer and light 
was determined in vitro for optimized level of MHC-I response. 
 
 
6.2 Introduction 
    Cytotoxic T lymphocyte (CD8 T lymphocytes)-mediated immunity is believed to 
be critical for the full protection from diseases, such as HIV, malaria, and cancer [1]. 
 198 
Therefore, many research efforts have been directed to guide antigen into major 
histocompatibility complex (MHC)-I processing pathways of antigen presenting cells, 
which is critical for the generation of CD8 T cell responses. Dendritic cells, the most 
potent antigen presenting cells, endocytose, process, and load antigens onto MHC 
class I or II molecules for the presentation to naive CD8 or naive CD4 T cells, 
respectively. Cytosolic processing of exogenous antigen proteins such as vaccines can 
be achieved by MHC-I pathway, and further potentiate CD8 T cell response. The 
MHC-I presentation of vaccines [2] involves the endocytosis of the antigen, 
transmigration of the antigen into cytosol, degradation of the antigen in proteasome, 
the display of immune complex from the degraded antigenic peptide on the surface of 
antigen presenting cells, and the communication with CD8 T cells.  
    Several challenges are associated with the direct vaccination of free antigen [3], 
which include inherent instability of soluble antigens, low internalization efficiency of 
antigens, and the lack of manipulation over a phenotype of immune response, etc. 
Nanoparticle-based vaccine delivery system [4] has been developed for the hope to 
overcome these limitations by providing protection against premature degradation of 
antigen, and enabling  targeted delivery and sustained release of payloads, effective 
interaction with antigen presenting cells, and multivalent presentation, etc. Poly (γ-
glutamic acid) (PGA), N-trimethyl chitosan (TMC), poly(lactide-co-glycolide) (PLGA) 
are the most extensively studied polymers [5] as either nanogels or nano-micelles for 
the delivery of ovalbumin to dendritic cells and other immune cells. 
    It is reported [6–8] that antigens of conventional vaccines typically end up in the 
MHC-II pathway after being localized in phagosomes and lysosomes, and elicit CD4 
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T cell response instead of CD8 T cell response. For CD8 T cell-inducing vaccination, 
functionally intact antigen must be transported across barriers to reach intracellular 
sites of action. The sequestration of antigens in endocytic compartments can impede 
the cytosolic MHC-I processing and subsequent presentation [9]. 
    Among the current strategies to overcome the endocytic sequestration of cargos, 
photochemical internalization (PCI), developed by Berg and colleagues [10], is a highly 
efficient technology which takes advantage of photochemical rupture of endocytic 
vesicles which enables the cytosolic release of therapeutic payloads. PCI-capable 
photosensitizers include a series of phthalocyanine and porphyrin derivatives which 
contain hydrophobic fused aromatic rings and hydrophilic sulfonate groups. The 
amphiphilic nature of PCI-capable photosensitizers exhibits specific affinity with the 
membrane of endocytic vesicles, where PCI-capable photosensitizers generate reactive 
oxygen species (ROS) upon a light irradiation [11], and are responsible for the 
oxidative rupture of endolysosomal membrane [12], followed by the subsequent release 
of cargos from endolysosomal compartment into cytosol.  The most commonly 
studied PCI-capable photosensitizers include aluminum phthalocyanine disulfonate 
(AlPcS2a, excited at 660-670 nm light) [13] and the chemical structure of AlPcS2a is 
shown in Figure 6.1A. Other PCI-capable photosensitizers such as meso-
tetraphenylporphine disulfonate (TPPS2a) and Amphinex were also studied, both of 
these two photosensitizers are excited at 435 nm light [14]. PCI-capable 
photosensitizers are non-toxic in the absence of light, and has been demonstrated to 
enhance the efficacy of various therapeutic agents, such as macromolecular 
chemotherapeutics, proteins, genes, etc, in more than 80 cell lines and animal models 
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[10].  Håkerud et al. [15] studied the intradermal delivery of free photosensitizer 
TPCS2a and ovalbumin to mice, and the PCI effect increased the stimulation of CD8 
T-cell responses as measured by antigen-specific proliferation and secretion of pro-
inflammatory cytokines. Additionally, photosensitizer (TPCS2a) was also reported to 
facilitate the cytosolic delivery of ovalbumin-loaded liposomes [16] or ovalbumin-
loaded PLGA (poly(lactic-co-glycolic acid)) nanoparticles [17].  
    In the published studies of the PCI-facilitated vaccine delivery, photosensitizers 
and the antigens were administered separately, and there are no published studies that 
co-delivery both photosensitizers and OVA simultaneously. The discrepancy in their 
endocytosis rate by antigen presenting cells and circulation profiles in body fluid can 
impact the efficiency of PCI-facilitated vaccination. Therefore, it is of great 
importance to develop a complex system for the co-delivery of PCI-capable 
photosensitizers and antigen-loaded delivery vehicles simultaneously, and to elicit 
cytosolic delivery of antigens with subsequent MHC-I presentation and activation of 
CD8 T cell response.  In this study, we proposed a co-delivery of both AlPcS2a 
photosensitizer and OVA simultaneously via a new amino acid-based synthetic 
biodegradable biomaterial. 
   Synthetic amino acid based poly (ester amide)s (AA-PEA) is a new family 
of biodegradable polymers synthesized from 3 building blocks: amino acids, 
dialcohol, diacids.  AA-PEAs have been engineered into electrospun 
nanofibrous membranes, melt-spun fibers, microspheres, nanospheres, micelles, 
3D microporous hydrogels and films for multiple biomedical applications, such 
as coating as drug eluting stents including the latest biodegradable magnesium 
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alloy-based [18–23], treatment of burn wounds [24], non-viral gene vectors [25–27], 
coating of sutures for reducing suture-induced inflammatory response [28], and 
delivery vehicles for mast cell stabilizers to treat diabetic retinopathy [29], and 
other synthetic or protein-based drugs [30,31].  The current status of AA-PEAs 
and their distance relative, amino acid-based poly(ester urea urethane) (AA-
PEUU) have recently been reviewed [32–35].  
    Among the amino acids for AA-PEA synthesis, arginine (Arg) is the most 
unique as it can retain cationic charge over a wide range of pH due to its high pI 
value (10.76) of its pendant guanidine group. Arg-based PEAs are cationic at a 
physiological pH, suitable to form electrostatic complex with other negatively 
charged materials or payloads [36]. Chu et al. have demonstrated that Arg-based 
PEAs facilitated the penetration through cell membrane with an excellent cell 
biocompatibility, and worked as effective delivery systems for therapeutic 
agents including genes [37]. 
    In this study, we aimed to develop a biodegradable cationic Arg-based 
poly(ester amide)s nano-carrier in complex with anionic PCI-photosensitizer, AlPcS2a, 
as the delivery vehicles for ovalbumin (OVA). As the most typically studied antigen, 
OVA can be cytosolically degraded into residues 257–264 (SIINFEKL) peptide, and 
presented with the murine Kb MHC-I molecule on the surface of dendritic cells to 
further potentiate CD8 T cell response. The Arg-based PEA nanoparticles f are 
expected to form an electrostatic complex with anionic AlPcS2a, and provides an 
efficient encapsulation of OVA which exhibits anionic charge in aqueous environment. 
The delivery performance of the Arg-based PEA nanoparticles was examined in 
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dendritic cells, and the light-facilitated rupture of endocytic compartments in dendritic 
cells was studied. The MHC-I presentation of OVA-loaded nanoparticles in dendritic 
cells was also validated in vitro. 
 
6.3. Experimental 
6.3.1 Chemicals and cells 
    SIINFEKL peptide (OVA254-267), chlorophenol red-β-D-galactopyranoside 
(CPRG), fluorescein isothiocyanate (FITC), 4-nonylphenyl-polyethylene glycol (NP-
40), methyl-β-cyclodextrin, α-chymotrypsin from bovine pancreas and QuantiPro 
BCA assay kit were from Sigma Aldrich (Milwaukee, WI).  Aluminum 
phthalocyanine disulfonate (AlPcS2a) was from Frontier Scientific (Logan, UT). 
Ovalbumin (OVA) was from Hyglos GmbH (Regensburg, Germany). Lysotracker 
green DND and Hoechst 33342 were from Cell Signaling Technology (Beverly, MA). 
Nystatin, chloropromazine, amiloride hydrochloride were from Cayman Chemical 
(Ann Arbor, MI).  Snakeskin dialysis tubing (MWCO = 10 kDa) were from Pierce 
(Rockford, IL). Fluorescein isothiocyanante labeled ovalbumin (FITC-OVA) was 
from Molecular Probes (Eugene, OR).  The monomer Arg-4 (tetra-p-toluenesulfonic 
acid salt of bis-L-arginine butane-1, 4-diester), Phe-4 (tetra-p-toluenesulfonic acid salt 
of bis-L-phenylalanine butane-1, 4-diester) and NA (di-p-nitrophenyl adipate) were 
synthesized according to our previously studies [38,39].     
    DC2.4 cells were generously donated by Dr. Kenneth Rock (University of 
Massachusetts Medical Center) and were maintained in RPMI 1640 media 
supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM MEM Non-
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Essential Amino Acids, 0.055 mM 2-mercaptoethanol, 100 U/mL penicillin, 100 
μg/mL streptomycin, and 10 mM HEPES buffer. B3Z T cell hybridoma were 
generously donated by Dr. John Frelinger (University of Rochester Medical Center) 
and were maintained in RPMI 1640 supplemented with 10% FBS, 2mM glutamine, 1 
mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.055 mM 2-
mercaptoethanol and 10 mM HEPES buffer. Cells were incubated in water-jacketed 
incubator at 37 °C in 5% CO2. 
 
6.3.2 Synthesis of Arg-Phe-PEA polymer 
    The amphiphilic copolymer, arginine (Arg) and phenylalanine (Phe) based 
poly(ester amide)s (Arg-Phe-PEA) were synthesized according to our prior published 
study [40]. Briefly, monomer NA (1.0 mmol), Arg-4 (0.5 mmol) and Phe-4 (0.5 mmol) 
in 1.5 mL of dry DMSO were mixed well by vortexing. The solution was heated to 
70 °C with stirring to obtain a uniform mixture. Triethylamine (0.31 mL, 2.2 mmol) 
was added dropwise to the mixture at 70 °C under vigorous stirring until a complete 
dissolution of the monomers. The reaction vial was then kept for 24 hrs at 70 °C. The 
resulting polymer was precipitated in cold ethyl acetate, filtered, and purified by a 
Soxhlet extractor with ethyl acetate for 24 hrs. The purified Arg-Phe-PEA polymer 
was dried in vacuo at room temperature.     
 
6.3.3 Preparation of OVA-loaded Arg-Phe-PEA(AP) nanoparticles 
    Preparation of Blank Arg-Phe-PEA nanoparticles. Blank Arg-Phe-PEA 
nanoparticles were prepared via a single-step nanoprecipitation method as previously 
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described [40]. Briefly, the Arg-Phe-PEA polymer was dissolved in DMSO (20 
mg/mL). The resulting Arg-Phe-PEA solution was then added into 1% poly(vinyl 
alcohol) (PVA) aqueous solution dropwise under stirring at room temperature. The 
residual organic solvent and free molecules were removed by repeated washing the 
nanoparticle solution with Amicon Ultra-4 centrifugal filter (MWCO=100 kDa).  
    Preparation of OVA-loaded Arg-Phe-PEA nanoparticles. To prepare ovalbumin 
(OVA) loaded Arg-Phe-PEA nanoparticles, the Arg-Phe-PEA polymer was dissolved 
in DMSO and mixed with the same volume of OVA solution in PBS on ice. The final 
concentration of Arg-Phe-PEA and OVA in the mixture was 20 mg/mL and 2 mg/mL, 
respectively. The mixture solution was added into 1% poly(vinyl alcohol) (PVA) 
aqueous solution dropwise under stirring on ice, and repeated washed with DI water in 
Amicon Ultra-4 centrifugal filter (MWCO=100 kDa). In addition, fluorescein labeled 
ovalbumin (FITIC-OVA) was also loaded in Arg-Phe-PEA nanoparticles in exactly 
the same procedure.  
    To determine the loading content (LC) and encapsulation efficiency (EE) of OVA 
in the Arg-Phe-PEA nanoparticles, the filtered solution which contained the un-
encapsulated FITC-OVA was collected from the collector tube of the Amicon 
centrifugal filter. The fluorescence intensity was quantified (λex=488 nm, λem=520 
nm) on a PTI spectrofluorometer (Photon Technology International, South Brunswick, 
NJ), and calibrated against a standard curve of FITC-OVA.    
    Preparation of Arg-Phe-PEA(AP) nanoparticles. To prepare the electrostatic 
complex between anionic photosensitizer AlPcS2a and cationic OVA-loaded Arg-Phe-
PEA nanoparticles (OVA-loaded Arg-Phe-PEA(AP)), an aqueous solution of OVA-
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loaded Arg-Phe-PEA nanoparticles (10 mg/mL) was mixed with AlPcS2a in a final 
concentration of 10, 50 or 250 µg/mL. The mixture solution was stirred in dark at 
room temperature for 2 hrs and repeated washed with DI water in Amicon Ultra-4 
centrifugal filter (MWCO=100 kDa) to remove free AlPcS2a.  The concentration of 
AlPcS2a in the OVA-loaded nanoparticles was determined by inductively coupled 
plasma mass spectrometry (ICP-MS) according to the published procedure [41]. The 
complex of AlPcS2a and blank Arg-Phe-PEA nanoparticles was also prepared in the 
same method. 
    The morphology of the nanoparticles was observed on a FEI Tecnai Spirit T12 
TEM (FEI Co., Hillsboro, OR) at an operating voltage of 120 kV. Zeta potential and 
size of the nanoparticles were characterized at room temperature on a Zetasizer 
NanoZS system (Malvern, UK). 
 
6.3.4 Relative oxygen concentration in blank Arg-Phe-PEA(AP) solutions with 
irradiation 
    To probe the oxygen consumption rate, the relative concentration of oxygen was 
determined as a function of irradiation time in aqueous solution of blank Arg-Phe-
PEA(AP) nanoparticles. Clark-type oxygen electrode (Hansatech Instruments Ltd, UK) 
was used as previously described [42] to directly measure the partial pressure of oxygen, 
was inserted into the PBS solution of free AlPcS2a or blank Arg-Phe-PEA(AP) 
nanoparticles with an equivalent AlPcS2a concentration. 10% FBS was also present in 
each testing condition as the receptor for reactive oxygen species. Irradiation by LED 
arrays (660 nm, 25 mW/cm2, Elixa Ltd, Albuquerque, NM) was used for all the 
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following test including in vitro cell work. Before each measurement, the system was 
calibrated in PBS bubbled with air. Relative oxygen concentration was acquired by 
normalizing the measured partial pressure of oxygen in each sample to that of 
untreated PBS bubbled with air, and the results were plotted as a function of 
irradiation time. Relative oxygen concentration correlated with the oxygen 
consumption, and further reflected the efficiency of ROS generation. Relative oxygen 
concentration of non-irradiated solution of free AlPcS2a or blank Arg-Phe-PEA(AP) 
were also tested as the controls. 
 
6.3.5 In vitro release of OVA from Arg-Phe-PEA(AP) nanoparticles 
    In vitro release profiles of OVA from the Arg-Phe-PEA(AP) nanoparticles were 
examined in 10 mM phosphate buffer (pH 7.4) with or without the presence of α-
chymotrypsin (0.2 mg/mL). The release profiles were determined according to the 
previously published studies by Lee et al. [43]. FITC-OVA loaded Arg-Phe-PEA 
nanoparticles (1 mg/mL) were dispersed in PBS containing 0.02% sodium azide and 
0.2 mg/mL α-chymotrypsin. The suspension was then aliquoted to 1 mL/microfuge 
tube, and the microfuge tubes were kept at 37 °C. At 1, 2, 4, 8, 12, 24, 48 hrs, the 
microfuge tubes were centrifuged at 15,000 rcf for 10 min, and the supernatants were 
filtered through 0.22 µm syringe filter. The concentration of the released FITC-OVA 
in the supernatants was determined by a spectrofluorometer (λex=488 nm, λem=520 
nm) and calibrated against a standard curve of FITC-OVA. In the case of OVA release 
upon light irradiation treatment (at 660 nm, 1.5 J/cm2, 1 min), the release data were 
collected right after irradiation. Except the light irradiation treatment, the rest of the 
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experiments were performed in dark to minimize the photo-bleaching of the 
fluorophore. The percentages of the released FITC-OVA were plotted vs. time. Each 
test was performed in triplicate. 
 
6.3.6 Endocytosis of blank Arg-Phe-PEA(AP) nanoparticles  
    Endocytosis inhibition assay. DC2.4 cells were seeded in a 6-well plate (1 x 106 
cells per well) and pre-incubated for 4 hrs. The cells were treated with inhibitors that 
block different endocytic pathways [44,45] (nystatin, 50 μg/mL; chloropromazine, 30 
μM; amiloride hydrochloride, 50 μM; methyl-β-cyclodextrin, 3 mg/mL) for 0.5 hr 
before blank Arg-Phe-PEA (AP) nanoparticles were added and incubated for another 4 
hrs. The cells were then washed with PBS, harvested and subjected to flow cytometry 
assay on FACSAria fusion fluorescence activated cell sorter (BD Biosciences, 
Franklin Lakes, NJ). The effect of low temperature (4°C) on endocytosis was also 
studied.  Cells incubated with Arg-Phe-PEA(AP) nanoparticles at 37°C but not 
treated with any inhibitor were tested as the control. The mean fluorescence intensity 
for each sample was recorded on a FACSAria fusion fluorescence activated cell sorter 
(BD Biosciences, Franklin Lakes, NJ) and normalized to control. The tests were 
performed in triplicate. 
    Accumulated endocytosis study. To monitor the accumulated endocytosis of the 
blank Arg-Phe-PEA(AP) nanoparticles as a function of time, DC2.4 cells were seeded 
at 1 x 106 cells per well in a 6-well plate and pre-incubated for 4 hrs. DC2.4 cells were 
then incubated with blank Arg-Phe-PEA(AP) nanoparticles or free AlPcS2a with an 
equivalent concentration for 1, 2, 4, 8, 12, 24hrs. The cells were washed and harvested, 
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and the mean cellular fluorescence intensity was then examined by flow cytometry. 
Each test was run in 3 replicates. 
 
6.3.7 Light-facilitated cytosolic delivery of blank Arg-Phe-PEA(AP) nanoparticles 
    DC2.4 cells were seeded in a 35 mm glass-bottomed-dish (1 x 106 cells/well, 
MaTek, Ashland, MA) and incubated for 4 hrs. Blank Arg-Phe-PEA(AP) 
nanoparticles were added and incubated for 4 hrs. The cells were washed and labeled 
with Lysotracker green (50 nM) as per manufacturer’s instruction, and imaged alive 
by confocal microscopy (Zeiss LSM710, Carl Zeiss MicroImaging, Thornwood, NY). 
Light irradiation was then applied by LED arrays (120 arrays, 25 mW/cm2, Elixa Ltd, 
Albuquerque, NM) at 660 nm with light dosages of 0.5, 1.5 or 3 J/cm2. The Pearson’s 
coefficient for co-localization between Arg-Phe-PEA(AP) nanoparticles and 
Lysotracker before and after irradiation was determined with Fiji software (National 
Institutes of Health), 30 images were analyzed for each group. 
 
6.3.8 Endocytosis of OVA loaded in Arg-Phe-PEA(AP) nanoparticles 
    DC2.4 cells were seeded at 1 x 106 cells per well in a 6-well plate and pre-
incubated for 4 hrs. DC2.4 cells were then incubated with FITC-OVA-loaded Arg-
Phe-PEA(AP) nanoparticles or free FITC-OVA with an equivalent OVA concentration 
of 5 µg/mL for 4 hrs. The cells were washed and light irradiation was applied at 660 
nm by LED arrays (1.5 J/cm2). The cells were further incubated for another 4 hrs and 
then harvested, and the mean cellular fluorescence intensity was then examined by 
flow cytometry. Each test was run in 3 replicates. 
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6.3.9 Cytotoxicity of OVA-loaded Arg-Phe-PEA(AP) nanoparticles 
    DC2.4 cells were seeded at 1x104 cells per well in a 96-well plate and pre-
incubated for 4 hrs. The cells were incubated with the OVA-loaded Arg-Phe-PEA(AP) 
nanoparticles with various concentrations of AlPcS2a, free OVA or blank Arg-Phe-
PEA nanoparticles 4 hrs. The cells were washed and incubated for another 20 hrs 
before light irradiation was applied at 660 nm by LED arrays (0.5. 1.5 or 3 J/cm2). The 
viability of DC2.4 cells was determined 24 hrs post irradiation with MTT assay. The 
absorbance at 570 nm was recorded and normalized to the results of the untreated cell 
control to give the percentage of cell survival.  Cells incubated the above treatments 
but without light irradiation was also determined. Each experiment was run in six 
replicates. 
 
6.3.10 In vitro MHC-I cross presentation 
    DC 2.4 dendritic cells were seeded at 4 × 104 /well in round-bottomed 96-well 
plates and incubated for 4 hrs until cells were completely anchored. Free OVA, OVA-
loaded Arg-Phe-PEA(AP) nanoparticles with different concentrations of AlPcS2a 
were incubated with DC2.4 cells with an equivalent concentration of ovalbumin at 5 
µg/mL. DC2.4 cells were then washed with PBS twice, chased for another 20 hrs, 
before light irradiation was applied at 660 nm for 0.5, 1.5 or 3 J/cm2. B3Z cells were 
then added at 1 × 105 /well and co-cultured for 16 hrs [46]. For the positive control, 
SIINFEKL peptide (1 nM) was added simultaneously with B3Z cells. The medium 
was then replaced by 100 μL of CPRG lysis buffer (0.15 mM CPRG, 0.5% NP-40 in 
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PBS). The plates were kept in dark at room temperature for 72 hrs, and the absorbance 
at 570 nm was read on a Synergy HT microplate reader (BioTek, Winooski, VT). 
 
6.3.11 Statistical analysis  
    The data are presented as mean values with standard deviations (SD). All data 
were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison 
tests, and p < 0.05 was used for statistical significance. 
 
6.4. Results and discussions 
6.4.1 Characterization of OVA-loaded Arg-Phe-PEA(AP) nanoparticles 
    The synthesis of arginine(Arg) and phenylalanine (Phe) based poly(ester amide)s 
(Arg-Phe-PEA) was based on our prior published studies [40], and the ratio between 
Arg and Phe moieties in the polymers was 1:1, as shown in Figure 6.1A. The average 
molecular weight of the Arg-Phe-PEA polymer was detected as 1.93 × 104 Da, with a 
PDI of 1.27. The Arg-Phe-PEA polymer was reported [40] to form self-assembled 
structure in aqueous solution due to the hydrophilicity of Arg moieties that stayed on 
the outer layer of the nano-assembly, and the hydrophobicity of Phe moieties that 
stayed in the interior of the nano-assembly. Cationic charge was detected on blank 
Arg-Phe-PEA nanoparticles in aqueous solution, as shown in Table 6.1. The zeta-
potential for blank Arg-Phe-PEA nanoparticles was 26.2 ± 3.1 mV, with an average 
dimeter of 170.2 ± 8.9 nm. 
    The hydrophobic interior provided loading capacity for the relatively less 
hydrophilic protein such as bovine serum albumin (BSA) [40] and ovalbumin (OVA) 
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[47], and the scheme for the formation of OVA-loaded Arg-Phe-PEA nanoparticles was 
also shown in Figure 6.1A. The characterization of OVA-loaded nanoparticles was 
listed in Table 6.1 and Figure 6.2. Spherical structure was observed for OVA-loaded 
Arg-Phe-PEA nanoparticles was observed in aqueous dispersion. A slightly increased 
diameter was detected as 210.4 ± 9.2 nm compared to the blank nanoparticles, and the 
zeta-potential of the OVA-loaded Arg-Phe-PEA nanoparticles was 15.6 ± 6.5 mV. The 
loading content (LC) and encapsulation efficiency of OVA in Arg-Phe-PEA 
nanoparticles was detected as 6.2 % and 67.5% respectively. The Arg-Phe-PEA 
nanoparticles provided effective loading of OVA, and the loading efficiency was 
comparable to that of PLGA nanoparticles (45% to 70%) [47–49], which was extensively 
investigated as the delivery carriers for OVA-based vaccine. 
    The cationic charge on the surface of OVA-loaded Arg-Phe-PEA nanoparticles 
provided capability to form electrostatic complex with other anionic molecules. The 
two adjacent sulfonate groups on the photosensitizer AlPcS2a rendered it anionic 
charge in aqueous solution. And by mixing the cationic OVA-loaded nanoparticles 
and AlPcS2a, the electrostatic complex was formed and denoted as OVA-loaded Arg-
Phe-PEA(AP) nanoparticles. As shown in Figure 6.2, spherical structure was 
maintained in OVA-loaded Arg-Phe-PEA(AP) nanoparticles and we further studied 
the effect of the AlPcS2a concentration in feed on the size and zeta-potential of the 
complex structure. With the concentration of OVA-loaded Arg-Phe-PEA (10 mg/mL) 
and AlPcS2a (50 µg/mL) in feed, the resulting nanoparticles was denoted as OVA-
loaded Arg-Phe-PEA (AP 0.5), and we also studied the nanoparticles with higher ratio 
of AlPcS2a (OVA-loaded Arg-Phe-PEA (AP 2.5)), as well as the ones with lower ratio 
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of AlPcS2a (OVA-loaded Arg-Phe-PEA (AP 0.1)). As indicated in Table 6.1, the 
formation of electrostatic complex with AlPcS2a resulted in a decrease on the zeta-
potential of the nanoparticles, and OVA-loaded Arg-Phe-PEA(AP) exhibited a slightly 
cationic charge (4.3 to 6.3 mV) with various concentration of AlPcS2a, compared to 
15.6 mV for the nanoparticles with the absence of AlPcS2a. The AlPcS2a content in 
the nanoparticles didn’t introduce significant change in the diameter, as the 
nanoparticles exhibited DLS diameter ranging from 201.5 nm to 235. 2 nm.  
    To induce effective photochemical rupture of endolysosomes, AlPcS2a should be 
localized specifically in the lipid bilayer in the endolysosomes [50], instead of other 
subcellular compartments. The binding of AlPcS2a on the surface of the nanoparticles 
enabled the close contact between AlPcS2a and endolysosomal membrane. The 
scheme for photosensitizer induced cytosolic delivery of OVA, as well as the 
subsequent MHC-I processing and presentation, were illustrated in Figure 6.1B. 
 
 
 213 
 
 
Figure 6.1. A) Chemical structure of Arg-Phe-PEA polymers. The scheme for the 
formation of OVA-loaded Arg-Phe-PEA nanoparticles, and the electrostatic complex 
between anionic photosensitizer AlPcS2a with cationic OVA-loaded Arg-Phe-PEA 
nanoparticles (OVA-loaded Arg-Phe-PEA(AP)). B) Illustration of the light-facilitated 
cytosolic delivery of OVA by Arg-Phe-PEA(AP) nanoparticles in dendritic cells, and 
the subsequent MHC-I presentation to CD8 T cells. 
 
 
Table 6.1. Characterization of OVA-loaded Arg-Phe-PEA(AP) nanoparticles. 
 
 DLS 
diameter/ 
Zeta 
potential 
LC 
(OVA) 
EE 
(OVA) 
Content of 
AlPcS2a / 
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nm /mV /% /% wt% 
Blank Arg-Phe-PEA 170.2 ± 8.9 26.2 ± 3.1 NA NA NA 
OVA-loaded Arg-Phe-
PEA 
210.4 ± 9.2 15.6 ± 6.5  
 
6.2 % 
 
 
67.5% 
NA 
OVA-loaded Arg-Phe-
PEA (AP 0.1) 
201.5 ± 11.2 6.3 ± 1.2 0.15 % 
OVA-loaded Arg-Phe-
PEA (AP 0.5) 
228.7 ± 7.5 4.3 ± 1.4 0.36 % 
OVA-loaded Arg-Phe-
PEA (AP 2.5) 
235.2 ± 11.2 5.1 ± 2.2 1.9 % 
 
 
 
Figure 6.2. TEM images of A) OVA-loaded Arg-Phe-PEA nanoparticles in PBS. B) 
OVA-loaded Arg-Phe-PEA(AP) nanoparticles in PBS. C) OVA-loaded Arg-Phe-
PEA(AP) nanoparticles after 48 hrs incubation with α-chymotrypsin (0.2 mg/mL). 
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6.4.2 Relative oxygen concentration in blank Arg-Phe-PEA(AP) solution with 
irradiation 
    As the photosensitizing effect of AlPcS2a involves the photo-induced generation 
of free radical, and further interact with oxygen molecules to form reactive oxygen 
species (ROS). The relative oxygen concentration correlates with the consumption of 
oxygen, which reflected the efficiency of ROS generation by Arg-Phe-PEA 
nanoparticles. As shown in Figure 6.3A, significantly reduced relative oxygen 
concentration was observed when light irradiation was applied to the Arg-Phe-
PEA(AP) nanoparticles, when comparing to the counterpart in dark. The relative 
oxygen concentration treated by Arg-Phe-PEA(AP) nanoparticles decreased with 
irradiation time, which was 0.97 (with light dose of 0.5 J/cm2), 0.91 (1.5 J/cm2), and 
0.77 (3 J/cm2), respectively. In addition, relative oxygen concentration profile for Arg-
Phe-PEA(AP) nanoparticles was almost identical to that of free AlPcS2a, especially at 
the first 180 sec of irradiation at 660 nm (25 mW/cm2). The results suggested that 
AlPcS2a-loaded Arg-Phe-PEA(AP) nanoparticles was as competent as free AlPcS2a 
in ROS generation, and could provide an equivalent potential to initiate PCI. 
 
6.4.3 In vitro release of OVA from Arg-Phe-PEA(AP) nanoparticles 
    The lack of effective intracellular trigger [51] for the release of loaded 
antigen can be a challenge that reduced the delivery efficiency. Due to the 
enzymatic biodegradability of the Arg-Phe-PEA(AP) carriers [40], the release of 
OVA could be accelerated by enzymatic degradation. And we further 
investigated the release profile of OVA from nanoparticles incubated with α-
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chymotrypsin, an enzyme which preferentially attacks the hydrophobic amino 
acids such as phenylalanine, and cleaves the amide bonds. The release profile of 
OVA was shown in Figure 6.3B. In the testing groups without light irradiation, 
at the end of 48 hrs, 65% cumulative OVA was released from Arg-Phe-PEA(AP) 
in the presence of α-chymotrypsin (red curve), while only 23 % cumulative was 
achieved without any enzyme (black curve), indicating that OVA release was 
effectively accelerated by enzymatic degradation of the carrier. The results 
correlated well with the TEM morphology of OVA-loaded Arg-Phe-PEA 
nanoparticles in Figure 6.2B and 6.2C, in which the spherical nano-structure 
disappeared after 48 hrs incubation with α-chymotrypsin.  
    When light irradiation was applied at 660 nm (25 mW/cm2, 1.5 J/cm2, 1 min) 
right before the release test, the release of OVA from the light-irradiated Arg-Phe-
PEA(AP) nanoparticles didn’t exhibit any significant difference from the 
corresponding groups in dark. For example, without the presence of α-chymotrypsin, 
22% of total OVA was released from Arg-Phe-PEA(AP) in dark (black curve), vs. 18% 
released from Arg-Phe-PEA(AP) with 1.5 J/cm2 irradiation, which exhibited no 
significant difference between irradiated vs.  non-irradiation group. In addition, 60% 
of OVA was released from Arg-Phe-PEA(AP) nanoparticles when 1.5 J/cm2 
irradiation was applied (green curve), which exhibited no difference from the OVA 
released from Arg-Phe-PEA(AP) in dark (red cure).  The resulted suggested that 1.5 
J/cm2 irradiation didn’t impact the release of OVA, and enzymatic biodegradation 
played a key role in the accelerated OVA release profile observed in Figure 6.3B.  
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Figure 6.3. A) Relative oxygen concentration vs. irradiation time for Arg-Phe-
PEA(AP) nanocomplex or free AlPcS2a in PBS containing 10% FBS under irradiation 
(660 nm, 25 mW/cm2), the relative oxygen concentration was obtained by normalizing 
the oxygen partial pressure of samples to that of untreated PBS, probed by Clark-type 
micro electrode. Irradiation time that resulted in light dosages of 0.5, 1.5 or 3 J/cm2 
were marked as dotted lines on the time scale. B) In vitro release profile of FITC-
OVA from the Arg-Phe-PEA(AP) nanoparticles in PBS with or without the presence 
of α-chymotrypsin (0.2 mg/mL). In the case of OVA release with light irradiation, 
irradiation at 660 nm (1.5 J/cm2) was applied for 1 min, and the release profile was 
collected right after irradiation. Except when light irradiation was applied, the rest of 
the experiments were performed in dark.  Values represent the average ± SD (n=3). 
Statistical significance: ***, p < 0.001. 
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6.4.4 Endocytosis of blank Arg-Phe-PEA(AP) nanoparticles 
    Inhibition study was performed to explore the endocytosis pathway of blank Arg-
Phe-PEA(AP) nanoparticles, and the data was shown in Figure 6.4A.  Incubation of 
DC2.4 cells with Arg-Phe-PEA(AP) nanoparticles at 4 °C for 4 hrs resulted in a 43% 
decrease in the intracellular fluorescence. Similarly, inhibition of macropinocytosis 
(by amiloride) and the clathrin-mediated pathway (by chloropromazine) also resulted 
in a significant inhibition of transmigration of the nanoparticles. On the other hand, 
inhibition of caveolae (by nystatin) and lipid raft mediated endocytosis (by methyl-β-
cyclodextrin), resulted in no significant difference in intracellular level of the blank 
nanoparticles compared to control. We therefore conclude that the translocation of 
blank Arg-Phe-PEA(AP) nanoparticles in DC2.4 cells was energy-dependent and 
involved both macropinocytosis and clathrin-mediated endocytosis. 
    We further studied the accumulative endocytosis of blank Arg-Phe-PEA(AP) 
nanoparticles in DC2.4 cells as a function of time. As illustrated in Figure 6.4B, a 
distinct difference in intracellular AlPcS2a fluorescence was observed between Arg-
Phe-PEA(AP) nanoparticles and free AlPcS2a at the first 8 hrs, and the fluorescence 
intensity from the nanoparticle-treated DC2.4 cells was 2.5-fold higher than the free 
AlPcS2a at 4 hrs. The fluorescence signals from the free AlPcS2a, however, gradually 
increased with time until the difference in intracellular fluorescence between the two 
treatments narrowed at 12-20 hrs. Due to the low pKa of sulfonated groups in free 
AlPcS2a, the free AlPcS2a exhibits negative charge in biological environment [50], 
resulting in a slower rate of internalization due to the anionic nature of the cellular 
membrane. The incorporation of AlPcS2a in Arg-Phe-PEA(AP) nanoparticles 
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significantly enhanced the internalization efficiency of AlPcS2a at a relatively short 
incubation time (4 hrs). Hence 4 hrs were chosen in the following study as the 
incubation time between OVA-loaded nanoparticles and DC2.4 cells. 
 
Figure 6.4. A) Mean fluorescence of free AlPcS2a and blank Arg-Phe-PEA(AP) 
nanoparticles (c(AlPcS2a) = 0.5 μg/mL) in DC2.4 cells as a function of incubation 
time. B) Endocytosis inhibition studies. DC2.4 cells pre-treated with various 
endocytosis inhibitors or low temperature were incubated with blank Arg-Phe-
PEA(AP) nanoparticles for 4 hrs. Mean cellular fluorescence was recorded by flow 
cytometry and normalized to the control (cells incubated with nanoparticles but not 
treated by any inhibitor). Values represent the average ± SD (n=3). Statistical 
significance was compared with control. *, p < 0.05; **, p < 0.01, ***, p < 0.001. 
 
6.4.5 Light facilitated cytosolic delivery of blank Arg-Phe-PEA(AP) nanoparticles 
    The effect of AlPcS2a photosensitizer to induce cytosolic transmigration of Arg-
Phe-PEA(AP) nanoparticles was then evaluated by confocal microscopy and shown in 
Figure 6.5A. Before light irradiation was applied, the red pixels of Arg-Phe-PEA(AP) 
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nanoparticles co-localized with the green pixels of endolysosomes (merging into 
yellow pixels), and Pearson’s coefficient was determined as 0.67, indicating the 
endolysosomal sequestration of the nanoparticles. After 0.5 hr further incubation in 
dark, no significant change in Pearson’s coefficient were observed in the absence of 
irradiation. These results demonstrated that the blank Arg-Phe-PEA(AP) nanoparticles 
were largely entrapped inside endolysosomes. However, when 660 nm irradiation at 
1.5 J/cm2 was applied for 1 min, the transmigration the nanoparticles from 
endolysosomes into cytosol was observed, as a lower level of yellow pixels was 
observed, and red pixels from Arg-Phe-PEA(AP) nanoparticles was observed and 
diffused into cytosol. Significant difference in Pearson’s coefficient was also observed 
before and after irradiation, which further confirmed the endolysosomal escape upon 
660 nm irradiation. The reduction of green fluorescence from Lysotracker after 660 
nm irradiation indicated the disruption of endolysosomes.  Lysotracker is a pH-
specific probe for acidic endocytic compartments, it can only label the intact 
endolysosomes, instead of the ruptured one, in which the endolysosomal membrane 
was disintegrated and the acidic pH character was no longer maintained.   
    The effect of light dose on the cytosolic delivery of in the Arg-Phe-PEA(AP) 
nanoparticles was also investigated, as shown in Figure 6.5B. At a lower light dose 
(0.5 J/cm2), the difference in Pearson’s coefficient before and after irradiation was not 
statistically significant, which suggested that 0.5 J/cm2 was not sufficient to result in 
effective endosomal escape of the blank nanoparticles. However, at higher light doses 
of 1.5 J/cm2 and 3 J/cm2, significant difference in Pearson’s coefficient was observed, 
indicating effective endolysosomal escape of the blank nanoparticles. 
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Figure 6.5. DC2.4 cells incubated with blank Arg-Phe-PEA(AP) nanoparticles for 4 
hrs. A) Intracellular fluorescence of Lysotracker (green), blank Arg-Phe-PEA(AP) 
nanoparticles (red), and nuclei (blue) was recorded before irradiation and 0.5 hr post 
irradiation (660 nm,1.5 J/cm2). B) Pearson’s coefficient for co-localization degree 
between blank Arg-Phe-PEA(AP) nanoparticles and Lysotracker before and 0.5 hr 
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after irradiation was applied at various light dose (660 nm, 0. 0.5, 1.5 or 3 J/cm2).  
Values represent the average ± SD (n=30). Statistical significance: *, p < 0.05. 
 
6.4.6 Endocytosis of OVA loaded in Arg-Phe-PEA(AP) nanoparticles 
    To demonstrate that Arg-Phe-PEA(AP) carrier can promote the uptake of OVA, 
flow cytometry was performed to investigate the endocytosis of FITC-OVA in DC2.4 
cells, and the results were shown in Figure 6.6. Comparing with the internalized free 
FITC-OVA, the mean cellular fluorescence from OVA loaded in Arg-Phe-PEA(AP) 
was enhanced by 5.1-fold (without irradiation) and 5.6-fold (with irradiation) 
respectively. However, the uptake of OVA-loaded nanoparticles was not affected by 
irradiation, as no significant difference in mean cellular fluorescence was observed 
before and after irradiation. Several nano-delivery vehicles were reported to increase 
the rate of uptake of OVA-based antigens including liposomes [52], PLGA 
nanoparticles [47] or chitosan nanogels [53]. Consistent with the published studies, the 
result suggested that OVA loaded in Arg-Phe-PEA(AP) was more efficient in cellular 
uptake than free OVA. As effective antigen presentation positively correlated with the 
level of internalized antigen in antigen presenting cells, enhanced intracellular level of 
OVA loaded in nano-carriers is expected to elicit increased antigen-specific immune 
response. 
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Figure 6.6. Uptake of FITC-OVA loaded in Arg-Phe-PEA(AP) nanoparticles or free 
FITC-OVA in DC2.4 cells. Light irradiation at 660 nm (1.5 J/cm2) was applied 4 hrs 
after incubation and cellular fluorescence was measured by flow cytometry. A) The 
histogram of FITC-OVA in DC2.4 cells. B) The mean cellular fluorescence from 
FITC-OVA in DC2.4 cells.  Values represent the average ± SD (n=3).  Statistical 
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significance was compared between FITC-OVA loaded nanoparticles and free FITC-
OVA.  **, p < 0.01. 
 
6.4.7 Cytotoxicity of OVA-loaded Arg-Phe-PEA(AP) nanoparticles with irradiation 
    Figure 6.5 demonstrated the PCI effect of Arg-Phe-PEA(AP) nanoparticles. PCI 
techniques highlighted the light-facilitated rupture of endocytic compartments and the 
subsequent release of cargos in cytosol. However, overdose of light or photosensitizers 
may lead to cell death, and suppression of antigen presenting cells by excessive 
photosensitizing effect should be avoided in antigen delivery. In light of this, we 
investigated the toxicity of OVA-loaded Arg-Phe-PEA(AP) nanoparticles with 
different dose of light irradiation and the results were shown in Figure 6.7.  
Firstly, blank Arg-Phe-PEA nanoparticles, free OVA or OVA-loaded Arg-Phe-
PEA without photosensitizer (Arg-Phe-PEA(AP0)) didn’t exhibit any significant 
toxicity at all testing conditions, which suggested the biosafety of the blank 
nanoparticles, as well as the antigen. Any cytotoxicity should be attributed to the 
photosensitizer AlPcS2a and its photosensitizing effect. Secondly, without light 
irradiation (0 J/cm2), no cytotoxicity was observed for OVA-loaded Arg-Phe-PEA(AP) 
with all the three AlPcS2a concentrations (AP0.1, 0.1 µg/mL; AP0.5, 0.5 µg/mL; 
AP2.5, 2.5 µg/mL). The results suggested the biocompatibility of AlPcS2a-containing 
nanoparticles in dark, and any toxicity from these nanoparticles should be related to 
the photosensitizing effect. Thirdly, significant toxicity (<50% survival of DC2.4 cells) 
was evident for OVA-loaded Arg-Phe-PEA(AP2.5) at 1.5 J/cm2 and 3 J/cm2, 
indicating that higher concentration of AlPcS2a in combination with higher light dose 
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was not good for antigen delivery to DC2.4 cells. However, slight toxicity was 
observed for OVA-loaded Arg-Phe-PEA(AP0.5) irradiated at 1.5 J/cm2, or OVA-
loaded Arg-Phe-PEA(AP0.1) at 3 J/cm2, it’s reasonable to expect that DC2.4 cells 
would maintain viable and proper biological functional at these treatment conditions. 
Photosensitizer (TPCS2a) facilitated delivery of ovalbumin by liposomes was reported 
by Hjálmsdóttir et al. [16] and photosensitizer (TPCS2a) facilitated delivery of 
ovalbumin by PLGA nanoparticles was reported by Bruno et al. [17]. However, the in 
vitro screening for optimized concentration of photosensitizer as well as the light dose, 
were absent in the reported studies. Waeckerle-Men et al. [54] studied the free 
photosensitizer Amphinex facilitated vaccination of free OVA, in which a declined 
IFN- γ secretion was observed at higher concentration of photosensitizer (0.05 µg/mL) 
due to excessive death of antigen presenting cells, and the in vitro MHC-I immune 
response was dependent on both light dose and the concentration of photosensitizer. 
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Figure 6.7. Survival of DC2.4 cells after incubation with OVA-loaded Arg-Phe-
PEA(AP0) with no AlPcS2a, OVA-loaded Arg-Phe-PEA(AP0.1) with 0.1 µ/mL 
AlPcS2a, OVA-loaded Arg-Phe-PEA(AP0.5) with 0.5 µ/mL AlPcS2a, OVA-loaded 
Arg-Phe-PEA(AP2.5) with 2.5 µ/mL AlPcS2a, blank Arg-Phe-PEA, free OVA, and 
the equivalent concentration of OVA in all the samples were 5 µg/mL. Light 
irradiation was applied at 660nm with light dose of 0, 0.5, 1.5 or 3 J/cm2. Values 
represent the average ± SD (n=6).  Statistical significance was compared between 
non-irradiated group with the groups that received different light dose. **, p < 0.01, 
***, p < 0.001. 
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6.4.8 Light-facilitated MHC-I presentation of OVA-loaded Arg-Phe-PEA(AP) 
nanoparticles  
    To further investigate the interaction between light-facilitate delivery of OVA-
loaded Arg-Phe-PEA nanoparticles and DC2.4 cells, in vitro B3Z assay of MHC-I 
presentation was performed.  B3Z [55] is a CD8 T-cell hybridoma that specifically 
recognizes ovalbumin residues 257–264 (SIINFEKL) presented on the murine Kb 
MHC-I molecule containing the LacZ reporter gene driven by transcriptional control 
of the nuclear factor of activated T cells (NFAT) element. The presentation of the 
SIINFEKL epitope to B3Z cells activates NFAT and results in the induction of β-
galactosidase synthesis by B3Z. The amount of β-galactosidase produced can be 
measured by the hydrolysis of the chromogenic substrate CPRG (chlorophenol red-β-
D-galactopyranoside) and is an indication of the amount of MHC-I immune-
complexes presented on the surface of antigen presenting cells.  
    As suggested in Figure 6.8, firstly, blank Arg-Phe-PEA nanoparticles didn’t elicit 
any MHC-I response. Secondly, all non-irradiated particulate formulations of OVA 
enhanced MHC I antigen presentation compared to free OVA, which can be correlated 
to the enhanced endocytosis of OVA in Figure 6.6. Thirdly, when light irradiation was 
applied, OVA-loaded Arg-Phe-PEA(AP0.5) with 1.5 J/cm2 irradiation resulted in 5-
fold increase in MHC-I response compared to free OVA, and 2-fold increase 
compared to its non-irradiated counterpart. Additionally, OVA-loaded Arg-Phe-
PEA(AP0.5) with 3 J/cm2 irradiation, and OVA-loaded Arg-Phe-PEA(AP2.5) with 0.5 
J/cm2 irradiation, induced significantly enhanced MHC-I response than the non-
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irradiated ones, as well as free OVA. The result is positively correlated with the PCI 
effect in Figure 6.5. The PCI effect by Arg-Phe-PEA(AP) induced effective rupture of 
endolysosomes, and the leaky endocytic compartments release antigen to the cytosol, 
where the proteasomes can digest OVA to MHC-I binding peptides that consequently 
can be presented to CD8 T cells. 
    However, OVA-loaded Arg-Phe-PEA(AP2.5) with higher light dose (1.5 and 3 
J/cm2) exhibited reduced MHC-I presentation compared to both non-irradiated ones, 
and it could be dependent on the viability result (Figure 6.7), in which higher dose of 
photosensitizers/higher light dose induced significant cytotoxicity.  
    In general, the Arg-Phe-PEA(AP) nanoparticles proved enhanced and cytosolic 
delivery of OVA, and elicit enhanced level of MHC-I antigen presentation when 
facilitated with light. The stimulated MHC-I response was dependent on the 
concentration of photosensitizer and light dose. The level of MHC-I presentation 
correlates with the activation of cytotoxic CD8 T cells and the adaptive immunity 
against tumors, and the light-facilitated Arg-Phe-PEA(AP) delivery systems could 
hold the potential to be developed as the platform for tumor vaccine delivery. 
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Figure 6.8. MHC-I antigen presentation (B3Z assay) by DC 2.4 cells. DC2.4 cells 
were incubated with the OVA-loaded Arg-Phe-PEA(AP0) with no AlPcS2a, OVA-
loaded Arg-Phe-PEA(AP0.1) with 0.1 µ/mL AlPcS2a, OVA-loaded Arg-Phe-
PEA(AP0.5) with 0.5 µ/mL AlPcS2a, OVA-loaded Arg-Phe-PEA(AP2.5) with 2.5 
µ/mL AlPcS2a, blank Arg-Phe-PEA, free OVA, and the equivalent concentration of 
OVA in all the samples were 5 µg/mL. Cells incubated with SIINFEKL peptide was 
also tested as positive control. Light irradiation was applied at 660nm with light dose 
of 0, 0.5, 1.5 or 3 J/cm2. The β-galactosidase in B3Z cells after MHC-I presentation 
was quantified calorimetrically by the absorption at 570 nm, which reflected the level 
of MHC-I presentation. Values represent the average ± SD (n=3).  Statistical 
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significance was compared between non-irradiated group with the groups that received 
different light dose. *, p < 0.05; **, p < 0.01, ***, p < 0.001. 
 
6.5 Conclusions 
    A biodegradable arginine and phenylalanine based poly(ester amide)s 
nanoparticles in complex with PCI-photosensitizer AlPcS2a, were developed for the 
light-facilitated cytosolic delivery of ovalbumin. The OVA-loaded Arg-Phe-PEA(AP) 
nanoparticles exhibited slightly cationic charge, and the average diameter was between 
200 – 240 nm, with the OVA loading content of 6.2% and encapsulation efficiency of 
67.5%, respectively. The enzymatic biodegradability of the Arg-Phe-PEA(AP) 
enabled enzyme-accelerated release of OVA, and significantly enhanced the 
internalization rate by dendritic cells, compared to free OVA. In vitro PCI effect by 
Arg-Phe-PEA(AP) nanoparticles was validated in dendritic cells, and enabled the 
cytosolic transmigration of the OVA-loaded nanoparticles to further potentiate MHC-I 
immune response. The MHC-I response by OVA-loaded Arg-Phe-PEA(AP) 
nanoparticles was dependent on the light dose, as well as the concentration of the 
photosensitizer. Medium level of both light dose and AlPcS2a concentration lead to 
significant MHC-I presentation, while excessive photosensitizing effect introduced 
cytotoxicity to dendritic cells, and further adversely impacted the efficiency of MHC-I 
presentation. The Arg-Phe-PEA(AP) delivery systems achieved the simultaneous 
delivery of both photosensitizer and antigens, and the light-facilitated PCI-effect 
enhanced the access of antigens into cytosol for subsequent MHC-I processing and 
presentation. The biodegradable and light-facilitated poly(ester amide)s nanoparticles 
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have the promising potential to be developed as the platform for vaccine delivery, to 
elicit CD8 T cell immunity against multiple diseases including cancer. 
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Appendix 
 
Appendix I. JC-1 mitochondrial membrane potential assay 
JC-1 cationic dye exhibits potential-dependent accumulation in mitochondria, 
indicated by a fluorescence emission shift between green (JC-1 monomers, λem = 525 
nm) and red (J-aggregates, λem = 590 nm). Consequently, mitochondrial 
depolarization is indicated by a decrease in the red/green fluorescence intensity ratio. 
The potential-sensitive color shift is due to concentration-dependent formation of red 
fluorescent J-aggregates. JC-1 can be used as an indicator of mitochondrial potential in 
a variety of cell types. 
1. HCT116 cells or MDA-MB-435/MDR cells were seeded in 6 well plate (0.3 × 106 
cells/well) and pre-incubated for 24 hrs. Vehicles or free drug were then added and 
incubated for predetermined time. Cells were then washed twice with PBS (phosphate 
buffer saline, pH 7.4), harvested by incubation with 1 mL of accutase per well for 3-5 
min, and pelleted by centrifugation (200 rcf, 5 min). 
2. JC-1 stock (2.5 mg/mL in dimethyl sulfoxide) was equilibrated to room 
temperature, and diluted to 10 µg/mL in PBS by vigorous agitation to avoid the 
formation of any precipitation or flakes. Cells were re-suspended in JC-1/PBS solution 
in the concentration of 1 × 106 cells/mL, returned to the incubator, and incubated at 37 
°C for 15-30 min for labelling. Untreated cells stained with JC-1 was used as negative 
control, and cells treated with CCCP (carbonyl cyanide 3-chlorophenylhydrazone, 5 
µM) simultaneously with JC-1 staining, was used as positive control. CCCP is the 
typical mitochondrial membrane potential disrupter. 
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3. After sufficient incubation with JC-1 dyes, each sample was washed once with 2 
mL of PBS and resuspended in 0.5 mL PBS by gentle flicking the tube.  
4. Flow cytometry was performed immediately after staining, on a flow cytometer 
with 488 nm excitation using emission filters appropriate for Alexa Fluor 488 dye and 
R-phycoerythrin. Gate on the cells, excluding debris. CCCP-treated sample was used 
to perform standard compensation. 
5. The percentage of cell population stained with higher level of green fluorescence 
and lower level of red fluorescence was recorded for each sample, which indicated the 
percentage of cells with depolarized mitochondrial. As suggested in Figure A1, the 
population that fell in quadrant 3 represented cells with mitochondrial depolarization. 
Each test was performed in 3 replicates. 
 
Figure A1. JC-1 assay of HCT116 cells treated with CCCP (carbonyl cyanide 3-
chlorophenylhydrazone, 5 µM) for 30 min. Flow cytometry detection of cellular 
fluorescence from J aggregates or JC-1 monomers were recorded. 50,000 cells were 
analyzed for each sample.  
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Appendix II. Annexin V apoptosis assay 
    The appearance of phosphatidylserine (PS) residues (normally hidden within the 
plasma membrane) on the surface of the cell is an early event in apoptosis, and can be 
used to detect and measure apoptosis. During apoptosis, PS is translocated from the 
cytoplasmic face of the plasma membrane to the cell surface. Annexin V has a strong, 
Ca2+ dependent affinity for PS and therefore can be used as a probe for detecting 
apoptosis. 
1. HCT116 cells or MDA-MB-435/MDR cells were seeded in 6 well plate (0.3 × 106 
cells/well) and pre-incubated for 24 hrs. Vehicles or free drug were then added and 
incubated for predetermined time. Cells were then washed twice with PBS (phosphate 
buffer saline, pH 7.4), harvested by incubation with 1 mL of accutase per well for 3-5 
min, and pelleted by centrifugation (200 rcf, 5 min). 
2. Annexin V binding buffer was prepared: 0.01 M HEPES, pH 7.4; 0.14 M NaCl; 2.5 
mM CaCl2 
3. Wash cells once annexin V binding buffer, and resuspend cells in binding buffer at 
1-5 ×106 cells/mL. 
5. Add 5 μL of FITC-conjugated annexin V staining solution (eBioscience 88-8007) to 
100 μL of the cell suspension. Incubate 10-15 minutes at room temperature, protected 
from light. 
7. Wash cells with 2 mL binding buffer and resuspend in 200 μL binding buffer. 
8. Add 5 μL of propidium iodide staining solution (eBioscience 88-8007). 
9. Analyze by flow cytometry immediately after staining, on a flow cytometer with 
488 nm excitation using emission filters appropriate for Alexa Fluor 488 dye and R-
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phycoerythrin. Gate on the cells, excluding debris. Percentage of early apoptotic cells 
were identified with higher level of green fluorescence (stained with annexin V FITC) 
and lower level of red fluorescence (stained with propidium iodide). As suggested in 
Figure A2, cell populations that fell in quadrant 3 represent early apoptotic cells, cells 
in quadrant 1 are live cells and cells in quadrant 1 and 2 are late apoptotic cells or dead 
cells. 
 
Figure A2. Annexin V assay of MDA-MB-435 cells treated with free Gambogic acid 
(1 µM) for 24 hrs. Flow cytometry detection of cellular fluorescence from annexin V-
FITC or propidium iodide were recorded. 50,000 cells were analyzed for each sample.  
 
 
Appendix III. Western blot assay for cleaved caspase-3     
    Western blot assay enables the separation and specific detection of individual 
protein in a complex sample. Proteins are separated. Proteins are commonly separated 
using polyacrylamide gel electrophoresis (PAGE) according to physical properties as 
they are forced through a gel by an electrical current. Electrophoretic transfer of 
proteins involves placing a protein-containing polyacrylamide gel in direct contact 
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with a piece of protein-binding membrane and sandwiching between two electrodes 
submerged in a conducting solution. When an electric field is applied, the proteins 
move out of the polyacrylamide gel and onto the surface of the membrane, where the 
proteins become tightly attached. The result is a membrane with a copy of the protein 
pattern that was originally in the polyacrylamide gel. Immunostaining was then 
performed on the blotted membrane, and the specificity of the antibody-antigen 
interaction enables a target protein to be identified in the midst of a complex protein 
mixture. Western blotting can produce qualitative and semiquantitative analysis for the 
target protein. 
1. HCT116 cells were cultured in T75 flask and grew to 80-90% confluency. Vehicles 
or free drugs were added and incubated for predetermined time. Cells were then 
washed twice with ice cold PBS.   
2. 500 µL of RIPA (radioimmunoprecipitation) lysis buffer was added to each flask, 
cells were immediately scraped off and transfer to a microcentrifuge tube on ice. 
Probe sonication was performed to cell lysate three times for 10-15 seconds to 
complete cell lysis and shear DNA. 
3. Total protein amount in each sample was determined by BCA (bicinchoninic acid) 
assay and stored at -20° C. 
7. Immediately prior to protein electrophoresis, diluted samples with SDS sample 
buffer containing DTT (Cell Signaling) so that the final total protein concentration in 
each sample was 1 mg/mL and heated the diluted samples to 95–100 °C for 5 min. 
Samples were then microcentrifuged at 10000 rcf for 5 min and stored on ice. 
8. Protein electrophoresis was performed with 4-20% Tris-glycine mini wedge-well 
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gel (Novex), rinsed in running buffer (25 mM Tris base, 190 mM glycine, 0.1% SDS). 
35 µL samples were loaded in each lane and electrophoresis was performed at 225V 
for 45-60 min. 
9. Protein band was then transferred to PVDF membrane in transfer stack rinsed in 
transfer buffer (25 mM Tris base, 190 mM glycine, 20% methanol). 
10. The transferred membrane was blocked at room temperature for 1 hr in blocking 
buffer (5% bovine serum albumin in TBST buffer (Tris-buffered saline containing 
0.1% Tween 20)), then washed three times for 5 min each with TBST buffer. 
11. The membrane was incubated with primary antibody cleaved caspase-3 (Asp175) 
rabbit mAb (Cell Signaling, 1:1000 dilution in blocking buffer) at 4°C overnight, and 
washed three times for 5 min each with TBST buffer. 
12. The membrane was incubated with anti-rabbit IgG, HRP-conjugated secondary 
antibody (Cell Signaling, 1:2000 dilution in blocking buffer) for 1 hr at room 
temperature, and washed three times for 5 min each with TBST buffer. 
13. The membrane was incubated with LumiGLO (Cell Signaling) developing solution 
with gentle agitation for 1 min at room temperature. The membrane was drained, 
wrapped in plastic wrap and exposed to X-ray film for 1.5 min to develop western blot 
image.  
 
 
Appendix IV. 3D multicellular spheroid culture and viability assay 
    Evaluations of anti-tumor delivery system are usually completed in 2D cell 
culture systems, in which cells were grown in monolayer on a hard and flat surface. 
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Oftentimes, successful nanoparticle delivery observed in 2D cell culture studies does 
not translate to similar results in vivo. The extracellular matrix from 2D culture was 
less dense in monolayer apical side compared to cells in 3D environment, and 
limitations in monolayer cultures were observed that failed to account for extracellular 
barriers that are present in vivo.  3D culture systems that more closely mimic in vivo 
tumor tissues in terms of functionality and morphological, provide a more predictive 
platform for assessing in vivo efficiencies of delivery vehicles. Such systems can serve 
to bridge the considerable gap between traditional 2D monolayer experiments and in 
vivo studies. 
1. Monolayer of MDA-MB-231 breast carcinoma were maintained in Dulbecco's 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, 100 unit/mL penicillin, and 100 μg/mL streptomycin.  
2. At 80-90% of confluency, cells were harvested by incubation with accutase, 
resuspended in complete DMEM medium supplemented with 2.5% Matrigel (BD 
Bioscience), and seeded in ultra-low-attachment 96-well plate (CellCarrier, Perkin 
Elmer) at 0.5 x 104 cells/well. 
3. The plate was centrifuged at 1000 rcf for 10 min, before it was returned to incubator 
and cultured for 3 days to obtain multicellular spheroids with average diameter of 400-
500 µm. 
4. Vehicles or free drug was incubated with spheroids for predetermined time and 
washed with culture medium twice. 10 µL of WST-1 assay reagent (Sigma Aldrich) 
was added to each well, returned to the incubator and incubated for 4 hrs.  
5. The contents in the ultra-low-attachment 96 well plate was transferred to regular 
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flat-bottom 96 well plate and mixed well on orbital shaker. The absorbance in each 
well was measured on microplate reader at 450 nm. Untreated spheroids were 
analyzed as control and the viability of spheroids was normalized to control. 10 
replicates were measured for each treatment.  
 
 
 
Appendix V. DNA ladder assay for apoptosis detection 
    Apoptosis is a programmed physiological mechanism for cell death. 
Fragmentation of chromatin DNA at the nucleosomal level (around185 bp) is one of 
the hallmarks of apoptosis. The DNA fragmentation can be detected as laddering using 
gel electrophoresis. 
1. MDA-MB-435/MDR cells were seeded in 6 well plate (0.3 × 106 cells/well) and 
pre-incubated for 24 hrs. Vehicles or free drug were then added and incubated for 
predetermined time. Cells were then washed twice with PBS (phosphate buffer saline, 
pH 7.4), harvested by incubation with 1 mL of accutase per well for 3-5 min, and 
pelleted by centrifugation (200 rcf, 5 min). 
2. Resuspend the pellet thoroughly in 200 µL of Resuspension Solution (GenElute 
Mammalian Genomic DNA Miniprep Kit, Sigma Aldrich). All the following reagents 
were from the same DNA miniprep kit.  
3. Add 20 µL of the Proteinase K solution to the sample, followed by 200 µL of Lysis 
Solution C. Vortex thoroughly, and incubate at 70 °C for 10 minutes. 
4. Add 500 µL of the Column Preparation Solution to each pre-assembled GenElute 
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Miniprep Binding Column and centrifuge at 12,000 rcf for 1 minute. Discard flow-
through liquid. 
5. Add 200 µL of ethanol (95–100%) to the lysate; mix thoroughly by vortexing 5–10 
seconds.  
6. Transfer the entire contents of the tube into the treated binding column. Use a wide 
bore pipette tip to reduce shearing the DNA when transferring contents into the 
binding column. Centrifuge at 6500 rcf for 1 minute. Discard the collection tube 
containing the flow-through liquid and place the binding column in a new 2 mL 
collection tube. 
7. Add 500 µL of Wash Solution to the binding column and centrifuge for 1 minute at 
6,500 rcf. Discard the collection tube containing the flow-through liquid and place the 
binding column in a new 2 mL collection tube. 
8. Add another 500 µL of Wash Solution to the binding column; centrifuge for 3 
minutes at maximum speed (12,000-16,000 rcf) to dry the binding column. Centrifuge 
the column for one additional minute at maximum speed if residual ethanol is seen. 
Discard the collection tube containing the flow-through liquid and place the binding 
column in a new 2 mL collection tube. 
9. Pipette 200 µL of the Elution Solution directly into the center of the binding 
column; centrifuge for 1 minute at 6,500 rcf to elute the DNA. To increase the elution 
efficiency, incubate for 5 minutes at room temperature after adding the Elution 
Solution, then centrifuge. 
10. DNG gel electrophoresis was performed in Flashgel system (Lonza). As prepared 
DNA samples were diluted with Flashgel loading dye (1:5 v/v) and loaded onto 1.2% 
 244 
 
FlashGel DNA Cassette at 5 µL per lane.  The electrophoresis was performed at 275 
V for 5 min and the DNA bands were visualized on the FlashGel Dock. 
 
 
 
Appendix VI. Gelatin zymography 
    The invasion and metastasis of tumor cells has been shown to require proteolytic 
activity in order to degrade components of the extracellular matrix (ECM). A major 
group of proteases that has been directly associated with tumor metastasis is the matrix 
metalloproteinases (MMP). The gelatinases MMP-2 and MMP-9 are two members of 
the MMP family that have been extensively studied owing to their consistent 
association with tumor invasion and metastasis.  Gelatin zymography identifies 
gelatinolytic activity of MMP using sodium dodecyl sulfate (SDS)-polyacrylamide 
gels impregnated with gelatin, after protein electrophoresis, the non-denatured MMP 
can degrade the gelatin, leaving a cleared zone that can be detected by Coomassie blue 
staining. The gelatinolytic results correlate directly with the activation status of MMP. 
1. 3× 105 MDA-MB-435/MDR cells per well were seeded in a 6-well plate pre-
incubated for 24 hrs. 
2. Cell were then treated with vesicles in serum-free DMEM for 24 hrs. 
3. The media were collected and centrifuged (400 rcf, 5 min, 4 ºC). The supernatant 
(75 µL) was mixed with 25 µL sample buffer (250 mM Tris-HCl, pH 6.8; 40% 
glycerol; 8% SDS; and 0.01% bromophenol blue). The mixture was vortexed and kept 
at room temperature for 10 – 15 min. 
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4. The gels were provided with 1% type B gelatin (w/v). Gently pull the comb out 
from the stacking gel and peel off the tape from the bottom of the cassette. Place the 
cassette into the gel apparatus and fill the buffer chambers with running buffer (0.1% 
SDS, 25 mM Tris base and 190 mM glycine, pH 8.3). 
5. Load the samples (as prepared from step 3) and run the gel at constant voltage (125 
V, starting current should be approximately 30–40 mA/gel) until the bromophenol 
blue tracking dye reaches the bottom of the gel (approximately 90 min).  
6. Carefully remove the gel from the cassette and place it in plastic tray containing 100 
mL of renaturing solution (2.5% v/v Triton X-100 in DI water). Incubate the gel for 30 
min at room temperature with gentle agitation. 
7. Decant the solution and rinse the gel at least once with 300 mL of DI water. 
Incubate the gel at room temperature for an additional 30 min in 100 mL of 
developing buffer (50 mM Tris-HCl buffer containing 10 mM of CaCl2, 0.02% NaN3, 
pH 7.6) with gentle agitation. 
8. Decant the developing buffer and replace it with 100 mL of fresh developing buffer. 
Incubate the gel at 37°C for approximately 16 hrs in a closed container. 
9. Decant the developing buffer and stain the gel in staining solution (0.5% Coomassie 
blue R-250, 5% methanol, and 10% acetic acid in DI water.) until the gel is uniformly 
dark blue.  
10. Destain the gel with destaining solution (10% methanol, 5% acetic acid in DI 
water) until areas of gelatinolytic activity appear as clear bands over the background. 
 
